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Abstract 
Between 1999 and 2003, a large colorectal cancer (CRC) case-control study was 
conducted in Newfoundland and Labrador (NL). The primary aim of this thesis was to 
explore relations between use of alcohol and tobacco and CRC risk. The specific 
objectives were to (i) determine the extent of non-participation bias by comparing the 
differences in demographics between participants and non-participants; (ii) explore mis-
reporting for tobacco and alcohol use using provincial sales data and the Canadian 
Community Health Survey (CCHS) 1.1 and 3.1 data for alcohol and tobacco; (iii) 
examine impact of tobacco smoking on risk of CRC; (iv) examine impact of alcohol 
consumption on risk of CRC 
Newly diagnosed CRC cases identified in 1999-2003 in NL, Canada were 
frequency-matched by age and sex with controls selected using random digit dialing 
(RDD). Cases (n = 702) and controls (n = 717) completed self-administered 
questionnaires assessing health and lifestyle variables. Measures of tobacco use included 
type of tobacco, age of initiation of smoking, years of smoking, years since started 
smoking, number of cigarettes smoked daily, pack years, and years since abstention from 
smoking. Estimates of alcohol intake included types of beverage, years of drinking, and 
number of drinks daily. Odds ratios were estimated using multivariate logistic regression. 
The study found a 49% higher risk of CRC among cigarette smokers than non-
smokers. The risk tended to increase significantly with cigarette smoking years, amount 
of cigarettes smoked daily, cigarette pack years and the risk significantly decreased with 
years of abstention from smoking. Smoking demonstrated a stronger cancer risk in men 
than women, in drinkers than non-drinkers and in obese men than obese women. The 
study demonstrated that the effect of alcohol intake on odds of developing CRC differed 
by weight status. Alcohol consumption tended to reduce the odds of developing CRC in 
non-obese. In the obese (BMI ~ 30), the odds of CRC (OR = 2.25) were greater in 
drinkers than in non-drinkers. The odds of developing CRC increased with number of 
drinking years and numbers of drinks daily in obese. The effect of drinking on CRC risk 
was stronger among obese subjects who smoked. 
In conclusion, this thesis reported that cigarette smoking increased the risk of 
CRC. Alcohol drinking decreased CRC risk in non-obese and cigarette non-smokers, but 
drinking increased the risk of CRC in the presence of cigarette smoking and obesity. Low 
participation rates may limit the generalizability of the results. 
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Chapter 1 Introduction 
1.1. Colorectal cancer 
The colon and rectum make up the large intestine (large bowel, see Figure 1). The 
large intestine is the last part of the digestive system. The colon is the first four to five 
feet of the large intestine and the rectum is the last several inches [IJ. The colon consists 
of the ascending, transverse, descending, and the sigmoid colon. The section from the 
cecum to the mid-transverse colon is also known as the right colon and the remainder, the 
left colon. 
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Organs of the digestive system are responsible for converting food into energy 
and help pass waste out of the body Pl. Food is digested in the stomach and the small 
intestine. As nutrients are removed from food, it changes into a watery mass which passes 
on through the small intestine into the colon. The colon absorbs the water and the semi-
solid waste (feces) passes to the rectum where it is stored. During a bowel movement, the 
feces are passed out of the body through the anus. 
Colorectal cancer (CRC) is a disease originating in the epithelial cells lining the 
gastrointestinal tract. CRC, also called bowel cancer, includes cancerous growths in the 
colon, rectum and the appendix [2l. Table 1 presents the coding of CRC in the 
International Classification of Diseases 9th revision (ICD-9) and 1oth revision (ICD-1 0) 
[).4l. CRC usually develops slowly over a period of many years. A polyp is a growth of 
tissue that develops on the lining of the colon or rectum. Adenomatous polyps or 
adenomas are very likely to become cancers. CRC usually begins as a noncancerous 
polyp which may eventually become a cancerous growth. More than 95% of CRCs are 
adenocarcinomas which evolve from glandular tissue. In approximately 85% of CRCs, 
the tumour arises from an adenomatous polyp that is visible through a scope [S,6l. 
The majority (approximately 75%) of CRCs are sporadic, arising from somatic 
mutations and clonal evolution at the tumour site Pl. The remainder of cases are 
comprised of hereditary syndromes, i.e., familial adenomatous polyposis (F AP; 1 %) and 
hereditary nonpolyposis colorectal cancer (HNPCC; 4-7%), family/personal history of the 
disease or adenomatous polyps (15-20%), or other high-risk conditions (inflammatory 
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bowel diseases, previous diagnoses for cancers of the ovary, endometrium, breast, bile 
duct, pancreas, stomach; 1% ). 
Table 1. Coding of colo rectal cancer in the International Classification of Disease 9th revision and 
1Oth revision 
CRC ICD-9 ICD-10 
Malignant neoplasm of colon 153 C18 
Caecum 153.4 C18.0 
Appendix 153.5 Cl8.1 
Ascending colon 153.6 Cl8.2 
Hepatic flexure 153.0 C18.3 
Transverse colon 153.1 Cl8.4 
Splenic flexure 153.7 Cl8.5 
Descending colon 153.2 C18.6 
Sigmoid colon Sigmoid (flexure) 153.3 Cl8.7 
Overlapping lesion of colon Cl8.8 
Colon, unspecified 153.8,1 53.9 C18.9 
Malignant neoplasm of rectosigmoid junction 154.0 Cl9 
Malignant neoplasm of rectum 154.1 C20 
Malignant neoplasm of anus and anal canal C21 
Anus, unspecified 154.3 C21.0 
Anal canal 154.2 C21.1 
Cloacogenic zone C21.2 
Overlapping lesion of rectum, anus and anal canal C21.8 
1.2. Burden of colorectal cancer 
1.2.1. Incidence and mortality worldwide 
CRC is one of the most common neoplasm of the digestive system in the world [&J. 
Incidence of CRC ranks fourth in men after lung, prostate and stomach and third in 
women after breast and cervix uteri [&J. An estimated 1 million new cases of CRC are 
diagnosed every year, accounting for approximately 9.4% of total worldwide cancer 
cases [SJ. The estimated age-standardized incidence rates of CRC were 20.1 per 100,000 
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in men and 14.6 per 100,000 in women in 2002 worldwide [81• Nearly 1.2 million new 
cases of CRC and about 630,000 deaths from CRC occurred in 2007 worldwide 
according to an estimate from the American Cancer Society [91. There is a substantial 
variation in global trends of the incidence of CRC [91. The CRC incidence is increasing in 
certain countries such as Japan and Puerto Rico where risk was historically low. There 
are differential trends in CRC high risk countries with time [91. For example, trends are 
gradually increasing in England, stabilizing in New Zealand, or declining in the United 
States. The greatest increases in the incidence of CRC appear in some Asian countries 
including Japan, Hong Kong and Singapore, Eastern Europe (Hungary and Poland), Israel 
and Puerto Rico. The recent decrease in rates has been observed in some western and 
northern European countries. 
1.2.2. Incidence and mortality in Canada 
Canada is one of the countries with the highest incidence and mortality rates of 
cancer in the world [9· ' 01. An estimated 171,000 new cases of cancer and 75,300 deaths 
from cancer occurred in Canada in 2009 [I01. Three types of cancer accounted for over 
half of the new cases in men (prostate, lung and colorectal) and women (breast, lung and 
colorectal) [I01. Overall, CRC is the second leading cause of cancer death for both men 
and women [1°1. There were an estimated 22,000 new cases of CRC (12,100 in men and 
9,900 in women) and 9,100 deaths from CRC (4,900 in men and 4,200 in women) in 
Canada in 2009. In Canada, the CRC incidence rate tended to increase, but the mortality 
rate of CRC decreased between 1980 and 2009 in men. The age-standardized incidence 
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rate for CRC increased to 62.2 per 100,000 population in 2009 from 57.9 per 100,000 
population in 1980 and the age-standardized mortality rate for CRC decreased to 25.7 per 
100,000 population in 2009 from 32.3 per 100,000 population in 1980 in men [I OJ_ In 
women, both the age-standardized incidence and mortality rates for CRC decreased to 
41.2 and 16.3 per 100,000 in 2009 from 47.4 and 25.3 per 100,000 in 1980 [IOJ. 
1.2.3. Incidence and mortality in Newfoundland and Labrador 
The highest CRC incidence rates in Canada are seen among men in NL and 
among women in Prince Edward Island, Nova Scotia and NL; the lowest rates are in 
British Columbia for both sexes [IOJ. Mortality rates ofCRC for both sexes in NL are also 
the highest among the provinces, and are approximately twice as high in NL as they are 
in British Columbia [IOJ. Differences in incidence or mortality rates among provinces and 
territories may be due to variation in the prevalence of modifiable risk factors for CRC, 
but there is a clear need for further work to explore this hypothesis. This thesis aims to 
contribute to new knowledge in this area. 
1.3. Objective of the thesis 
The primary objective of this thesis was to explore relations between tobacco 
smoking and alcohol consumption and CRC risk. The specific objectives were to (i) 
determine the extent of non-participation bias by comparing the differences in 
demographics between participants and non-participants; (ii) explore mis-reporting for 
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tobacco smoking and alcohol consumption using provincial sales data and the Canadian 
Community Health Survey Cycle 1.1 (CCHS 1.1) and Cycle 3.1 (CCHS 3.1) data for 
tobacco and alcohol; (iii) examine impact of tobacco smoking on CRC risk; (iv) examine 
impact of alcohol consumption on CRC risk. 
1.4. Organization of the thesis 
This thesis is divided into nine chapters. Following this short introductory chapter 
of the burden of CRC worldwide, the objective of this thesis and the organization of the 
thesis, the second chapter reviews the incidence of CRC by geographic variations, race 
and ethnicity and demographics; the third chapter provides a literature review of CRC 
risk factors explored in this thesis. The fourth chapter introduces the data sources, study 
design and assessment methods, and describes the statistical methods employed in this 
thesis. The fifth chapter addresses the first objective, the extent of potential non-
participation bias by comparing the characteristics of participants and non-participants in 
the case and control groups in the NL population-based case-control study of CRC. The 
sixth chapter investigates the second objective, the reporting bias of self-reported tobacco 
smoking and alcohol consumption by comparing data from the case-control study with 
the provincial sales data of tobacco and alcohol, and self-reported data from two national 
surveys. The seventh chapter presents research on the third objective, the results of the 
relationship between tobacco smoking and CRC risk based on the database of the NL 
case-control study of CRC risk. The eighth chapter presents research on the fourth 
objective, the research results of the relationship between alcohol consumption and CRC 
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risk based on the database of the NL case-control study of CRC. The ninth chapter 
summarizes the results of this thesis and suggests future research. 
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Chapter 2 Socio-demographics of colorectal cancer 
Research and data have showed obvious differences in the cancer incidence 
across populations living in different geographic areas, and populations with different 
socio-demographic characteristics. The purpose of this chapter is to provide an overview 
of geographic and socio-demographics for CRC incidence. 
2.1. International and geographic variations 
There is at least a 25-fold variation in occurrence of CRC worldwide [&,9l. The 
incidence is higher in industrialized regions such as North America, Europe and Australia 
than in Asia, Africa, and South America [ttl. The highest incidence rates are in North 
America, Australia and New Zealand, Western Europe, and, in men especially, Japan. 
Incidence tends to be low in Africa and Asia and intermediate in southern parts of South 
America. The geographic distribution of colon and rectal cancer is similar, although the 
variation between countries is more striking for colon cancer. In high-risk populations, 
the ratio of colon to rectal cancer incidence is 2:1 or more. In low-risk countries, colon 
and rectal cancer rates are generally of the same magnitude. Significant geographic 
variation in CRC also exists within countries. For example, in the United States, the age-
adjusted incidence rates of CRC are highest in the Middle Atlantic region, followed by 
New England region, East and West North Central regions, East South Central and South 
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Atlantic regions, West South Central and Pacific regions, with the lowest rate observed in 
the Mountain region [121• 
The large geographic differences for colon and rectal cancers may mainly be 
explained by different environmental exposures. There are strong correlations 
internationally between risk of large bowel cancers and per capita consumption patterns 
of meat [l3l, fat [l 4l, and fibre [ISJ. Epidemiologic studies have found consistent evidence 
that physical inactivity, excess body weight, and a central deposition of adiposity have 
major influences on risk of colon cancer [161• Evidence from the study of immigrants has 
illustrated that the risk of colon cancer is quite labile to environmental changes; when 
populations moved from low-risk to high-risk areas, the incidence of CRC increased 
rapidly within the first generation [I?, ISJ suggesting that dietary and other environmental 
factors constitute a major component of risk. 
There has also been variation in CRC rates among provinces in Canada which had 
the highest incidence rates of CRC. Incidence rates are obviously higher in eastern 
provinces than western provinces, for both men and women (see Table 2). The age-
standardized CRC incidence rate for males was the highest in NL and Nova Scotia, being 
87 and 75 per 100,000 males and the lowest in British Columbia, being 53 per 100,000 
males in 2009 [IOJ. The age-standardized CRC incidence rate for females was the highest 
in Prince Edward Island and NL, being 53 and 52 per 100,000 and the lowest in British 
Columbia, being 36 per 100,000 females in 2009 [IOJ. Provincial mortality rates had a 
similar pattern to incidence rates across the provinces. The age-standardized CRC 
mortality rate for males was the highest in NL, Prince Edward Island and Nova Scotia, 
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being 41 31 and 33 per 100,000 males and the lowest in British Columbia, being 21 per 
100,000 males in 2009 [IOJ. The age-standardized CRC mortality rate for females was the 
highest in NL and Prince Edward Island, being 26 and 23 per 100,000 males and the 
lowest in Alberta and British Columbia, being 14 and 13 per 100,000 females in 2009 [I OJ. 
While the factors that cause these real differences are not well understood, several factors 
including historical tobacco smoking patterns and lower socioeconomic status may be 
associated with the geographic variation. 
Table 2. Estimated new cases and age-standardized incidence and mortality rates per 100,000 for 
colorectal cancer by sex among provinces and territories in Canada in 2009 
Incidence Mortality 
Province/territory Male Female Male Female 
N Rate N Rate N Rate N Rate 
Newfoundland and Labrador 290 87 200 52 130 41 100 26 
Prince Edward 55 65 55 53 25 31 25 23 
Nova Scotia 450 75 390 52 190 33 170 21 
New Brunswick 300 64 240 40 120 25 100 15 
Quebec 3,200 69 2,600 43 1,350 29 1,250 19 
Ontario 4,400 60 3,700 41 1,800 24 1,500 15 
Manitoba 440 65 360 42 200 30 160 17 
Saskatchewan 380 63 300 40 160 26 120 15 
Alberta 1,000 59 780 38 370 22 290 14 
British Columbia 1,450 53 1,200 36 580 21 480 13 
Canada 12,100 62 9,000 41 4,900 26 4,200 16 
Source: Canadian Cancer Statistics 2009 [IOJ. 
When comparing provincial incidence and mortality with national rates from 1986 
to 1996, CRC incidence rates increased significantly among men in NL (! OJ. Among 
women in Prince Edward Island, both incidence and mortality rates increased 
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significantly during the same period, even though these rates are based on small numbers 
and may be imprecise. The reasons for provincial differences in CRC incidence and 
mortality are not known, but may be associated with differences in exposure to 
modifiable risk factors such as tobacco smoking and lower intake of vegetables and fruits 
and genetic factors. 
2.2. Race and ethnicity 
The incidence of CRC varies significantly by race and ethnicity. Cancer statistics 
of the United States from the Centers for Disease Control and Prevention showed the 
incidence and mortality rates for CRC were highest in Blacks, followed by Whites, then 
Hispanic [1 91 . The incidence rate of CRC was low in American Indian/Alaska Native and 
Asian/Pacific Islander. Table 3 presents the age-adjusted incidence and mortality rates for 
CRC by races in the United States in 2006. However, other statistics found Japanese has 
relatively high incidence rate than other Asian people. For example, Japanese individuals 
born in the United States had higher rates than those of Whites in the United States in 
both men and women (38.4 per 100,000 in men and 27.6 in women), the rates in Japanese 
individuals living in Hawaii (51.2 per 100,000 in men and 30.8 in women) and Los 
Angeles (48.0 per 100,000 in men and 32.8 in women) were among the highest in the 
world [&,201. 
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Table 3. Estimated aged-adjusted incidence and mortality rates per 100,000 for colorectal cancer by 
races in the United States in 2006 
Race/ethnicity 
Incidence Mortality 
Male Female Total Male Female Total 
White 53.0 39.9 45.8 19.9 14.1 16.6 
Black 63 .0 49.2 54.7 30.8 20.1 24.3 
Asian/Pacific Islander 40.5 31.7 35.5 12.5 9.8 11.0 
American Indian/Alaska Native 34.4 26.7 30.2 13.2 9.4 1 1.1 
Hispanic 47.3 33.2 39.3 15.3 10.8 12.8 
All races 54.1 41.1 46.8 20.5 14.5 17.1 
Source: United States cancer statistics: 1999-2006 incidence and mortality web-based report [!91. 
2.2.1. Genetics and race and ethnicity 
The differences in incidence rates among various races and ethnic groups may be 
explained by genetic factors and environmental lifestyle factors, especially diet and 
exercise. Microsatellite instability (MSI) is a condition manifested by damaged DNA due 
to defects in the normal DNA repair process and is seen in over 85% of patients with 
Hereditary Non-Polyposis Colorectal Cancer (HNPCC) and in 15-20% of sporadic CRC 
patients [21•221 • Mutations in the mismatch repair genes have been found among African 
American patients who have either confirmed or suspected HNPCC [231. 
2.2.2. Environment and race and ethnicity 
Several studies have shown that migrants to the United States from Japan and 
other countries where rates of CRC were lower than in the United States had higher rates 
than those who remained in their native country. Also, first and second generation 
American offspring from these migrant groups developed these cancers at rates reaching 
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or exceeding those of the white population in the United States [241 . Further support of this 
observation was shown by the reduced incidence in certain religious groups such as the 
Mormons or Seventh Day Adventists who limit the consumption of meat, meat products, 
tobacco, alcohol and caffeine [251 . Jews ofEastem European descent (Ashkenazi Jews) are 
at increased risk of developing CRC. The observed increased incidence of CRC in 
Ashkenazi Jews compared to other populations was unexplained but likely had a genetic 
component [26-301. This group tended to have a genetic mutation that increased the risk of 
developing CRC. This genetic mutation was not common among other ethnic groups. 
2.3. Socio-demographic characteristics 
2.3.1. Age 
As with most malignancies, the development of CRC is associated with age. 
Statistics data have showed an increased incidence of CRC with increasing age [31-351. In 
the United States, on average, one in 20 people will develop the disease in the course of a 
lifetime and ninety percent of cases occur in patients over age 50 l36•37l. However, recent 
studies have reported increased rates of CRC among younger people. For example, the 
proportion of African patients under 40 years with CRC was 19% in South Africa [331 and 
38% of CRC occurred in patients aged younger than 40 years old in Egypt [341 . An 
increase in incidence rate of CRC was observed among young men and women aged 20-
49 in the United States from 1992 to 2005 [381. The aging of the body may not directly 
affect cancer risk, but instead it may be that the cumulative exposure to risk factors such 
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as tobacco smoking, alcohol consumption or cancer-causing substances with concomitant 
damage to DNA over time eventually leads to the disease in some individuals [J91. The 
high prevalence of cancer in older individuals may simply reflect prolonged exposure to 
carcinogens and decreasing efficiency of repair mechanisms [J91. 
2.3.2. Sex 
In terms of incidence, CRC ranks fourth in frequency in men and third in women 
worldwide [81. Studies of gender differences in CRC have shown shifts in incidence and 
site distribution which can be attributed, in part, to environmental and behavioral factors 
[401 • In high-risk populations, rectal cancer and left-sided colon cancer have been more 
frequent in older men, whereas right-sided colon cancer has been more commonly found 
in older women. Among known associations with reduced CRC risk, women appeared to 
ingest more dietary fibre, benefit more from physical activity, have lower body mass, and 
consume less alcohol [401 • Although these differences may contribute to the risk 
differential, hormonal events during reproductive years also appear to affect women's risk 
at older ages. Previous studies have found that the effect of drinking on CRC was larger 
for men than for women [4 '1. The elevated risk related to alcohol intake among men 
compared with women may be because of the generally lower consumption of alcohol 
among women; it is possible that men exhibit a greater range in the amount of alcohol 
drunk, which makes effects easier to detect. Also, preferred beverages may differ 
between the sexes, or there may be hormone-related differences in alcohol metabolism or 
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susceptibility to alcohol [421 • Female sex hormones are known to affect cholesterol and 
bile salts metabolism which in turn have been linked to the development ofCRC [431. 
2.3.3. Marital status 
Studies conducted in developed countries found a significant relationship between 
CRC risk and marital status but the results tended to be inconsistent. For example, a 
hospital-based case-control study conducted in Italy between 1983 and 2001 found that 
compared to married subjects, those who have never been married were at reduced risk of 
cancer of the colon [44J. This Italian study showed that there was 20% and 30% lower risk 
of developing CRC for those who never married (OR: 0.8 and 95% CI: 0.6-0.9), or were 
widowed (OR: 0.7 and 95% CI: 0.8-1.0) relative to those who had married, but there was 
no significant difference in the risk between divorced and married subjects (OR: 1.0 and 
95% CI: 0.7-1.3). Another population-based case-control study conducted in Montreal of 
Canada showed that subjects who had ever been married had a 42% lower risk of colon 
cancer (OR: 0.58 and 95% CI: 0.48-0.84) than did individuals who had never been 
married [451 . One analysis on the data of cancer incidence in the United States shows the 
highest age-adjusted incidence rates among single black men and women. The 
mechanism of how marital status affects CRC is unknown. The relation between marital 
status and cancer incidence is variable across cancer sites, calendar periods and 
populations [46-501. 
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2.3.4. Education 
Years of education are generally chosen as an indicator of socioeconomic status 
because it, applied to every adult individual, is more stable over one's lifetime than either 
occupation or income (SIJ and is easily obtainable and recordable [521. Variation in risk of 
CRC as well as other cancers by education level has been observed in epidemiological 
studies conducted mainly in Western countries over years. Studies seemed to show a 
increased risk of CRC among people who had a higher education (S3-581. A case-control 
study conducted in Athens, Greece in 1979-1980 showed the risk of colon cancer was 
increased in men with 12 years or higher education compared to no education (OR = 1.3) 
[S31. The hospital-based case-control study conducted in six Italian centres between 1985 
and 1996 found that compared to individuals with fewer than seven years of education, 
the OR of colon cancer for those with 16 years education or higher was 2.45 (95% CI: 
1.87-3.23) in men and 1.29 (95% CI: 0.88-1.90) in women [541 . In this study, no 
significant association was found between education and risk of rectal cancer [541. Several 
other studies also suggested that the risk of developing CRC increased with higher 
education level [SS-S?J . Studies also showed that the risk of rectal cancer increased with 
higher education level l58l. 
2.3.5. Economic status 
An increased risk of developing CRC is associated with higher economic status. 
Surveillance system statistics in men aged 35-64 years old in Hong Kong showed the risk 
of developing CRC decreased with reduced income level, i.e., the relative risk (RR) was 
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0.84 for medium income vs higher, 0.54 for lower vs higher, and 0.81 for lower vs 
medium [591. A hospital-based case-control study conducted in 1983-1988 adjusting by 
sex among those under the age of 75 in Milan, Italy showed that those belonging to social 
class I-II (high income with UK Registrar General ' s social class classification) had a 1.34 
times higher risk of developing CRC than social class IV-V; social class III had 1.15 
times higher risk of developing CRC than social class IV-V [571• Other studies in the 
United States and Sweden also showed that the risk of colon cancer decreased with a 
lower social class [58'60'611. Other investigators suggest that the effects of socio-economic 
status on CRC vary by the subsites of CRC. For example, the study conducted in six 
Italian centres between 1985 and 1996 found that the OR of colon cancer was 2.30 (95% 
CI: 1.82-2.90) in men and 1.33 (95% CI: 1.03-1.73) in women in the highest versus the 
lowest social class; the study found no association between social status and rectal cancer 
[54]. However, other studies have shown that the risk of rectal cancer increased with 
higher social class [55'57'62'631. 
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Chapter 3 Review of genetic and environmental risk factors of 
developing colorectal cancer 
A substantial number of cohort and case-control studies have been conducted to 
investigate the association of CRC and colon or rectal cancer with various modifiable 
lifestyle risk factors or other factors in both general populations and/or population 
subgroups. Many studies have found obvious differences in the cancer incidence between 
populations with a number of risk factors. However, many of these studies have been 
limited because they have not fully considered how interactions between risk factors may 
potentially confound or modify associations. The purpose of this chapter is to provide an 
overview of risk factors for CRC, concluding with a description of the rationale for the 
research presented in chapters 4-8. 
3 .1. Personal history of diseases and medications 
3 .1.1. Personal history of cancer 
A personal history of CRC increased the risk of developing a second primary 
colon cancer or other cancer, particularly at the site of an anastomosis from the previous 
surgery [641. Women with a history of breast, endometrial, or ovarian cancer also had an 
increased risk of developing CRC [651. This might be because such patients have genetic 
mutations which put them at increased risk of multiple cancers. This hypothesis has been 
supported by evidence in a study which found women diagnosed with endometrial cancer 
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have mutation for inherited Lynch syndrome which puts these patients at high risk for 
colon as well as endometrial, ovarian and gastric cancer [66l. 
3 .1.2. Personal history of intestinal polyps 
Polyps of the colon, particularly adenomatous polyps, are a risk factor for colon 
cancer. Villous adenomas become cancerous up to 25% of the time, and tubular 
adenomas became cancerous about 5% of the time [361. Adenomatous colonic polyps are 
small outgrowths from the inner lining of the colon and are different from other types of 
polyps that do not present an increased risk for the development of CRC. Adenomatous 
polyps may take from seven to twelve years to progress from normal mucosa to adenoma 
to cancer [361. They are common in obese individuals and also in individuals with a high-
fat consumption and in certain families. It is estimated that 19-41% of the general 
population will develop adenomatous polyps and about 10% ofthese individuals will also 
have a first-degree relative with a history of CRC [671• These dysplastic adenomas are 
precancerous and are classified as villous, tubulovillous, or tubular. Villous lesions 
comprise only 10% of adenomas but are more likely to be malignant. Tubular adenomas 
account for 75% of adenomas but only 5% of malignancies. Patients with multiple polyps 
have twice the risk for cancer than those with a single polyp [671 . The overall risk of 
adenomatous polyps progressing to cancer has been reported as approximately 2-5%, 
with polyp size being a major risk factor. Polyps that are less than 0.5 mm in diameter are 
unlikely to progress to malignancy while those greater than 2 mm have been shown to 
have about a 46% malignancy rate over a 10-year interval [68l. 
19 
3 .1.3. Personal history of inflammatory bowel disease 
Chronic inflammatory bowel disease (IBD), including ulcerative colitis and 
Crohn's disease, is a condition in which the colon is inflamed over a long period of time 
l69l. These inflammatory bowel conditions have been associated with an increased chance 
of developing CRC l69l. Ulcerative colitis is a medical condition in which the inner lining 
of the colon becomes ulcerated in multiple places; this chronic disorder of unknown 
aetiology affects children and adults, with a peak incidence in the early third decade. 
Studies showed a significant increase in mortality from CRC among CRC patients with 
IBD compared with normal CRC patients [70-731. Long duration and early onset of the 
disease are risk factors for CRC. The risk of Crohn's disease developing into CRC is not 
as high as it is for ulcerative colitis, but Crohn's disease tends to cause cancer at a 
younger age than in the general population. 
The increased risk for developing CRC due to IBD is likely related to damage to 
the intestinal lining, which decreases the normal mucosal barriers that usually protect the 
lining l74J. Other reasons for the increased risk of developing CRC in patients with IBD 
could include chronic stimulation of the intestinal lining, which may lead to abnormal 
cell growth (dysplasia) that may progress to cancer, and the loss of enzymes that 
normally reduce the effect of toxins in the intestine [741. 
3.1.4. Diabetes 
CRC occurs more frequently in patients with type 2 (non-insulin-dependent) 
diabetes mellitus l7S-SIJ. They also tend to have lower survival rates and higher recurrence 
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rates. The Nurse's Health Study examining the relationship between diabetes and risk of 
developing CRC in a cohort of 118,403 women aged 30 through 55 years who, in 1976, 
had not been previously diagnosed with cancer at baseline, found that diabetes mellitus 
conferred an increased risk of developing CRC [761. This study showed that patients with 
diabetes were 1.43 (95% CI: 1.1 0-1.87) times more likely to develop CRC and 2.39 (95% 
CI: 1.46-3.92) times more likely to die of CRC than non-diabetes. Another recent study 
[821 which used data from the Singapore Chinese Health Study, a prospective cohort study 
of61 ,320 Singapore Chinese men and women aged 45-74 years old, found that a history 
of physician-diagnosed diabetes mellitus was statistically significantly associated with 
CRC risk in both men (RR: 1.5 and 95% CI: 1.2-2.1) and women (RR: 1.4 and 95% CI: 
1.0-1.9). People with non-insulin dependent diabetes mellitus being at a higher risk of 
developing CRC may be probably due to hyperinsulinemia [831 and high concentrations of 
insulin-like growth factor-! (IGF-1) [84•851. 
3 .1.5. Hypercholesterolemia 
Hypercholesterolemia is a condition of a higher serum total cholesterol level 
which causes sclerotic changes in blood vessels, potentially leading to hypoxia of large 
intestine tissue and changes in the homeostasis of its cells [861. Some studies also explored 
the relationship between hypercholesterolemia and CRC risk. One study which measured 
cholesterol levels in 7,926 Japanese-Americans for over 20 years reported an increase in 
serum cholesterol was associated with a decrease in risk of colon cancer, but not rectal 
cancer [871. However, several other studies showed a positive relationship between serum 
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cholesterol levels and the risk of CRC [88-901. It is unclear how hypercholesterolemia is 
associated with CRC risk. The relationship between factors causing hypercholesterolemia 
and factors leading to CRC development has not been fully investigated. It has been 
hypothesized that molecular genetic changes in normal epitheliun1 may lead to 
adenomatous polyps and might result in CRC [91•921. A recent review suggested that the 
increased risk of CRC associated with hypercholesterolemia may be due to relationships 
between the modifiable risk factors for both CRC and hypercholesterolemia [861. 
3.1.6. Nonsteroidal anti-inflammatory drugs 
Both cohort and case-control studies have shown that use of aspirin and non-
aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) were associated with reduced 
CRC risks [93-971. Furthermore, a study examining aspirin and non-aspirin-NSAID use 
among the initially cancer-free cohort of postmenopausal women in the Iowa Women's 
Health Study found that, during the 11 years of follow-up for proximal colon cancer, the 
multi variable-adjusted hazard ratios of proximal colon cancer for women reporting use of 
aspirin or non-aspirin NSAIDs two or more times weekly were 0.67 (95% CI: 0.51-0.87) 
and 0.71 (95% CI: 0.52-0.97) compared with nonusers of each [981 . A hospital-based case-
control study reported ORs of 0.4 (95% CI: 0.2-0.8), 0.6 (95% CI: 0.4-1.0) and 0.6 (95% 
CI: 0.4-1.1) for proximal colon, distal colon, and rectal cancers, respectively, among 
recent NSAID users compared with nonusers. Another case-control study reported that, 
compared with nonusers, aspirin users had OR of 0.6 (95% CI: 0.5-0.8) and 0.8 (95% CI: 
0.6-0.9) for proximal and distal colon cancers, respectively [991. A cohort study found a 
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stronger effect of use of NSAIDs on proximal colon cancer than for distal colon or rectal 
cancer and the adjusted RRs among recent users with more than 12 months of cumulative 
use for proximal colon, distal colon, and rectal cancers were 0.48 (95% CI: 0.34-0.68), 
0.77 (95% CI: 0.55-1.08) and 0.81 (95% CI: 0.49-1.32), respectively [991. The potential 
anti-cancer effects of NSAIDs and aspirin may be exerted through the inhibition of COX 
and lipoxygenase (LOX) enzymes which play key roles in the metabolism of arachidonic 
acid and other polyunsaturated fatty acids. 
3 .1. 7. Hormone replacement therapy 
Several population-based case-control studies and cohort studies have found 
decreased risk of colon cancer among ever-users of hormone replacement therapy (HRT) 
in women [J00-1061. The Women' s Health Initiative (WHI) study conducted in the United 
States reported that relatively short-term use of estrogen and progestin was associated 
with a decreased risk (hazard ratio: 0.56 and 95% CI: 0.38-0.81) of CRC [I07J. A meta-
analysis of HRT and colon cancer in women showed a 15% decreased risk of colon 
cancer (RR: 0.85 and 95% CI: 0.73-0.99) for ever users of menopausal hormones versus 
non-users [1081• A recent nested case-control study showed a 66% decreased risk of CRC 
(OR: 0.34 and 95% CI: 0.15-0.79) among users of both oral contraception and HRT 
compared to non-users of both classes of hormone [1091. The inverse relationship between 
colon cancer and HRT may be a consequence of replacing the declining endogenous 
estrogen level and thus reducing the likelihood that the estrogen receptor (ER) gene may 
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be silenced by methylation [IIOJ. There is evidence showing that almost all colon cancers 
arise in cells in which the ER gene has been silenced [III]. 
3.2. Family history of colorectal cancer 
3 .2.1. Familial risk of colo rectal cancer 
Approximately 16-20% of patients with CRC have a fust-degree relative with 
CRC [II2J. People who have a family history of colon cancer in first-degree relatives 
(parents, siblings, children) are at 2-3 fold increased risk of CRC [IIJ-J ISJ and colon cancer 
[1 16•1171. In some cases, the connection may not be hereditary or genetic. Instead, cancers 
within the same family may result from shared exposure to an environmental carcinogen 
(cancer-causing agent) or from diet or lifestyle factors. The likelihood ratio of colon 
cancer in a first-degree relative was 23.0 (95% CI: 6.4-81.0) for patients without a 
personal history of cancer [II&J _ Family history of CRC may interact with environmental 
risk factors of colon cancer. For example, the case-control study conducted in northern 
Italy between 1992 and 1996 showed that compared to subjects with no family history of 
CRC and in the lowest tertile of risk score of environment factors (positive family history, 
high education, low occupational physical activity, high daily meal frequency, low intake 
of fibre, low intake of calcium and low intake of ~-carotene), the ORs of colon cancer 
was 2.27 (95% CI: 1.89-2.73) for subjects without family history and in the highest 
environmental risk factor score, 3.20 (95% CI: 2.05-5.01) for those with family history 
and low risk factor score and 7.08 (95% CI: 4.68-10.71) for those with family history 
high risk factor score [ 119]. 
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3.2.2. Microsatellite instability of colorectal cancer 
Microsatellite instability (MSI) is defined as a change of any length due to either 
insertion or deletion of repeating units, in a microsatellite within a tumour when 
compared to normal tissue (1201 • MSI does not describe a particular tumour phenotype but 
refers to the observation of instability at a given tumour. Five markers (two 
mononucleotide repeats and three dinucleotide repeats) are used to define and distinguish 
types of MSI CRC cases. CRC cases can be divided into high-frequency MSI (MSI-H) 
CRC cases if two or more of the five markers show instability (i.e., have insertion or 
deletion mutations), low-frequency MSI (MSI-L) cases if only one of the five markers 
show instability and microsatellite stable (MSS) cases if lacking apparent instability, i.e., 
none of the markers exhibit MSI. Approximately 60-70% of tumours fall into the group 
lacking MSI and the remaining tumours are nearly evenly split between the MSI-H and 
MSI-L groups [1201. 
3.3. Hereditary colo rectal cancer syndromes 
Genetic alterations play a role in the development of all colorectal malignancies. 
Two main genetic colorectal cancer syndromes are FAP and HNPCC [I2I-I23J which 
account for 1% and 4-7% of CRC cases respectively [?J_ 
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3.3 .1. Familial adenomatous polyposis 
F AP is an autosomal dominantly inherited disorder marked by the emergence of 
hundreds to thousands of colorectal adenomatous polyps during the second or third 
decade of life [121 -1231. Patients with this disorder have a strong predisposition for early 
CRC, as well as for other malignancies. In addition, several variants of the syndrome 
exist, namely Gardner syndrome, Turcot syndrome and attenuated adenomatous 
polyposis coli (APC). The incidence of F AP has been estimated to be approximately 
1/10,000 and men and women are equally affected [1241. 
F AP is an autosomal dominant disease with almost 1 00% penetrance by 40 years 
of age [1221• Mutations in the adenomatous polyposis coli (APC) gene are responsible for 
the syndrome. One allele with the mutated gene is inherited from an affected parent. An 
acquired (somatic) mutation in the other APC allele results in the development of 
adenomas. However, one third of cases arise from new germline mutations in the APC 
gene. The absence of a family history in these cases can delay diagnosis, sometimes until 
after colon cancer has developed. An APC gene mutation can be identified in 87% of the 
patients with the disorder [1251. 
3.3 .2. Hereditary nonpolyposis colorectal cancer 
HNPCC or Lynch syndrome, is the most common form of hereditary CRC [126•1271. 
HNPCC is inherited in an autosomal dominant fashion. Mutations in five DNA mismatch 
repair (MMR) genes are currently implicated in the pathogenesis of this disorder. Fifteen 
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per cent to 60% of families with the clinical diagnosis of HNPCC are found to have 
mutations in these genes; the mutation prevalence depends on features of the family 
history [1281• Other less commonly implicated genes are hPMSI, hPMS2, and hMSH6. 
The DNA mismatch repair proteins recognize and correct small sequence errors that 
occur during DNA replication. Mutations in both copies of a DNA mismatch repair gene 
lead to the accumulation of DNA sequence errors predominantly in segments of DNA. 
These segments of DNA contain multiple, short, repeated sequences known as 
microsatellites. When these errors occur in critical growth-regulatory genes, 
carcinogenesis may ensue. Tumours in patients with HNPCC characteristically 
demonstrate microsatellite instability (MSI) - the widespread expansion or contraction of 
these short sequences of DNA. In HNPCC, approximately 90% of CRCs and 80% of 
adenomas demonstrate rnicrosatellite instability [1 291. 
3.4. Diet and foods 
National and international studies have described associations between CRC and 
specific dietary habits [41 •1221. The 'Western' diet, generally characterized as high in 
animal fat, red and processed meats, and lower in fruits, vegetables and fibre content, has 
been linked to an increased risk of CRC. 
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3.4.1. Red and processed meats 
There is convincing evidence that consumption of red meats and processed meats 
are associated with risk of CRC [411• The term "red meat" refers to beef, pork, lamb and 
goat from domesticated animals, and "processed meat" refers to meats preserved by 
smoking, curing, or salting or by the addition of preservatives [4 11. Ham, bacon, pastrami, 
salami, sausages, bratwursts, frankfurters and hot dogs are examples of processed meats. 
Several cohort studies reported a significantly increased risk of CRC for the 
highest intake groups of red meat compared to the lowest [1 30-1341 • Meta-analysis on seven 
cohort studies showed a 43% increased risk of CRC (RR: 1.43 and 95% CI: 1.05-1.94) 
per time/week of red meat intake and a 29% increased risk (RR: 1.29 and 95% CI: 1.04-
1.60) per 100 g/day [411 • A recently published meta-analysis of 15 prospective studies 
further confirmed this increased risk (RR: 1.28 and 95% CI: 1.18-1.39) per 120 g/day of 
red meat intake [1351 • The potential mechanisms for the association of CRC and red meat 
consumption are that high temperatures in cooking (frying, grilling, and barbecuing) red 
meats cause acids and creatine to react together to form heterocyclic amines [1361• 
Incompletely burnt meats produce polycyclic aromatic hydrocarbons [1 371, and gut 
bacteria produce N-nitroso compounds, which are potentially carcinogenic [1 381• In 
addition, haem promotes the formation of N-nitroso compounds and also contains iron. 
Free iron can lead to production of free radicals and the condition of iron overload can 
also activate oxidative responsive transcription factors, pro-inflammatory cyctokines and 
iron-induced hypoxia signaling [1391. 
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Studies showed a significantly increased risk of CRC for the highest intake group 
of processed meat compared to the lowest [130' 140-1421 . The mechanism for the association 
of CRC with processed meat is that preservatives added to processed meat which may 
contribute to N-nitroso compound production and exposure. N-nitroso compounds are 
suspected mutagens and carcinogens [1431• Many processed meats contain high levels of 
nitrites. Similar to red meat, some processed meats may be cooked at high temperatures, 
resulting in the production of heterocyclic amines and polycyclic aromatic hydrocarbons. 
In addition, people who consume large amounts of meat and processed meats tend 
to consume less poultry, fish and vegetables [411 • So it is conceivable that the relations 
between red meat and processed meat and CRC risk could possibly be due, at least in part, 
to low intakes of these other foods. 
3 .4.2. Fish and shellfish 
High fish and shellfish intake may be associated with a decreased risk of CRC. 
Several studies showed significantly decreased risk of CRC for the highest intake group 
of fish and/or shellfish compared to the lowest [141' 1441• The European Prospective 
Investigation into Cancer and Nutrition (EPIC) study, which prospectively followed 
478,040 men and women from 10 European countries who were free of cancer at 
enrolment between 1992 and 1998, found CRC was inversely associated with intake of 
fish, suggesting a 31% decreased risk (RR = 0.69 and 95% CI: 0.54-0.88; ~rend < 0.001) 
for higher than 80 g/day versus lower than 10 g/day [1411. Another study, in which 14,727 
women aged 34-65 years old were enrolled at mammographic screening clinics in New 
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York and Florida in 1985-1991, found that there was a progressive decline in risk of CRC 
with increasing intake of fish and shellfish [1441. There was a 51% decreased risk of CRC 
for 41h quartile versus 1st quartile of fish and shellfish intake (RR: 0.49 and 95% CI: 0.27-
0.89). Fish n-3 polyunsaturated fatty acids may protect against cancer [1451. Increased 
concentrations of short-chain fatty acids (SCF As) and eicosanopentaenoic acid (EPA) 
may contribute to reduced risk of CRC [146•1471 by modifying signaling pathways [148"1511. 
3 .4 .3. Foods containing animal fats 
Animal fats include tallow, lard and suet, produced as part of the slaughtering 
process, and butter [41 1. There is limited evidence suggesting that animal fat increases risk 
of CRC [4 11, but one study showed significantly increased risk of colon cancer only with 
increased intake of animal fats (beef, pork, or lamb) [1301• The study reported a 89% 
increased risk of colon cancer (RR: 1.89 and 95% CI: 1.13-3.15) for the highest quintile 
groups of animal fats compared to the lowest in women [1 301. The potential mechanism 
may be because animal fats reflect the consumption of energy-dense diets, which increase 
the risk of obesity. Obesity influences the level of circulating leptin which has been 
associated with CRC [1521. 
3 .4 .4. Foods containing sugars 
These is limited evidence suggesting that sugars may increase risk of CRC [411. 
Foods containing sugars include refined and other added sugars, honey, fruit juices and 
syrups. Case-control studies showed significantly increased risk of CRC with increased 
intake of sugars in foods [1 53•1541• The study conducted in Italy showed a 43% increased 
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risk of CRC (OR: 1.43 and 95% Cl: 1.19-1.73) for the highest versus lowest intake 
quintile of refined sugars [1531. The study conducted in Belgium showed a 25% increased 
risk of CRC among "heavy consumers of carbohydrates" compared to "light consumers 
of carbohydrates" [1 541 . Cohort studies reported a 37% increased risk of CRC for the 
highest versus the lowest quintile of sucrose or fructose (RR: 1.3 7 and 95% CI: 1.05-1. 78; 
P = 0.008) in men [1551. Animal studies found sucrose and fructose are associated with 
increased colonic proliferation whereas these sugars may interfere with levels of blood 
glucose and/or triglycerides directly or though hormones like insulin [1561. 
3.4.5. Milk and dairy products 
CRC risk may decrease with increased intake of milk and dairy products. There is 
evidence that milk probably protects against CRC [4 11 . Cohort studies showed a 
significantly decreased risk ofCRC with increased intake of milk [134' 1571. A recent pooled 
analysis from 10 cohort studies found that milk intake was related to a significant reduced 
risk of CRC of 0.78 (95% Cl: 0.69-0.88) for the highest intake group compared to the 
lowest [1581. Milk may reduce CRC risk because of its calcium content. Calcium is an 
important micronutrient, and it has been demonstrated that intracellular calcium directly 
influences cell growth and apoptosis [1591. Calcium may also bind to bile and fatty acids, 
preventing them from damaging the intestinal lining [1601. 
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3.4.6. Dietary calcium and calcium supplements 
Calcium probably protects against CRC [411 . Both cohort and case-control studies 
showed that dietary calcium reduced the risk of colon cancer [161 ' 1621. Cohort studies 
showed significantly decreased risk of CRC for calcium supplements compared to none 
[1631. Another study found a 24% decreased risk ofCRC (RR: 0.76 and 95% CI: 0.56-0.98) 
for the highest intake group of calcium supplements compared to the lowest [1641 . A 
pooled analysis found a 22% decreased risk for the highest intakes of dietary and 
supplemental sources and a larger effect for total calcium for combining dietary and 
supplemental sources (RR: 0.78 and 95% CI: 0.69-0.88) than for calcium from food 
sources (RR: 0.86 and 95% CI: 0.78-0.95) compared to the lowest intake [1581 . A double-
blind, placebo-controlled intervention trial showed that calcium supplementation was 
associated with a statistically significant 15-20% reduction in the incidence of 
metachronous colorectal adenomas [1651. Calcium may direct growth-restraining and 
differentiation- and apoptosis-inducing actions on normal and tumour colorectal cells [1591. 
Animal studies found that increased dietary calcium intake induced apoptosis in normal 
mouse distal colonic epithelium without affecting cell proliferation compared to controls 
[1661. This observed effect of calcium on apoptosis may result from precipitation of toxic 
or cytolytic fecal bile acids or fatty acids. Calcium may have an indirect effect on the 
colonic mucosa by precipitating bile acids and may thus inhibit their cytoxic effects [1 671. 
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3.4.7. Foods containing dietary fibre 
Foods containing dietary fibre include both foods naturally containing the 
constituent and foods having the constituents added which probably protect against CRC 
[411. Foods high in fibre include vegetables as well as grains. A combined analysis of 13 
case-control studies found a reduction in CRC risk with increasing intake of dietary fibre 
[1681• Cohort studies showed a 25% decreased risk of CRC (Adjusted OR: 0.75 and 95% 
CI: 0.59-0.95) for the highest versus lowest quintile of fibre intake [1691• Meta-analysis of 
eight cohort studies showed a 10% reduction in the CRC risk (RR: 0.90 and 95% CI: 
0.84-0.97) for intake of per 10 g/day [411. The effect of fibre on CRC may be because fibre 
dilutes faecal contents, decreases transit time and/or increases stool weight [1701. 
3.4.8. Vegetables and fruits 
There is limited evidence suggesting that non-starchy vegetables, garlic, fruits and 
foods naturally containing folate protect against CRC [411• Several cohort studies showed 
a significantly decreased risk of CRC for the highest intake groups of non-starchy 
vegetables compared to the lowest [171-1741. Cohort studies have showed significantly 
decreased risk of CRC with increased intake of fruits [175•1761 . The population-based 
prospective mammography screening study in women conducted in central Sweden found 
that total fruit and vegetable consumption was inversely associated with CRC risk and 
individuals who consumed fewer than 1.5 servings of fruit and vegetables per day had a 
RR of developing CRC of 1.65 (95% CI: 1.23-2.20) compared with individuals who 
consumed more than 2.5 servings [1751 . A study among the elderly conducted in Japan 
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found no evidence of a protective effect of any dietary variables on CRC, but a reduced 
risk of all sites combined and of the colon for combined intake of all vegetables and fruits, 
fruit intake alone and dietary vitamin C P75•1761. 
Studies examining the relationship between vegetable and fruit consumption and 
colon cancer risk reported modest decreased risk in association with higher consumption 
[lt 7•177•1781. Most case-control studies of colon cancer and vegetable and fruit consumption 
reported some degree of reduced risk with higher consumption of at least one category of 
vegetable or fruit [1781• Decreased risks of colon cancer have been particularly consistent 
for raw vegetables, green vegetables, and cruciferous vegetables. A meta-analysis of 
sixteen case-control studies of the relationship between vegetable intake and development 
of colon cancer found a combined OR of 0.48 (95% CI: 0.41-0.57) for highest versus 
lowest quintiles of consumption [1681. Several cohort studies also showed a statistically 
significant decreased effect of vegetables on the risk of developing CRC [1 71 -1741. Cohort 
studies have illustrated that fruit intake significantly decreases the risk of developing 
CRC [176•1791. Fruits, in particular citrus fruits, are sources of vitamin C and other 
antioxidants such as phenols and flavonoids as well as potentially bioactive 
phytochemicals. Vitamin C traps free radicals and reactive oxygen molecules, protecting 
against oxidation damage [411 • It also regenerates other antioxidant vitamins such as 
vitamin E [1801. Vitamin C also inhibits the formation of carcinogens and protects DNA 
from mutagenic attack [1811• Beta-carotene and other carotenoid antioxidants are also 
found in fruits . Some fruits contain high levels of flavonoids, including apples and 
grapefruit. Flavonoids have antioxidant effects and can also inhibit carcinogen-activating 
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enzymes. Flavonoids can also alter the metabolism of other dietary agents. For instance, 
quercetin, directly inhibits expression of an enzyme that helps to metabolise toxins, 
resulting in decreased DNA damage [1821. The phytochemical antioxidants contained in 
fruits could reduce free-radical damage generated by inflammation. Studies reported that 
apples given in physiological quantities inhibited carcinogen-induced mammary cancer in 
rodents in a dose-response manner [1831. Fruits and vegetables may reduce risk of CRC 
because these foods naturally contain folate, which plays an important role in the 
synthesis and methylation of DNA [1 841. Cohort studies that investigated dietary folate 
found a significantly decreased risk of CRC for the highest intake group compared to the 
lowest [1851. Meta-analysis showed a summary effect estimate (RR) of 0.84 (95% CI: 
0.76-0.93) per 100 Jlg /day [185-1881. One study of serum folate levels also showed a 
significantly decreased risk of CRC for the highest intake group compared to the lowest 
[189] 
Garlic is one type of allium vegetable. Studies showed significantly decreased risk 
for the highest consumers of garlic [1901. Preclinical evidence with model carcinogens and 
transplantable tumours supports an anticancer effect of garlic and some of its allyl 
sulphur components. Animal studies demonstrate that allyl sulphides effectively inhibit 
colon tumour formation and also can inhibit cell growth in the laboratory [191-1941. 
3.5. Lifestyle factors 
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3.5.1. Physical activity 
Physical activity can be classified into occupational (at work), household (in the 
home), transportational or recreational (leisure). The evidence that physical activity of all 
types protects against colon cancer is convincing [411. While three studies showed a 
significantly decreased risk of CRC for the highest total physical activity groups 
compared to the lowest (1 95-1971, two studies observed the decreased effect of total physical 
activity on CRC risk in men [81 •1981. Some studies showed a significantly decreased risk of 
colon cancer for the highest occupational activity groups compared to the lowest [199•2001. 
A number of studies have showed significantly decreased risk of colon cancer for the 
highest recreational physical activity groups compared to the lowest [81•200-2051. Studies 
which investigated the relationship between colon cancer and frequency of physical 
activity found significantly decreased risk for the highest frequency of physical activity 
compared to the lowest in men [81 •1981 . Several studies also found significantly decreased 
risk when comparing high with low intensity of physical activity [81 •2061. It has been 
estimated that physical activity of two hours or more per week can significantly reduce 
the risk of developing CRC [851. Individuals with high levels of activity throughout their 
lives were found to have the lowest risk [117•1781. Inactivity tends to slow the speed at 
which food contents pass through the colon and may also cause constipation, both of 
which increase the length of time the colon lining is exposed to colonic contents. There 
are a number of other mechanisms by which physical activity may protect against CRC. 
These include a reduction in insulin resistance, the beneficial effect of physical activity 
on body fatness, as well as reduced gut transit time [207•2081. 
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3.5.2. Body fatness 
The evidence that greater body fatness and abdominal (central) fatness are 
associated risk of CRC is convincing [41'2061. Body fatness is commonly estimated using 
the body mass index (BMI), a measure of weight adjusted for height and is calculated as 
weight in kilograms divided by height in metres squared (kg/ m2 ) [2091• Many cohort 
studies showed a significantly increased risk of CRC with increased body fatness [411. 
Meta-analysis of 28 cohort studies showed a 3% increased risk of CRC (RR: 1.03 and 
95% CI: 1.02-1.04) with one unit increase of BMI and a larger effect on rectal than colon 
cancer [411 . A report published in 2002 by IARC evaluated all available studies on obesity 
(BMI>30 kg/m2) and CRC risk and found that obesity increased CRC risk and elevated 
risks in men and women with risks being stronger for men than women [2101 . Cohort 
studies show that there was about a 50-100% higher risk in the highest quartile of BMI 
compared to with the lowest quartile [2101. Although BMI is a commonly used proxy for 
fatness, it does not reflect how fat is distributed in the body and it has also been criticized 
for not accounting for muscle mass. Thus some studies have examined the impact of 
waist circumference as a proxy for abdominal fatness, on risk of CRC. Several studies 
showed a significantly increased risk of CRC with increased waist circumference [204•2 11-
2141. Meta-analysis on four cohort studies showed a 5% increased risk of CRC (RR: 1.05 
and 95% Cl: 1.03-1.07) per 2.5 em (1 inch) increase of waist circumference [4 11 . Some 
studies found increased risk of CRC with increased waist to hip ratio [204•2 11 -2151; meta-
analysis on five cohort studies showed a 30% increased risk of CRC (RR: 1.30 and 95% 
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CI: 1.17-1.44) with 0.1 increment of waist to hip ratio [411 . There is evidence to suggest 
that waist to hip ratio (WHR) appears to be superior indicators of obesity than BMI. One 
recent study conducted among men reported a 2.1-fold increased risk of colon cancer for 
men comparing a high WHR to those with a low WHR, whereas a high BMI (>29.2 
kg/m2) conferred a 1.7-fold increased risk of colon cancer compared to a BM1<24.8 
kg/m2 [2161. One prospective study found a 2-fold elevated risk for CRC among men and 
women with a waist size greater than 99.1 em compared to a waist size less than 83.8 em 
[2121. There are several potential mechanisms by which body fatness may increase the risk 
of CRC. Abdominal fatness increases the level of insulin resistance and the pancreas 
compensates by increasing insulin production which increases the risk of colon cancer 
[2071 . Obesity is characterized by a low-grade chronic inflammatory state [2171. Adipocytes 
produce pro-inflammatory factors and obese individuals have elevated concentrations of 
circulating tumour necrosis factor (TNF)-alpha [2181, interleukin (IL)-6 and C-reactive 
protein compared with lean people [2191, as well as of leptin which also functions as an 
inflammatory cytokine [2201. Chronic inflammation can result in DNA damage and cancer 
promotion because a chronic inflammatory environment can increase proliferation and 
differentiation, inhibit apoptosis and induce angiogenesis [2211. 
3.5.3. Adult attained height 
The evidence that the factors that lead to greater adult attained height increase the 
risk of CRC is convincing [411. Cohort studies showed significantly increased risk of CRC 
with increased attained height [200•204•222-2251. Meta-analysis of 12 cohort studies reported a 
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9% increased risk of CRC (RR: 1.09 and 95% CI: 1.06-1.12) per 5 em increase in height 
[411. Adult height is unlikely to directly modify the risk of CRC. It is a marker for genetic, 
environmental, hormonal and nutritional factors which affect growth during the period 
from preconception [411 . 
3.5.4. Tobacco smoking 
A total of 60 epidemiological studies have reported an relationship between 
tobacco smoking and CRC in the last three decades, but few were specifically designed to 
study the effects of tobacco smoking, and only a few found a significantly increased risk 
for CRC among smokers. Of 16 prospective cohort studies conducted in the United States, 
10 in Europe and three in Japan, most showed a small elevated risk for colon cancer, 
rectal cancer or CRC among smokers. Only a few studies showed that former and/or 
current smokers exhibit a significantly increased risk of 1.2-1.4 for colon cancer [226'2271 
rectal cancer [226-2301 or CRC P98,231 ,232l, relative to those who have never smoked. Of all 
cohort studies, one showed a statistically significantly decreased risk among smokers [2331. 
Many case-control studies which examined the association between active 
smoking and cancer of the colon and rectum were conducted in European countries [234-
2421, in Asia [243-2521 and in the United States [58'253-2591. Of these case-control studies only 
a few showed statistically significant increased risk among former or current smokers or 
ever-smokers [255,257,2601. There are studies reporting a statistically significant reduction in 
risk for cancer of the colon [2461 and rectum among smokers [26 11. 
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A dose-response relationship between smoking and CRC has been identified in 
some studies, but the association seems to be inconsistent by subgroups such as subsites 
of CRC and gender. Several cohort studies reported statistically significant dose-response 
trends with amount smoked daily for colon cancer [226•2271, rectal cancer [226•227•2291 and 
CRC [23 1•2321. Some case-control studies have also shown a statistically significant 
positive trend of increasing risk with increasing number of cigarettes smoked daily for 
colon cancer [256•2571, rectal cancer [2561 and CRC [2501 . In another two studies, this pattern 
of increasing risk was apparent only in men [252•2551 but not among women in the same 
study. However, the relationship between CRC and amount of smoking is somewhat 
inconsistent. For example, studies showed a statistically significant trend of increasing 
risk with increasing pack years of smoking [227•23 1•2321, but another study indicated this 
association was limited to those who started smoking before the age of 30 years [2621. 
The relationship between smoking and the risk of colon and rectal cancer was 
investigated separately in the majority of previous cohort and case-control studies and 
risk patterns are generally consistent between colon and rectal cancer in these studies [2631. 
However, some studies found inconsistent results of the relationship between subsites of 
CRC and smoking. While several studies showed the effect of smoking was more 
apparent for rectal cancer than for colon cancer [246-249•256•2641, a few studies reported a 
stronger effect of smoking on colon cancer than rectal cancer [265•2661. 
Several previous studies, which explored the relationship between cigarette 
smoking and microsatellite unstable colon cancer or CRC provide inconsistent results. 
one case-control study found that cigarette smoking was associated with MSI-H CRC [2671. 
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One case-control study conducted in the United States found that cigarette smoking 
increased the risk of both colon cancer with MSI-positive and MSI-negative compared to 
controls, but the risk was significantly higher for MSI-positive tumour than MSI-negative 
tumour [2681. Another case-control study also found that the risk ofMSI-positive CRC was 
increased in patients who smoked [2691, but other could not confirm this [2701. 
Previous studies by gender are somewhat inconsistent. Several cohort studies 
have reported that the association between smoking and CRC is stronger in men than in 
women [198•228•271 1. However, one study reported a significantly increased risk associated 
with smoking only in women and not in men [2721 and another showed the association 
between smoking and CRC was equally strong in both sexes [2311. While two case-control 
studies showed smoking was a risk factor only in men [252•2551, three showed no clear 
gender differences [257-2591. This thesis found the effect to be stronger among males than 
females. 
In some studies, drinking alcohol is considered as a confounder of the relationship 
between CRC and smoking and its potential confounding effect is adjusted for 
[226•265•273•2741. Few studies have evaluated whether the association between smoking and 
CRC was modified by alcohol consumption even though in a study that examined the 
joint effect of smoking and drinking, a significant increase in risk of polyps was found 
only among subjects who were both smokers and drinkers [2751. 
Several studies examined the combined effects of smoking and body weight on 
colon or rectal cancer [256•2571 . One study which investigated whether the association 
between smoking and CRC was modified by body weight found the risk of rectal cancer 
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was significantly greater among heavier women [2561. Another study found that smokers 
with a high BMI displayed higher risk of colon cancer than those with a lower BMI [2571. 
There are methodological weaknesses in many previous studies. Inadequate 
adjustment for various potential confounders (e.g. alcohol, physical activity, body size, 
dietary factors) or unidentified confounders could account for the small increase in risk 
found with smoking in some studies. For example, smokers are more likely than non-
smokers to be physically inactive [2761, to use alcohol, to have poorer dietary habits (e.g. 
lower consumption of fruits and vegetables and higher consumption of fat and meat) and 
they are less likely to be screened for CRC [2771. Each of these factors, in turn, is 
positively associated with CRC risk [11 71. Thus, if these potential confounders are 
inadequately controlled for or not controlled for in the analysis, then smoking may appear 
to increase the risk for CRC even if it has no direct effect on risk. A few potential 
confounders were adjusted for in most of the cohort studies. One third of the published 
studies considered only age or other relevant demographic factors [11 7•226•227•23 1•271•278-2821. 
Some studies adjusted only for demographic factors and alcohol use [226•265•2741. Less than 
half of the studies considered two or more of the potential confounders mentioned above 
[198,206•227•231•232•262•266•281 -2861. The extent to which residual effects of potential confounders 
can explain the small increase in risk associated with smoking cannot be determined for 
certain. In some studies, adjustment for alcohol [2731 and other risk factors [2621 
substantially reduced the magnitude and the significance of the effect of smoking. In 
other studies, the risk estimate associated with smoking was reduced by up to 10% 
although the association remained statistically significant [23 1•2321. None of the prospective 
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studies has evaluated whether the association between smoking and CRC was modified 
by other characteristics such as alcohol intake, body weight, and others. In about half of 
the case-control studies, demographic factors and at least two of the potential 
confounders discussed above were adjusted for in the analyses [236•237•240•242•250•25 1•255-
259'264'287'2881. Few studies have examined the association of tobacco smoking with other 
factors such as obesity and alcohol intake on CRC. 
3.5.5. Alcohol intake 
In 1957, Stocks first reported a marginally elevated risk of developing CRC 
among daily beer drinkers compared with abstainers [2891. Subsequently, this association 
with cancers of the large bowel has been explored in other studies. The measures of 
alcohol drinks include the number of alcoholic drinks per time period and ethanol intake 
in grams or milliliters per time period. The number of drinks is less likely to be precise 
because the size and strength of each drink is unknown. However, previous studies 
showed increased risk of CRC with increased consumption of total drinks and ethanol. 
For example, some studies found significantly increased risk of CRC for the highest 
intake group of total alcohol drinks compared to the lowest [249•273•290•29 11. Several other 
studies showed significantly increased risk of CRC for the highest intake group of 
ethanol compared to the lowest [198•200•226•249•292-2941. 
Some studies investigated the association of subsite of CRC with types of 
beverage. For example, the National Health and Nutrition Examination Survey 
(NHANES) I Epidemiologic Follow-Up Study (NHEFS) which includes a prospective 
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cohort population representative of the general United States population which consisted 
of 10,220 participants prospectively followed over a decade, showed that the 
consumption of one or more alcoholic beverages a day at baseline was associated with 
approximately 70% greater risk of colon cancer (RR: 1.69 and 95% CI: 1.03-2. 79), with a 
strong positive dose-response relationship [2951. This association appeared to be 
exclusively related to daily drinking of one or more drinks of liquor (RR: 2.48 and 95% 
CI: 1.66-4.53). Additionally, an increased risk of 73% was observed for more than 34 
years of alcohol drinking history compared with nondrinkers (RR: 1. 73 and 95% CI: 
1.08-2.78). Other studies found that consuming more than seven alcoholic drinks a week 
increased the risk of developing CRC by 72% [2961. Pooled analysis of primary data from 
eight cohort studies in five countries in North America and Europe, which consisted of 
489,979 women and men with no history of cancer other than non-melanoma skin cancer 
at baseline, found that increased risk for CRC was limited to persons with an alcohol 
intake of 30 g/d or greater [2971. Compared with nondrinkers, the pooled multivariate 
relative risks were 1.16 (95% CI: 0.99-1.36) for persons who consumed 30-44 g/d and 
1.41 (95% CI: 1.16-1.72) for those who consumed 45 g/d or greater [2971. However, the 
epidemiologic findings on the relationship between alcohol consumption and CRC are 
inconsistent. Many studies have not reported any statistically significant increased effects 
of alcohol intake on CRC. For example, among twenty cohort studies reporting 
marginally increased risk for the highest intake group of total alcoholic drinks when 
compared to the lowest [1 71,186,187,199,204,214,249,265,273,283,290,298-306]' only four studies showed 
a statistically significant increase [249•273•290•2911. Two studies reported no effect on risk [3071 
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and three studies reported decreased risk; none was statistically significant [292•308-3 111. The 
inconsistencies may be the consequence of small sample sizes, differences in control 
groups or study methods, or differences in preferred beverages between the sexes and 
across countries. These inconsistencies could also be possibly due to population 
differences in susceptibility to, and metabolism of, alcohol. 
Several studies showed that the effects of alcohol consumption on CRC risk 
varied by subsite of CRC and MSI status [3121. When comparing MSI+ to MSI- tumours 
this study observed that long-term alcohol consumption increased the probability of 
having a tumour with MSI (OR for MSI-positive vs. MSI-negative colon cancer for 
alcohol: 1.6 and 95% CI: 1.0-2.5). The likelihood of having MSI in the tumour from the 
combined effects of high alcohol consumption and smoking cigarettes showed a 70% 
excess in risk from the additive model l312l . 
3 .6. Research questions 
In general, CRC has been considered an outcome of interactions between several 
genetic and environmental factors. However, studies exploring the relationships between 
CRC and some of these factors have been inconclusive. This thesis focuses on the 
relationship between CRC and tobacco smoking and alcohol consumption. The primary 
analysis was based on the data in the Newfoundland and Labrador population-based case-
control study of CRC and the relevant methodological issues also constitute one 
component of this thesis. Four specific objectives in this thesis are: (a) assessing non-
participation bias; (b) assessing reporting bias of lifetime tobacco smoking and alcohol 
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consumption; (c) investigating the effects of tobacco smoking on CRC incidence; (d) 
investigating the effects of alcohol intake on CRC incidence. 
3.6.1. Non-participation bias of cases and controls 
A trend of decreasing response rates in population surveys is a growing concern 
in epidemiological research due to the increased likelihood of non-response bias [3131. 
Low response rates may compromise the generalizability of population survey data [3141, 
especially when the percentage of non-respondents is large and when non-respondents 
differ greatly from respondents [3151. Non-response is an important source of inaccurate 
reporting of alcohol and illicit drug use in population surveys [31 3'3161. The resulting 
underestimates of consumption could change the association between risk variables and 
prevalence [3131. Unforturiately, non-response bias is usually difficult to determine 
because researchers rarely have information about non-respondents. Few studies on non-
response bias in surveys in the alcohol and drug field have provided a clear answer to the 
issues raised. While some studies found no significant non-response bias in estimating 
population attributes [317-3191, others indicated that bias exists [3201 and there is a serious 
chance of bias when a response rate is below 70 percent [3211. The degree of non-response 
bias is likely related to the focus of the study [3201. Several studies about direction of non-
response bias in surveys provide conflicting results. Some studies showed that non-
participants were more likely to abstain from alcohol than participants [322'3231, whereas 
others indicated non-participants were more likely to drink and were more likely to be 
heavier drinkers than participants [3241. In the population-based case-control study of CRC 
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conducted in NL, of 1,171 eligible CRC cases, 702 completed and returned the 
questionnaires, a participation rate of 60%. Of 1,602 controls of meeting eligibility 
criteria, 717 completed questionnaires were returned and the participation rate was 45%. 
Therefore, non-participation is the main source of potential bias for assessing exposure to 
risk factors for developing CRC such as cigarette smoking and alcohol use in this 
population. One of the objectives of the analyses presented in this thesis was to assess the 
extent and direction of non-response bias operating in the NL population-based case-
control study of CRC and the degree of its impact on prevalence estimates reported to 
date. 
3.6.2. Reporting bias of tobacco smoking and alcohol consumption 
The population-based case-control study of CRC conducted among NL residents 
to investigate the relationship between developing CRC, tobacco smoking and alcohol 
intake were based on self-reporting of participants. It is a concern, especially in the 
context of case-control studies, when cases and controls are asked about exposure in the 
past. Recall bias is a possibility in any case-control study that uses an anamnestic 
response, since the cases and controls, by definition, are people who differ with respect to 
their disease experience and this difference may affect recall [3251. The accuracy of recall 
is usually related to the amount of time elapsed between the exposure and the recall [3261. 
Lifetime measures might be inaccurate because of the concern about the accuracy of 
long-term recall after 18 years [3271. For a variety of reasons, including issues of social 
desirability or sensitivity, subjects may not be willing to report an exposure accurately. 
When researchers gather baseline characteristic data, subjects may underestimate the 
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number of cigarettes they smoke or amount of alcohol they drink [3281 . Errors in recall of 
these past exposures result in misclassification of exposure statUs, thus biasing the results 
of the study. If the recall error differs between cases and controls, the misclassification is 
said to be differential; if the recall error is of similar magnitude, the error is said to be 
non-differential. Recall bias resulting from inaccurate recall of past exposure is perhaps 
the most often cited type of exposure identification bias. 
The bias caused by differential misclassification can either exaggerate or 
underestimate an effect [3251. Differential misclassification bias can lead either to an 
apparent association even if one does not really exist or to an apparent lack of association 
when one does exist [3281 . If the true RR or OR is close to 1.0, a non-differential 
misclassification may completely mask the association. Lifetime measures of alcohol 
consumption have been available for as much as a quarter century [3291. Several studies 
have found substantial discrepancies between alcohol consumption estimates based on 
survey data and those derived from sales data. Per capita consumption estimates derived 
from survey-generated self-reports of drinking behaviours have tended to yield estimates 
of per capita consumption at between 40% and 60% of the results obtained from sales 
data [3301. Lifetime alcohol drinking and tobacco smoking have been used to investigate 
the effect of alcohol consumption on chronic conditions such as cancer in case-control 
studies. However, few studies have been conducted to investigate the accuracy of self-
reporting lifetime alcohol intake and tobacco smoking. 
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3.6.3. Tobacco smoking and colorectal cancer 
While previous studies showed that incidence of CRC has been associated with 
lifestyle risk factors including dietary factors [33 1•3321, and physical inactivity [2041, studies 
on the relationship between CRC and tobacco use have been conflicting. Studies that 
found an association of CRC incidence with tobacco smoking showed that development 
of CRC might have been associated with specific types of tobaccos. For example, some 
studies found greater risk of developing CRC associated with smoking cigars and pipes 
but not smoking cigarettes [255,333•3341. Tobacco smoking might also affect subsites of the 
bowel. A study conducted in Hong Kong showed that cigarette smoking was related to 
rectal cancer risk but not to colon cancer risk [3351, but several studies have also shown a 
higher risk for colon cancer among cigarette smokers, especially among those with very 
long smoking histories [336-3381. The effect of tobacco use on CRC in the Canadian 
population may differ from that in other countries because Canadian tobacco brands and 
hence tobacco composition, may differ from those in other countries [339•3401. In Canada, 
only one study specifically on tobacco smoking and CRC has been carried out. This 
Montreal study did not provide any evidence for an association between tobacco smoking 
and CRC [3391 but cannot be generalized to other provinces such as NL where the 
population shows different lifestyle and genetic characteristics [257•340-3421. Therefore, to 
explore whether tobacco use is associated with the risk for CRC, whether different 
tobacco types influence risk differently, and whether tobacco is associated with cancer in 
specific parts of the bowel and whether other characteristics such as sex, survival status, 
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familial risk, drinking status, obesity and microsatellite instability (MSI) influence risk, 
further studies on the relationship between tobacco smoking and CRC are required. 
3.6.4. Alcohol consumption and colorectal cancer 
As described in Section 3.5.5., there are some limitations in studies that have 
previously examined relationship between CRC risk and alcohol consumption. For 
example, some studies included only one measure of alcohol consumption at baseline and 
could not investigate lifetime alcohol consumption, alcohol consumption at younger ages, 
or changes in alcohol consumption during follow-up [2971 . A further issue is whether the 
effects reported elsewhere can be demonstrated in Canada since almost all studies have 
been conducted in other countries and the alcohol content in alcoholic beverages made in 
Canada differs from that in other countries [3431. Canada has had the highest incidence rate 
of CRC in the world and NL has had the highest incidence rate in the country [9,3421. 
However, only one study on alcohol and CRC incidence has been carried out in Canada 
and that was done among men in Montreal, Quebec. The fmdings of this study cannot be 
generalized to other Canadian populations such as NL. One reason is that the relatively 
isolated community of NL exhibits different lifestyle and genetic characteristics from 
those observed in other parts of Canada [344l. For example, alcohol drinking or heavy 
drinkin I . h. h . NL th . h C d" . [345 346J b g preva ence IS Ig er m an m ot er ana Ian provmces ' , ut no 
studies have been conducted to investigate the effect of alcohol intake on CRC in the 
general population and subgroups in NL. Studies conducted in other populations showed 
that cigarette smoking [41 '2631 and obesity l347l may play a role in increasing CRC risk. 
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Historically, there has been a relatively high prevalence of tobacco use in NL [348-3501, and 
the province also has the highest prevalence of obesity in men and women (33.3% and 
34.5%) when compared with the prevalence reported for Canada as a whole l3501. 
However, there are no reports in the literature to investigate the combined effects of 
alcohol consumption, cigarette smoking and obesity on CRC risk. 
Further studies need to be conducted in this population to explore whether or not 
alcohol intake is associated with the risk of developing CRC, whether different alcoholic 
beverages influence risk differently, and whether alcohol is associated with cancer in 
particular parts of the bowel and whether other characteristics such as sex, survival status, 
familial risk, smoking status, obesity and microsatellite instability (MSI) influence risk. 
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Chapter 4 Research methods 
4.1. Data sources 
This thesis is based on several data sources: a) data from population-based case-
control study of CRC in NL; b) data of the CCHS 1.1 and CCHS 3.1 ; c) sales data of 
alcoholic beverages; d) wholesale sales data of tobacco; and e) Statistics Canada 
population data. The study on the relationship between tobacco smoking and alcohol 
consumption and CRC, as well as the study on non-participation bias, were based on the 
data of the case-control study of CRC, which included the demographic and clinical 
information of 1,171 eligible CRC cases identified from the Newfoundland Cancer 
Registry (NCR) who consented to participate in the study of CRC, and the demographic 
information of 1,602 eligible controls randomly selected from the NL population who 
consented to participate in the study of CRC. The analyses on the bias of self-reported 
tobacco smoking and alcohol consumption was based on the data of the case-control 
study, data concerning tobacco and alcohol sales, population data obtained from Statistics 
Canada and Health Canada, and data of the two cross-sectional surveys, CCHS 1.1 and 
3.1 , obtained from Statistics Canada. 
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4.1.1. Data of the case-control study of colorectal cancer 
4.1.1.1. Introduction to the case-control study 
Case-control studies are particularly useful in the evaluation of potential risk 
factors for diseases of long latency such as cancer [35 1 •3521. The major strengths of a case-
control study are that it can simultaneously evaluate many causal hypotheses, permit the 
evaluation of interaction in which two or more causes of the disease modify the strength 
of one another, permit the evaluation and control of confounding, and contribute rich 
information compared to a cohort study because of the large number of ill persons 
observed in a case-control study [3531. Additionally, case-control studies are often a 
relatively inexpensive type of epidemiological study, usually conducted by small teams 
or individual researchers in single facilities. They can be done in less time and require 
fewer participants than prospective studies. The current thesis, which explores the 
relationship between CRC and tobacco smoking and alcohol consumption in NL, is a 
component of a large study on CRC conducted in NL and Ontario (ON) by the Canadian 
Institute of Health Research Team in Interdisciplinary Research on Colorectal Cancer 
(TIRCRC, Principal Investigator: John R. McLaughlin) which consists of health 
researchers throughout the provinces of ON and NL who are conducting serial linked 
CRC studies that involve a wide range of scientific disciplines (details on the project at: 
http://www.mshri.on.ca/colorectalcancer/). The design was used to identify risk factors, 
including tobacco smoking and alcohol consumption, which may contribute to 
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developing CRC by comparing the exposures in a group randomly selected from the NL 
population who had not had CRC when selected (see Figure 2). 
The NL population-based case-control study of CRC collected information on 
tobacco smoking and alcohol consumption, and relevant epidemiological factors from 
cases and controls and blood samples from CRC cases. The database of the case-control 
study also stored demographics of all eligible cases identified in NCR and consenting, 
participating controls were selected randomly from the NL population. Eligible cases 
were NL residents between 20 and 74 years old, diagnosed with CRC between 1999 and 
2003, with histologically confmned primary adenocarcinoma of the colon or rectum. 
Controls were randomly selected from the general population within the same five year 
range and sex as cases. Population controls were contacted by telephone using random 
digit dialing (RDD). Data collection was performed under the auspices of the Clinical 
Epidemiology Unit and Health Research Unit of Memorial University of Newfoundland. 
The study was under the supervision of the two principal investigators (Patrick Parfrey 
and Ban Y ounghusband). Telephone interviews were also adapted, given the literacy 
level of certain parts of the population. In rare instances, when telephone contact could 
not be made, data were collected with personal interview. A detailed description of the 
recruitment of controls has been reported elsewhere [3541. 
4.1.1.2. Ethics review of this thesis 
The study is one component of the Interdisciplinary Research on the Determinants, 
Impact and Control of Colorectal Cancer (IRDICC), a population-based study in ON and 
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NL funded by the Canadian Institute for Health Research (the principal investigator: John 
Ross McLaughlin; the period from: 2006-04-01 to: 2011-03-31). The Ethics Review 
Board ofthe Memorial University ofNewfoundland approved this study [see Appendix 1: 
The letter of ethics approval from the Memorial University Human Investigation 
Committee (HIC 01.70)]. The database includes all relevant data in the proposed study of 
tobacco and alcohol and CRC in NL population. The self-administered questionnaires for 
data collection of tobacco smoking and alcohol consumption and other epidemiological 
variables previously used are attached (Appendix II). The primary study includes 702 
CRC patients who were diagnosed in the NL population between 1999 and 2003 and 717 
controls randomly selected from NL population during the period of the cases diagnosed. 
No participants were contacted by the author for any further information. The case and 
control database were obtained from the supervisor of the author, Dr. Peizhong Peter 
Wang who is conducting the epidemiological study of genetic and environmental factors 
of CRC based on the data requested as one of principal investigators (see Appendix Ill). 
This thesis also analyzed sale data of tobacco (Appendix IV and V), sales data of 
alcohol beverages (Appendix VI and VII), population data (Appendix V and VII), and the 
data of the CCHS 1.1 and CCHS 3.1 in the assessment of the accuracy of self-reported 
alcohol consumption and tobacco smoking in the NL case-control study of CRC. While 
these data can be obtained though the websites of Health Canada and Statistics Canada or 
through the Research Data Centres of Statistics Canada, and no human subjects were 
involved, this thesis utilized these datasets in which individuals cannot be identified, and 
as a result an ethical review was not required. 
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4.1.2. Sales data of tobacco and alcohol and population data 
4.1.2.1. Sales data of tobacco 
The sales data of tobacco were obtained from the Cigarette and Fine-Cut (cut up 
into shreds) Sales Charts 1980-2008 of Health Canada [3481; this data can be reviewed in 
Appendix IV. Health Canada through its Tobacco Control Programme (TCP) provides 
relevant and timely information to support decision making and development of effective 
anti-tobacco policies and programs. The TCP monitors and analyzes changes in tobacco 
consumption patterns, public attitudes, retailer behaviour to youth access restrictions, 
industry practices and the product in support of TCP's programs and mandate. The sales 
data are provided to Health Canada by manufacturers and importers of tobacco products. 
The provision of this data to Health Canada is mandatory under Section 13 of the Federal 
Tobacco Reporting Regulations. Cigarette and fine-cut tobacco sales data are provided 
monthly by the companies to Health Canada (received by the 15th of every month for the 
previous month). Once received, the data are examined completeness and accuracy. Once 
the completeness and accuracy of the data are determined, the data is entered into Health 
Canada wholesale sales database. The data for cigarettes and fine-cut provide a very 
accurate national picture of legal, wholesale cigarette and fine-cut sales. Annual totals for 
the previous year are published on the website once a year (usually posted mid-year for 
the previous year). These reports are available nationally and provincially for wholesale 
tobacco sales since 1980. 
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4.1.2.2. Sales data of alcoholic beverages 
The sales data of alcohol beverages in NL were obtained from Statistics Canada 
[3551, and can be reviewed in Appendix VI. The Public Sector Statistical Program of 
Statistics Canada is a component of the Canadian System of National Accounts and 
collects data from the provincial and territorial government liquor authorities on the value 
and volume of sales of alcoholic beverages, and on financial information. The 
information is used by governments, by the liquor, wine and beer industries, international 
agencies and researchers. 
The target population consists of all provincial and territorial government liquor 
authorities. Data are collected for all units of the target population; therefore, no sampling 
is done. Response to the survey is mandatory and data are collected directly from survey 
respondents, extracted from administrative files and derived from other Statistics Canada 
surveys and/or other sources. Data are collected directly from provincial and territorial 
government liquor authorities and complemented with data extracted from administrative 
files. Additional data are also provided by the International Trade Division of Statistics 
Canada. Minimal error detection procedures are used to minimize errors. Imputation is 
performed for certain information not provided, and non-response. Analysis, review and 
cross-checking ensure high quality data. Volume of sales of alcoholic beverages in litres 
of absolute alcohol is calculated by multiplying the sales volume by the percentage of 
alcohol content. The conversion rate was 5% for beer, 11.5% for wine and 40% for spirit 
[346,355] 
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4.1.2.3. Population data 
This thesis needs the population data to calculate annual per capita alcohol and 
tobacco use and create the weighting variable to estimate annual per capita alcohol and 
tobacco use based on the sample of controls in the case-control study. The population 
data were obtained from Statistics Canada (JS6J. The estimates program of population in 
Statistics Canada provides annual estimates of population by age and sex for Canada, 
provinces and territories. The estimates program is used in the calculation of 
demographics, social and economic indicators in which the population or part thereof, 
serves as the denominator. These data are used in calculation of weights for use in 
Statistics Canada's Surveys. 
The population universe covered by the Demographic Estimates Program is 
similar to the population universe of the Census. Post-censal estimates are obtained by 
the component method, using the most recent census of population adjusted to July 1 and 
for net census undercount (the number of people missed by a census who were meant to 
be counted) as the base population. The component method consists in taking the 
population figures from the most recent census, adjusted for census net undercoverage, 
and adding or subtracting the number of births, deaths, and components of international 
and interprovincial migration. Annual population for each five year age group for NL was 
extracted from the Demographic Estimates Progran1 and population aged 20-74 for NL 
was calculated by SUlllffiing estimates of population of each age group to obtain an 
estimate of the population aged 20-74 in NL. Annual population aged 20-74 in NL can be 
reviewed in Appendix V and VII. 
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4.1.3. National health survey data 
The data of the CCHS 1.1 and CCHS 3.1 were analyzed and compared with the 
case-control study data to examine any differences in patterns of self-reported drinking 
and smoking in Canadians between the case-control study and the CCHS. The CCHS is a 
cross-sectional survey that collects information related to health status, health care 
utilization and health determinants for the Canadian population. It relies upon a large 
sample of respondents and is designed to provide reliable estimates at the health region 
level. The objectives of the CCHS are to support health surveillance programs by 
providing health data at the national, provincial and sub-provincial levels; provide a 
single data source for health research on small populations and rare characteristics; and to 
create a flexible survey instrument that includes a rapid response option to address 
emerging issues related to the health of the population. Data are available for the 2001, 
2003 and 2005 periods. However, the data in 2001 and 2005 were selected for the 
comparison of the estimates and patterns of alcohol use and smoking with the case-
control study data. 
4.1.3.1. Canadian Community Health Survey Cycle 1.1 
The analysis was based on data collected from September 2000 to November 
2001 from the first cycle of the CCHS [3571 . The data and relevant information on the 
CCHS can be obtained through the Research Data Centre of Statistics Canada. The 
CCHS 1.1 covered approximately 98% of the Canadian population aged 12 or older. The 
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CCHS 1.1 questionnaire was administered using computer-assisted interviewing (CAl). 
Sample units selected from the area frame were interviewed using the Computer-Assisted 
Personal Interviewing (CAPI) method, while units selected from the RDD and telephone 
list frames were interviewed using the Computer-Assisted Telephone Interviewing (CATI) 
method. The area frame, as designed for the Labour Force Survey (LFS), uses a 
multistage stratified cluster design [3581. A complete description of the LFS area frame is 
given elsewhere [3591. At the Canada level, the response rate was 84.7% for the CCHS 1.1 
sample which consists of 139,827 individuals. The response rate was 86.8% in NL. The 
NL sample consists of 3,870 respondents aged 12 years and older. CCHS 1.1 collects 
data in all health regions of the province. The analyses undertaken for this thesis include 
a total of 3,017 respondents aged 20-74 years old in NL. 
4.1.3.2. Canadian Community Health Survey Cycle 3.1 
The Public Use Microdata File (PUMF) contains data collected for CCHS Cycle 
3.1 between January 2005 and December 2005 [3601 . The CCHS 3.1 collects responses 
from persons aged 12 or older, living in private occupied dwellings in 122 health regions 
covering all ten provinces and one health region per territory, totaling 125 health regions. 
Excluded from the sampling frame are individuals living on Indian Reserves and on 
Crown Lands, institutional residents, full-time members of the Canadian Forces, and 
residents of certain remote regions. The CCHS covers approximately 98% of the 
Canadian population aged 12 and over. At the Canadian level, the response rate was 
78.9% for the CCHS 3.1 sample which consists of 132,947 individuals. The response rate 
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was 85.7% in NL, consisting of 4,111 respondents aged 12 years and older. CCHS 3.1 
collects data in all health regions of the province. The analyses described in this thesis 
include 3,239 respondents aged 20-74 years old in NL. 
4.2. Case-control study of colo rectal cancer 
4.2.1. Case and control identification 
4.2.1.1. Case identification 
Eligible CRC cases were NL residents between 20 and 74 years old, newly-
diagnosed with CRC between January 1999 and December 2003, with histologically 
confirmed primary adenocarcinoma of the colon or rectum. Records of the NCR were 
reviewed to identify cases and pathology reports were sought to confirm the diagnosis. 
Pathology reports retrieved by the NCTRF from provincial pathology laboratories were 
reviewed by the study pathologist. The recruitment and survey of cases were carried out 
during the period between November 2001 and April 2006. Eligible cases were then 
contacted through their attending or family physician to inform them of the study. 
Eligible cases indicated their willingness to participate by informing their attending 
physician through calling a 1-800 number, or by responding to a follow-up phone call 
from NCTRF staff. There were a total of 1,664 newly-diagnosed cases of CRC in NL 
during the period from 1999 to 2003 [3771. A total of 1,171 CRC cases diagnosed in 1999-
2003 which accounted for 84.8% of all eligible cases (1 ,388) [3771 were considered to be 
eligible and consented to participate in the study. Table 4 presents the number and 
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percentage of these new CRC cases by ICD-9 and ICD-10. Confirmation of diagnosis 
using both biopsy (526) and pathology methods (638) was available for 99.49% of all 
cases. Only 7 cases were diagnosed using other methods including X-Ray. Of 1,171 CRC 
cases, colon cancer patients accounted for 65.67% and rectosigmoid junction and rectal 
cancer cases accounted for 34.33%. The mean age of the cases was 61.2 years old (SD: 
9.4, range 20.0-74.0). 
Table 4. Number and percentage of incident colorectal cancer cases aged 20-74 years old by the 
International Classification of Diseases 91h revision and 1 01h revision diagnosed in Newfoundland and 
Labrador in 1999-2003 
CRC 
Colon cancer 
Malignant neoplasm of colon 
Caecum 
Appendix 
Ascending colon 
Hepatic flexure 
Transverse colon 
Splenic flexure 
Descending colon 
Sigmoid colon 
Overlapping lesion of colon 
Colon, unspecified 
Rectum cancer 
Malignant neoplasm of rectosigmoid junction 
Malignant neoplasm of rectum 
Malignant neoplasm of anus and anal canal 
Anus, unspecified 
CRC 
ICD-9/ lCD-I 0 
153/ 
153.4/ 
153.5/ 
153.6/ 
153.0/ 
153.1/ 
153.7/ 
153.2/ 
153.3/ 
153.8/ 
153.9/ 
154.0/ 
154.1/ 
154/ 
154.3/ 
Cl8 
Cl8.0 
Cl8.1 
Cl8.2 
Cl8.3 
Cl8.4 
Cl8.5 
Cl8.6 
Cl8.7 
Cl8.8 
Cl8.9 
Cl9 
C20 
C21 
C21 .0 
Sample (%) 
769 ( 65.67) 
769 ( 65.67) 
190 ( 16.23) 
I ( 0.09) 
122 ( 10.42) 
3 1 ( 2.65) 
76 ( 6.49) 
34 ( 2.90) 
56 ( 4.78) 
230 ( 19.64) 
4 ( 0.34) 
25 ( 2.13) 
402 ( 34.33) 
91 ( 7.77) 
310 ( 26.47) 
1 ( 0.09) 
I ( 0.09) 
1,171 (100.00) 
Among 702 CRC cases in this study, 335 cases with intermediate or high familial 
risk and 367 with low familial risk were identified (14 cases with familial risk 
unidentified). The familial risk was identified by genetic counselors reviewing the 
familial history questionnaire returned by cases. The proband is classified as belonging to 
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either a high familial risk family, an intermediate familial risk family, or a low (sporadic) 
risk family (Box 1). This criteria has been used in the ON study ofCRC [361 1. 
There were a total of 68 MSI-H CRC cases and 634 MSI-L or MSS cases (45 
cases with MSI unidentified). Tumour tissues were sought from hospital pathology 
laboratories and stored in the biospecimen repositories of the Faculty of Medicine at 
Memorial University of Newfoundland. MSI status was assessed from matched normal 
and tumour tissue from formalin fixed, paraffin-embedded blocks. MSI-H and MSI-L or 
MSS of all CRC cases were further identified through the analysis of blood samples 
obtained from cases according to the published international guidelines [1201. 
Box 1. Criteria used to classify probands in the Newfoundland Familial Colorectal Cancer Registry 
(NFCCR) 
High familial risk/HNPCC (Amsterdam criteria!): 
I. At least three relatives with colorectal cancer, one a first degree relative to other two, and 
2. At least two successive generations affected with colorectal cancer, and 
3. Colorectal cancer djagnosed under 50 year in at least one affected member, and 
4. Does not have Familial Adenomatous Polyposis (F AP). 
Intermediate familial/other risk (familial [# l-3], other (pathologic[#5-ll ], other [#4.12])): 
I. Proband has two relatives with any of the HNPCC cancers2 and 2 of the 3 are first degree relatives, or 
2. any family member with an HNPCC cancers2 ~35 years of age, or 
3. Proband <50 and relative with colon cancers <50 (I 51 or 2"d degree relative only), or 
4. Proband ~35 years of age, or 
5. Proband with multiple primary colon cancers, or 
6. Proband with other multiple primary colon cancer(s)2, or 
7. Proband has multiple polyps, or 
8. Peutz-Jeghers or hamartomatous polyps, or 
9. Juvenile polyp, or 
10. Inflammatory bowel disease, or 
11. Unusual colorectal cancer hjstologies3, or 
12. Ashkenazi Jewish 
Low (sporadic) risk 
l. All other colorectal cancer cases (probands) not classified as high or intermediate risk or high risk 
Note: 1 Ll ' J. ~ Colorectal, endometrial, gastric, small bowel, gastroesophageal, liver, pancreas, biliary tract, 
ovarian, kidney, ureter, brain, and lymphoma. 3 Carcinosarcoma, adenosquamous, spindle cell, metaplastic, 
choriocarcinoma, signet ring, undifferentiated, trophoblastic differentiation, small cell neuroendocrine 
carcinoma. 
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4.2.1.2. Recruitment of controls 
Eligible controls were NL residents between 20 and 74 years old, and without a 
diagnosis of previous CRC. Controls were frequency-matched with cases according to 
sex and five-year age group to improve the efficiency of the study. Controls were 
randomly selected from the NL population using the RDD method. Bell Aliant, one of 
North America's largest regional communications providers supplied 238 non-
institutional exchanges (i.e., the three-digit prefix of a seven-digit telephone number), 
with working banks of four digit numbers used for residential customers. Non-active 
numbers, fax numbers, or non-residential numbers were removed from the residential 
telephone list. A list of 192,000 possible residential telephone numbers was provided by 
Bell Aliant based on the total residential lines in the working banks. This list was used to 
randomly select numbers for contact. Experienced interviewers made the initial contact 
by dialing the randomly selected telephone numbers in a sequential order until the desired 
number of controls was reached. A total of 15,500 random residential telephone numbers 
were randomly selected to be used for recruiting controls. The recruitment and survey of 
controls were carried out during the period between January 2004 and December 2006. 
4.2.1.3. Participating rates 
A total of 1,171 cases or 84.4% of eligible cases consented to participate in the 
study and were sent the study package. Of those cases, 702 or 59.9% completed and 
returned the questionnaires. Participating cases (702) accounted for 50.6% of all eligible 
cases (1 ,388). Among 1,602 eligible controls or 78.9% of eligible controls identified 
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using RDD who consented verbally to participate in the survey, a total of 717 controls 
which accounted for 44.8% of consented controls (1,602) or 35.3% of eligible controls 
(2,030) returned the survey packages and the signed consent forms at the end of 
December 2006. A detailed description of the recruitment of controls has been reported 
elsewhere [3541. 
Figure 2. Population-based case-control design of colorectal cancer in Newfoundland and Labrador 
NL Population Aged 
~ 20-74 
I 
I I 
II Eligible Cases 1 " Eligible Controls N= l ,l71 N= l ,602 
I I 
I I I I 
1 Non-Participants I Participants ~ Participants I Non-Participants N=496 N=702 N=717 N=975 
·-II Alcohol and Tobacco II Alcohol and Tobacco 
Prior to Diagnosis - - Prior to Survey 
4.2.2. Data collection 
All participants were asked to complete three self-administered questionnaires in 
the survey package; these questionnaires and data collection procedures have been 
utilized in the ON study of CRC [3611. The three questionnaires included in this survey 
package were as follows: (i) a Personal History Questionnaire (PHQ), (ii) a Family 
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History Questionnaire (FHQ), and (iii) a Food Frequency Questionnaire (FFQ). The 
tobacco smoking, alcohol consumption and other epidemiological risk factors were 
derived from the PHQ. The questionnaires were mailed to all consenting eligible 
participants with self addressed stamped envelopes. If a participant was unable to return 
fmished questionnaires within three weeks, a follow-up telephone call was made to 
ensure that the study package had been received. A telephone interview or assistance was 
offered when illiteracy or physical disability was a concern. There were 258 cases who 
died during the study period, and 143 who died before the survey was conducted. 
Therefore, proxies of deceased cases were used to complete the survey. Variables of 
tobacco smoking, alcohol consumption and covariates used in the analyses of this thesis 
were derived from the PHQ in Appendix II. 
4.2.2.1. Estimate oftobacco smoking 
The reported or derived variables of smoking included in the analyses are 
summarized in Table 5. Tobacco smoking, including cigarettes, cigars and pipes, was 
investigated. Subjects were classified into the cigarette smoking group (smoker) if they 
had smoked one cigarette a day for three months or longer, and the non-cigarette smoking 
group (non-smoker) if they had not smoked one cigarette a day for three months or longer. 
Cigarette smokers were further classified into former and current cigarette smokers. 
Former cigarette smokers were those who stopped smoking cigarettes about one year 
before cancer diagnosis or survey, and current cigarette smokers were those who still 
smoked at least one cigarette a day during the year prior to diagnosis or recruitment. 
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Former and current cigarette smokers were classified into two groups according to 
initiation of smoking in reference to the question: "When did you first start smoking at 
least one cigarette a day?" (younger than 16 years old and 16 years or older); both were 
also classified into three groups according to the number of cigarettes per day in 
responding to the question: "During periods when you smoked regularly, how many 
cigarettes did you typically smoke in a day?" (1-19 cigarettes daily, 20-29 and 30+); and 
classified into three groups of total number of years of cigarette smoking in responding to 
the question: "How many years, in total, did you smoke at least one cigarette a day for 
three months or longer (if stopped and restarted at least once, count only the time when 
smoking)?" (1-19 years, 20-29 and 30+); the three groups of number of years since 
starting to smoke cigarettes was estimated based on the initiation age of smoking and age 
at diagnosis (1-25 years, 26-35 and 36+); as were three groups of cigarette pack years (1-
19 pack years, 20-39 and 40+). 
Pack year is a way to measure the amount a person has smoked over a long period 
of time [2321. It is calculated by multiplying the number of packs of cigarettes smoked per 
day by the number of years the person has smoked [2321. For example, one pack year is 
equal to smoking 20 cigarettes per day for one year, or 40 cigarettes per day for half a 
year, and so on. Additionally, years of abstention from smoking cigarettes were also 
estimated and smokers were classified into four groups: zero year of abstention from 
smoking, 1-19, 20-29 and 30+. 
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Table 5. Reported or derived variables of tobacco smoking included in the analyses 
Tobacco types Variables Categories 
Cigarette Cigarette use 0 = Non-smoker 
Cigar 
Pipe 
Total tobacco (cigarette, cigar, 
Pipe) 
I cigar = 4 cigarettes 
1 pipe = 2.5 cigarettes 
Cigarette use status 
Age of smoking initiation 
Cigarette years 
Years since start smoking 
Cigarettes daily 
Cigarette pack years 
Years of abstention 
Cigar use 
Pipe use 
Tobacco use 
Tobacco use status 
Initiation age 
Smoking years 
Cigarettes or equivalent daily 
Smoking pack years 
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I = Smoker 
0 = Non-smoker 
I = Former smoker 
2 = Current smoker 
0 = Non-smoker 
I =<16 
2 = 16+ 
0 = 0 
I = 1-19 
2 = 20-29 
3 = 30+ 
0 = 0 
1 = 1-25 
2 = 26-35 
3 = 36+ 
0 =0 
I = 1-19 
2 = 20-29 
3 = 30+ 
0 = 0 
1 = 1-19 
2 = 20-39 
3 = 40+ 
0 = 0 
I = 1-19 
2 = 20-29 
3 = 30+ 
4 = Non-smoker 
O= No 
I = Yes 
O= No 
1 = Yes 
0 = Non-smoker 
1 = Smoker 
0 = Non-smoker 
I = Former smoker 
2 = Current smoker 
O= No 
1 = < 16 
2 = 16+ 
0 = 0 
I = 1-19 
2 = 20-29 
3 = 30+ 
0 = 0 
I = 1-1 9 
2 = 20-29 
3 = 30+ 
0 = 0 
1 = 1-19 
2 = 20-39 
3 = 40+ 
The same questions were used to investigate cigar and pipe smoking monthly 
rather than daily. The number of cigar and pipe smoked were estimated and converted 
into equivalent cigarettes (one cigar = four cigarettes and one pipeful = two and half 
cigarettes) in total tobacco analysis [362•3631. Tobacco smokers were determined based on 
smoking one cigarette daily or one cigar/pipe monthly for three months or longer. 
Subjects were classified into the tobacco smoking group (smoker) if they had smoked one 
cigarette a day or one cigar/pipe a month for three months or longer, and non-tobacco 
smoking group (non-smoker) if they had not smoked. Tobacco smokers were further 
classified into former and current smokers. Former tobacco smokers were those who 
stopped smoking tobacco before cancer diagnosis or survey, and current tobacco smokers 
were those who still smoked at least one cigarette a day or cigar/pipe among during the 
year prior to diagnosis or recruitment. 
4.2.2.2. Estimate of alcohol consumption 
Reported or derived variables included in the analyses are presented in Table 6. 
There were four groups of alcoholic beverages investigated in the PHQ: (1) beer, hard 
cider (at least 3% alcohol); (2) wine; (3) sake, sherry, port; and (4) spirits, liquor mixed 
drinks, brandy, liqueurs. Questions were asked to determine the level of consumption of 
the four types of beverages: "In your 20s, did you ever consume any alcoholic beverages 
at least once a week for 6 months or longer?"; answers included "yes", "no" and "don't 
know". Respondents who answered yes were required to report "For how many years?", 
and then to answer "During those years, how much did you typically consume?", with 
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response option of the number of 12 ounce cans or bottles of beer, 4 ounce glasses of 
wine, 1 ounce serving of sake, or 1 ounce shots liquor or spirits per day, per week and 
don't know. The same questions were asked of respondents about their experiences in 
their 30s and 40s, and 50s. Two questions were asked to estimate the number of alcoholic 
beverages a week: "When you were in your 20s, how many years in total did you 
consume at least one alcoholic beverage (of any type) a week?", with answer of the years 
consumed; the second question was used to summarize the average alcohol consumption 
and the answer was the number of alcoholic beverages a week: "On average, how many 
alcoholic beverages a week did you consume during those years? That is, how many 4 
ounce glasses of wine or 12 ounce cans or bottles of beer or hard cider, or 1 ounce 
servings of sake, sherry, port, or spirits, mixed drinks and cocktails." The same questions 
were asked concerning their experience in their 30s and 40s and 50s. Sake measures were 
merged into spirits measures because very few subjects reported drinking sake. 
This thesis defined beer drinkers if they ever consumed beer once a week for 6 
months or longer or beer non-drinkers; wine drinkers if they ever consumed wine once a 
week for 6 months or longer or wine non-drinkers; spirits drinkers if they ever consumed 
spirits once a week for 6 months or longer or spirits non-drinkers; Subjects were 
classified as alcohol drinkers if they ever consumed any alcoholic beverages once a week 
for 6 months or longer, or as alcohol non-drinkers. Derived variables on specific 
beverages were number of drinking years (0, 1-19, 20+), number of drinks daily/weekly 
(0, 1-2, 3+) and number of litres of absolute alcohol yearly (0, 1-4, 5+ ). Derived variables 
on total alcohol consumption in the analysis included types of beverage (0, 1-2 3+), 
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number of drinking years (0, 1-19, 20+), number of drinks daily (0, 1-2, 3+), and number 
oflitres of absolute alcohol yearly (0, 1-4,5-14, 15+). 
Table 6. Reported or derived variables of alcohol consumption included in the analyses 
Alcohol use Variables Categories 
Beer Beer drinker 0 = No 
1 = Yes 
Drinking years 0 = 0 
1 = 1-19 
2 = 20+ 
Drinks daily 0 = 0 
2 = 1-2 
3 = 3+ 
Litres yearly 0 = 0 
1 = 1-4 
2 = 5+ 
Wine Wine drinker 0 = No 
1 = Yes 
Drinking years 0 = 0 
1 = 1-19 
2 = 20+ 
Drinks weekly 0 = 0 
1 = 1-2 
2 = 3+ 
Litres yearly 0 = 0 
I = 1-4 
2 = 5+ 
Spirits Spirits drinker 0 = No 
1 = Yes 
Drinking years 0 = 0 
1 = 1-19 
2 = 20+ 
Drinks daily 0 = 0 
1 = 1-2 
2 = 3+ 
Litres yearly 0 = 0 
1 = 1-4 
2 = 5+ 
Total alcohol Drinker 0 = No 
1 = Yes 
Type of beverage 0 = No 
1 = One-two 
2 = Three+ 
Drinking years 0 = 0 
1 = 1-19 
2 = 20-39 
3 = 40+ 
Drinks daily 0 = 0 
1 = 1-2 
2 = 3-4 
3 = 5+ 
Litres yearly 0 = 0 
I = 1-4 
2 = 5-14 
3 = 15+ 
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4.2.2.3. Covariates 
The association of alcohol intake and tobacco smoking with the risk of developing 
CRC was investigated after adjusting for potential confounding of various demographic 
variables, chronic conditions and lifestyle measures. Specific covariates available for this 
thesis include age, sex, urban and rural residence, census division, place of birth, race, 
marital status, education attainment, household income, family CRC history, other cancer 
history, diabetes, cholesterol level, aspirin use, eating fruits, eating vegetables, eating red 
meats, body weight, and physical activity. 
Respondents were classified into three age groups (20-54, 55-64 and 65+), two 
groups of birth place (those born in Canada or not), two racial groups (Caucasians or 
others), two education groups (high school completed or less, and higher than high school 
education), two groups ofhousehold income groups (less than $30,000 or no income, and 
$30,000 or more), two groups of marital status (currently married/living as married, and 
other marital status including single, never married, separated, divorced or widowed), and 
two groups of residential areas (urban and rural). An urban area has a minimum 
population concentration of 1,000 persons and a population density of at least 400 
persons per square kilometre [218'3641. All territory outside urban areas is classified as rural. 
Technically, urban and rural residences were determined based on the definition of rural 
postal codes (i.e., individuals with a "0" as the second character in their postal code using 
Canada Postal System) [2 181. There are 10 census divisions in NL [3641; using the postal 
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codes reported by the respondents, subjects were classified into 10 census divisions to 
examine geographical variation in incidence of CRC in NL, and adjust for spatial effect 
in the association. 
Respondents were classified into two groups: those having a family history of 
CRC and those with no family history of CRC; those having other cancers diagnosed 
previously and those without previous cancer diagnosis; those having and not having 
been diagnosed with diabetes mellitus. Cholesterol level was investigated using response 
to the question: "Has a doctor ever told you that you had high cholesterol? If your doctor 
told you it was borderline, please tick 'no' ."; answer choices included ' yes ' and no' . 
Respondents were classified into those who did or did not regularly use aspirin (e.g. 
Anacin, Bufferin, Bayer, Excedrin, Ecotrin). 
Eating fruits was investigated using response to the question: "About one year 
before your recent cancer diagnosis or investigation, on average, how often did you eat a 
piece or serving of fruit?" A serving of fruit is: 1 medium-sized fresh fruit; Y2 cup of 
chopped, cooked or canned fruit; V4 cup of dried fruit; 6 ounces of fruit juice (50-100% 
pure juice). Respondents were classified into two groups: <3 servings per day, 3+ 
servings per day. Eating vegetables was investigated using response to the question: 
"About one year before your recent cancer diagnosis or investigation, on average, how 
often did you eat a piece or serving of vegetables? Please include green salads, beans, 
lentils, etc., and potatoes (not packaged potato chips)." A serving of vegetables is: 1 cup 
raw; leafy vegetables; Y2 cup of other vegetables, cooked or chopped raw; or 6 ounces of 
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vegetable juice. Respondents were classified into two groups: < 3 servings per day, 3+ 
servings per day. 
Eating red meat was investigated using response to the question: "About one year 
before your recent cancer diagnosis or investigation, on average, how often did you eat a 
serving of red meat (not chicken or fish)?" A serving of red meat is: 2-3 ounces of red 
meat (a piece of meat about the size of a deck of cards); and red meats include: beef, 
steak, hamburger, prime ribs, beef hot dogs, beef-based processed meat, veal, pork, bacon, 
pork sausage, ham, lamb, venison. Respondents were classified into two groups: <3 
servings of red meats per day, 3+ servings per day. 
Respondents were classified into non-obese (body mass index-BMI < 30) and 
obese (BMI ~ 30). BMI was estimated based on the height and weight questions: "About 
how tall are you, without your shoes on?"; and "How much did you weigh about one year 
before your recent cancer diagnosis or investigation?" Respondents were classified into 
physically active and non-physically active groups. Physically active was defined as 
participating regularly in physical activity including walking, jogging, running, bicycling, 
swimming laps, playing tennis; playing squash or racquetball; doing calisthenics or 
aerobics; vigorous dancing, using a rowing machine and lifting weights; playing football, 
soccer, rugby or basketball; doing heavy household work (such as using a non-power 
mower), shoveling, moving heavy loads, scrubbing floors; and doing any other strenuous 
activities including skiing, skating, hockey, hunting, sledding, tobogganing or water-
skiing for a total of at least 30 minutes a week - and respondents were asked about these 
kinds of physical activity in their 20s, 30s and 40s, and 50s. 
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4.3. Data analyses 
4.3.1. Assessing non-participation bias of cases and controls 
Non-participation bias was assessed based on the database of the NL population-
based case-control study of CRC in which some demographic and clinical variables of 
eligible cases and some demographic variables of eligible controls were available l365•366l. 
Differences between the eligible population and the participant population are of great 
importance as they may influence both the internal and the external validity of the study 
(3651; therefore an examination of these differences is an important part of this thesis. To 
determine non-participation bias, this study compared the differences in demographic 
characteristics between participating and non-participating controls, and the differences 
in demographic and clinical characteristics between participating and non-participating 
cases. The study also compared the differences in age, gender, rural-urban area and 
census division between the eligible cases and controls, and between participating cases 
and controls (other epidemiological factors on participating cases ad controls have been 
collected and analyzed in Chapters 7 and 8). Chi-square technique was used to examine 
any differences in characteristics between participants and non-participants; and 
statistical analyses were completed using SAS 9.1 l367l. 
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4.3.2. Assessing bias of self-reported tobacco smoking and alcohol intake 
The validity of self-reported tobacco smoking and alcohol consumption was 
assessed in terms of coverage; that is, the extent to which tobacco smoking and alcohol 
consumption is determined based on survey responses accounts for all tobacco and 
alcohol sold [368•3691. This approach has been extensively applied in similar studies where 
more valid and reliable data cannot be obtained from respondents directly [370-3721. Per 
capita cigarettes smoked, and litres of absolute alcohol consumption yearly, were 
calculated based on the weighted sample of controls in the case-control study, and the 
results were compared to the provincial sale data and two national surveys. 
4.3.2.1. Tobacco and alcohol consumption based on the case-control study data 
Tobacco and alcohol consumption for the population 20-74 years of age was 
estimated based on the weighted sample of controls; a weighting variable was created 
because unequal controls by age and sex were selected to match with cases on age and 
sex. The relative weighting variable was created based on the proportion of age group 
and sex [3731. The estimate procedure of weighting can be seen in Table 7. 
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Table 7. The weighting estimate Erocedure 
Poeulatioo A~?;ed 20-74 in 2001 t Controls Aged 20-74 Weighting Age Poeulation Proeortion Control Proeortion 
M (I) F (2) M (3) F (4) M (5) F (6) M(7) F (8) M (9) F (10) 
20-44 89,690 95,945 0.251 0.269 32 20 0.045 0.028 5.628 9.633 
45-49 21 ,325 21 ,950 0.060 0.061 20 11 0.028 0.015 2.141 4.007 
50-54 19,805 19,890 0.055 0.056 49 53 0.068 0.074 0.812 0.754 
55-59 15,055 15,105 0.042 0.042 59 49 0.082 0.068 0.512 0.619 
60-64 11 ,470 11 ,410 0.032 0.032 90 66 0.126 0.092 0.256 0.347 
65-69 9,465 9,695 0.027 0.027 79 48 0.110 0.067 0.241 0.406 
70-74 7,620 8,655 0.021 0.024 95 46 0.132 0.064 0.161 0.378 
Note: t 2001 Census data from Statistics Canada. (I)-males aged 20-74 in 2001. (2)-females aged 20-74 in 
2001. (3)-proportion of males by age. (4)-proportion of females by age. (5)-male controls. (6)-female 
controls. (?)-proportion of males by age. (8)-proportion of females by age. (9)-weighting for males by 
age=M(3)/M(7). (I 0)-weighting for females by age=F(4)/F(8). 
First, annual per capita tobacco and alcohol consumption were estimated using the 
sample of controls in the case-control study [350•3741; the results were compared to the sales 
data of tobacco and alcohol in NL. Annual per capita tobacco consumption (PCTC) per 
smoker aged 20-74 years old was derived as follows: 
PCTC 
Annual tobacco consumption in numbers for smokers 
Number of smokers in the sample of controls (20-74 years of age) 
where annual tobacco consumption in numbers is equal to sum of (number of cigarettes 
smoked daily times 365 for each smoker) in the sample of controls. Per capita tobacco 
consumption was estimated for cigarettes and total cigarettes (cigarettes, one cigar = 4 
cigarettes and one pipe = 2.5 cigarettes). Annual smoking packs of cigarettes and total 
cigarettes (one pack= 20 cigarettes) were also estimated based on the weighted sample of 
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controls in the case-control study; and the results were compared to the sales data of 
tobacco in NL to assess the accuracy of self-reported tobacco consumption. Cigarette 
smoker was defined as someone having smoked one cigarette a day for three months or 
longer and tobacco smoker was defined as having smoked one cigarette a day or one 
cigar/pipe a month for three months or longer. 
Annual per capita alcohol consumption (PCAC) per drinker aged 20-74 years old 
was derived as follows: 
Annual absolute alcohol consumption in litres for drinkers 
PCAC = ------------------------
Number of drinkers in the sample of controls (20-74 years of age) 
where annual absolute alcohol consumption in litres equals the sum of [drinking years 
times litres of alcohol consumed daily in 20s, 30s and 40s, and 50s (1 drink = 17.2 ml = 
0.0172 litres in Canada [3701) times 365 for each drinker] in the control sample divided by 
sum of drinking year for drinkers in the control sample. Drinker was defined as 
"consuming any alcoholic beverages once a week for 6 months or longer" in the case-
control study of CRC. PCAC was also estimated for the three major categories of 
alcoholic beverages (beers, wines and spirits). Percentage of annual alcohol consumption 
from beers, wines and spirits to total alcohol consumption was also estimated based on 
the weighted sample of controls in the case-control study. The results were compared to 
the sales data to assess the accuracy of self-reported beer, wine and spirit drinking. 
Second, the per capita tobacco and alcohol consumption, and the percentage by 
subgroups, were estimated using the weighted sample of controls from the case-control 
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study. The results were compared to the estimates from the CCHS data to examine any 
discrepancies of tobacco and alcohol consumption in the case-control study and the 
CCHS. 
Third, tobacco and alcohol consumption by subgroups among cases and controls 
in the case-control study of CRC was analyzed, as was the alcohol consumption by types 
of beverage. The aim of these analyses was to examine the patterns of tobacco and 
alcohol consumption among cases and controls, and thus find any differences in the self-
reported tobacco and alcohol consumption between cases and controls. 
The statistical analyses were performed using SAS 9.1 [3671. SAS PROC 
SURVEYMEANS was used to calculate the mean tobacco and alcohol consumption for 
types ofbeverage and subgroups; and SAS PROC TABULATE was used to calculate the 
percentages of tobacco and alcohol consumption for subgroups. 
4.3.2.2. Tobacco and alcohol consumption based on the sales data 
The tobacco smoked by smokers aged 20-74 was estimated based on the 
proportion of cigarettes consumed by smokers aged 20-74 years old to cigarettes smoked 
by daily and occasional smokers aged 12 years and older (0.9331 for NL) in CCHS 1.1. 
The annual litres of alcohol consumption for drinkers aged 20-74 years old were 
estimated using a proportion of alcohol consumption for population aged 20-74 to 
population aged 12 years and older (0.8956 in NL) in CCHS 1.1. The average annual per 
capita cigarette and alcohol consumption were estimated using the average annual 
cigarette and litres of alcohol sold for those aged 20-74 years old, dividing by the average 
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annual numbers of smokers or drinkers aged 20-74 years old from 1980 to 2003. The 
percentage of alcohol consumption from beer, wine and spirit to total alcohol 
consumption was estimated for the population aged 20-74 years old. The statistical 
analyses were performed using SAS 9.1 [3671. 
4.3.2.3. Tobacco and alcohol consumption based on the national survey data 
The estimate of annual per capita litres of alcohol consumption per drinker among 
Canadians aged 20-74 in NL was based on CCHS 1.1 and CCHS 3.1. The last 7 days 
method was used to estimate alcohol consumption [3711. This method requires people to 
complete a retrospective 'diary' showing how much alcohol they drank on each of the 
last 7 days [371 ]. The overall volume of ethanol for the week is the sum over all days of the 
number of drinks times the litres of ethanol assumed to be in a standard drink [37 11. In 
Canada, a standard drink equals to 0.0172 litres [3701. In the 2001 CCHS, the respondents 
were required to report the number of drinks of beer, wine, liquor or any other alcoholic 
beverage each day in one week prior to the interview day. The number of drinks in the 
past year was thus estimated by the number of drinks consumed in one week and 
multiplying this by 52 weeks. 
Similarly, the number of cigarettes smoked yearly was estimated based on the 
number of cigarettes per day as reported multiplied by 365 days among daily smokers. 
The number of cigarettes smoked by occasional smokers who have smoked at least 1 00 
cigarettes was estimated based on the questions: "On the days that you smoke, about how 
many cigarettes do you usually have?" and "In the past month, on how many days have 
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you smoked 1 or more cigarettes?" The CCHS survey weights were incorporated in the 
calculations to adjust for the sampling method. The rescaled weighting variable was used 
in the analyses [3751. The weight variables used by Statistics Canada were rebased to the 
sample sizes. This ensures that adjustments for sampling methods are retained, and the 
sample is maintained at the sample size rather than the population estimate. SAS PROC 
SURVEYMEANS [3671 was performed to calculate per capita litres of alcohol and amount 
of tobacco use. SAS PROC TABULATE was used to calculate the percentages of alcohol 
consumption and cigarettes smoked by subgroups. 
4.3.3. Effects of tobacco smoking and alcohol consumption on colorectal 
cancer 
4.3.3.1. Descriptive analyses 
The first step of data analysis was careful scrutiny of the raw data for error and 
correction of such errors, because the dataset involved various types of data saved in 
separate tables in Microsoft Access format. The data were reviewed for accuracy, 
consistency, completeness and manipulation. The variables were grouped in order to be 
compared with other studies. Chi-square analyses were performed to examine the 
distribution of each variable including exposure and covariates among cases and controls 
to see if it appeared reasonable and to help spot data errors [3511. The prevalence rate of 
lifetime alcohol use and tobacco smoking was estimated for subgroups such as male and 
female, and the 95% CI of the difference in the prevalence rate was calculated to test the 
null hypothesis that the prevalence rates (proportions) were identical [22l1. 
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4.3.3.2. Multivariate multilevel regression analyses 
First, applying multivariate multilevel logistic regression techniques investigate 
any potential clustering of CRC in a geographical area [3761. The F-test examined 
significant differences in the incidence between each division and the province [3761; and 
the incidence rates were estimated using a multilevel model because incidence rates are 
subject to random variation and may be inaccurate, particularly in small areas [3761. This 
problem can be alleviated by obtaining shrunken incidence estimates using a random 
effect model with small areas taken as random [3761. The data were analyzed in binomial 
form with the dispersion parameter fixed at one. This prevents the area variance 
component from becoming incorporated into the dispersion parameter. The following 
SAS procedure was used to calculate the shrunken incidence estimate for each census 
division, and the shrunken incidence rates per 100,000 population are estimated using 
[1 + exp[- (intercept+ log it )]11: 
PROC GLIMMIX; 
CLASS cd; 
MODEL ere/pop = I LINK = LOG IT SOLUTION DDFM = KENW ARDROGER; 
RANDOM cd I SOLUTION; 
RUN; 
where cd = census division, ere = number of CRC incidence in census division, and pop 
= population in census division. 
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The prediction of five-year incidence rate was based on incident CRC cases for 
each division obtained from NCR for this study and the 2001 census population for each 
division. The number of cases for each division was adjusted in order to estimate total 
number of cases in each division. For example, new CRC cases aged 75 years and older 
in NL account for 25.5% of total CRC cases in 1999-2003 and total CRC cases for each 
division equal to cases aged 20-74 years old plus estimated cases aged 75 years and older 
[JnJ. The analyses showed that the incidence rate per 100,000 was significantly higher in 
census division (CD) No. 2, 8 and 9 than the provincial rate and the rate was significantly 
lower in CD No. 3 and 7 (see Table 8), suggesting a potential clustering effect on the 
association between CRC and alcohol and tobacco use. Therefore, the estimates of the 
ORs for drinking and smoking also involved adjustment for spatial effect. 
Table 8. Observed and predicted five-year incidence rate (per 100,000) of colorectal cancer among 
Canadians aged 20-74 using multilevel model by Census Division in Newfoundland and Labrador in 
1999-2003 
CD 0 Observed Population Cases A Rate 
CD No. 1 242,875 799 32.88 
CDNo.2 24,371 115 47.31 
CD No.3 I 9,370 25 13. I I 
CD No. 4 22, I 62 67 30.07 
CD No. 5 40,466 I 04 25.62 
CD No.6 36,208 140 38.57 
CD No.7 37,335 51 13.60 
CD No. 8 42,188 203 48.14 
CD No.9 20,091 99 49.49 
CD No. 10 30,279 61 20.26 
NL 515,345 I ,664 32.29 
Predicted 
Rate 
31.07 
* 43.87 
* 13.98 
28.38 
24.36 
36.13 
** 13.71 
* 44.99 
* 45.66 
19.67 
& 95% CI 
21.81 - 44.23 
29.53- 65.13 
8.41-23.24 
18.52 -43.47 
16.33-36.34 
24.52- 53.20 
8.80-21.34 
30.92- 65.42 
30.51 - 68.30 
12.78-30.25 
Estimate 
0.1157 
0.4621 
-0.6844 
0.0249 
-0.1 281 
0.2671 
-0.7043 
0.4874 
0.5023 
-0.3427 
Probability 
0.4794 
0.0273 
0.0140 
0.8982 
0.4883 
0.1545 
0.0058 
0.0168 
0.0205 
0.1061 
Note: 0 CD: Census Division. COs were delineated without reference to administrative or other forms of 
divisions in NL and are numbered [3641. CD No. I =Avalon Peninsula-St. John's, CD No. 2=Burin Peninsula-
Marystown, CD No. 3=Soutb Coast-Channel-Port aux Basques, CD No. 4=St. George's-Stephenville, CD 
No. 5=Humber District-Corner Brook, CD No. 6=Central Newfoundland-Grand Falls-Windsor, CD No. 
7=Bonavista!Trinity-Clarenville, CD No. 8=Notre Dame Bay-Lewisporte, CD No. 9=Northern Peninsula-
St. Anthony, CD No. 1 O=Labrador-Happy Valley-Goose Bay. CD No. 11 (Nunatsiavut-Nain) was used for 
the fist time in the Canada 2006 Census; prior to 2006, Nunatsiavut-Nain was counted as part of CD No. 
I 0. T-test *P<0.05 **P<0.01 ***P<O.OOl. A this analysis was based on all incidences of CRC 1999-2003 
and eligible cases (1,388) accounted for 83.4%. 
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Second, Odds ratios (ORs) of CRC as estimates of relative risk, and the 
corresponding 95% confidence intervals (Cis), were computed separately according to 
various measures of cigarette smoking and alcohol drinking, and using multivariate 
multilevel logistic regression [3761. Each measure of smoking and drinking evaluated was 
modeled independently of one another given that these measures were highly correlated. 
Those who had never smoked served as the reference group in the analyses for smoking 
and those who had never drunk alcohol served as the reference group in the analyses for 
drinking. Age, sex and census division were included in all the analyses for smoking and 
drinking. 
Other covariates for inclusion were based on a p-value of univariate test and 
correlation with other variables. Based on univariate logit analysis of the pooled data set, 
any variable whose univariate test had a p-value < 0.20 was considered as a candidate for 
the multivariate logistic regression analyses [2191. All selected covariates by univariate 
analysis were included in the models regardless of their "statistical significance". The 
rationale for this approach is to provide as much control of confounding as possible 
within the given data set [2191. This is based on the fact that it is possible for individual 
variables not to exhibit strong confounding, but when taken collectively, considerable 
confounding may be present in the data [2191. Independent variables with particularly high 
inter-correlations (> 0.30) were identified, less precise measures were excluded [2201 and 
the variable pool was reduced to avoid synonymous variables and collinearity [2211. The 
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mean of the non-missing values for numeric variables was used as the estimate of missing 
numeric data, and the mode (most frequent) value is used as the estimate of missing 
categorical data [3781• Testing for linear trends was carried out by representing the 
categories of exposure with ordinal variables considered as continuous, and examining 
the significance of the coefficient with a z-test [351•3791 • All statistical tests performed were 
two-sided. Stratification analyses were performed to examine any interaction effect by 
sex, drinking/smoking status, weight (BMI), survival status of cases, subsite of CRC, 
familial risk level and MSI status of cases. 
The conventional logistic model ignores the hierarchical structure of the data and 
treats aggregate exposure as if it was measured at individual level. In this thesis, the 
dependent variable is incidence of CRC (case/control); the risk factor of interest is 
exposure to smoking/alcohol consumption; confounders included are age, sex and other 
covariates. The model is expressed by the following equation [2191: 
where Jl is the intercept parameter, and 1r iJ is the expected probability of incidence of 
CRC for the /'' individual in the i 1h region (CDi) with smoking/alcohol consumption 
and other predictor variables ( X 1 •.• X 11 ). The SAS codes are shown below [3671: 
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PROC LOGISTIC DESC; 
CLASS alcohol/tobacco covariates I P ARAM 
ORDINAL = INTERNAL; 
MODEL ere = alcohol/tobacco covariates; 
RUN; 
REF(Non-drinkers/Non-smokers) 
The PROC LOGISTIC and MODEL statements are required [3671. The LOGISTIC 
procedure fits linear logistic regression models for binary or ordinal response data by the 
method of maximum likelihood. The maximum likelihood estimation is carried out with 
either the Fisher scoring algorithm or the Newton-Rephson algorithm. The DESC option 
reverses the default ordering of the response values so that ere = 1 (case) is modeled. 
ORDINAL = INTERNAL specifies the sorting order for the levels of the response 
variable. The CLASS statement names the classification variables to be used in the 
analysis. The P ARAM = REF specifies the parameterization method for the classification 
variables. 
The data can be modeled using multilevel logistic models on the same data with 
SAS GLIMMIX procedure [3801. In this approach, the influence of alcohol/tobacco 
exposure on the outcome (CRC incidence) is included through adjustment of random 
effect of geographical area ( cd-census division) and other covariates. The model is 
expressed by the following equation [3811: 
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where J.l is the intercept parameter, r j - is a independently and identically-distributed 
random variable (i.i.d.) , N(o,a:) and nu is the expected probability of incidence of 
CRC for fh individual of the i'h category of smoking/alcohol consumption conditional 
on the predictor variables. The SAS codes are shown below [3801 : 
PROC GLIMMIX METHOD = RSPL; 
CLASS cd tobacco/alcohol covariates; 
MODEL crc(event=case) =tobacco/alcohol covariates; 
/SOLUTION DIST =BINARY LINK = LOGIT DDFM = SATTETH ODDSRATIO; 
RANDOM INTERCEPT I SUBJECT = cd SOLUTION; 
NLOPTIONS TECH = NRRIDG; 
RUN; 
where DIST = BINARY and LINK = LOGIT are used to fit dichotomous data. 
Multinomial response (i.e., colon or rectum cancer, deceased case or living case, CRC 
cases with low or intermediate/high familial risk, and CRC cases with MSS/MSI-L or 
MSI-H) are modeled using DIST =MULTINOMIAL and LINK= CUMLOGIT. 
The PROC GLIMMIX statement invokes the procedure [3801. The METHOD = 
RSPL specifies that the estimation technique in generalized linear mixed model is 
residual pseudo-likelihood with a subject-specific expansion. The CLASS statement 
instructs the procedure to treat the variables cd, as classification variable (i.e., it specifies 
that the linear predictor contains an intercept term that randomly varies at the level of the 
cd effect), and treat tobacco/alcohol and covariables as classification variables. The 
MODEL statement lists the same fixed effects as in the conventional approach, and the 
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event = case option instructs PROC GLIMMIX to model the probability of the incidence 
of CRC. The SOLUTION option in the model statement requests a listing of the solutions 
for the fixed-effects parameter estimates. The model option DDFM = SATTERTH uses 
the Satterthwaite method to adjust for denominator degree of freedom for tests of the 
fixed effects. The model option ODDSRA TIO requests calculation of OR and the 
corresponding 95% CI. The RANDOM statement identifies the group structure in the 
mixed model. The random statement with "intercept" argument produces the random 
intercept model. The SUBJECT = cd statement fits a GEE-type model with independence 
working covariance structure and subjects (clusters) defmed by the levels of cd. SAS has 
an alternative algorithm to ask for the random effect solutions by specifying the 
SOLUTION option in the RANDOM statement. Models fit with the GLIMMIX 
procedure usually require nonlinear optimization methods. One can control the 
optimization through options of the NLOPTIONS statement. In this study the TECH = 
NRRIDG option in the NLOPTIONS statement specifies an optimization technique of 
Newton-Raphson with ridging to help with the convergence of the procedure. 
This design effectively controlled for intra-class correlations among census 
divisions within cells of the design (i.e. the tendency for observations adjacent within 
spatial units to be similar to each other). Measures from within one geographic area may 
be highly correlated, whereas those from different areas may be more likely to be 
independent of each other [381 -3841. Given that groups of persons living in adjacent areas 
may share similar backgrounds and behaviors, and communicate with one another, loss of 
spatial independence between units may remain a problem. The multilevel analyses 
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conducted effectively dealt with the great bulk of spatial autocorrelation by virtue of 
nesting 10 census divisions. 
Model fit was evaluated using the model chi-square [219•385•3861. The model chi-
square is the difference between - 2LL for the model with only a constant and - 2LL for 
the model including all independent variables. If a model chi-square is statistically 
significant at the 0.05 level, this leads to rejecting the null hypothesis that all independent 
variables in the model are not related to the outcome. All statistical analyses were 
completed using SAS 9.1 [3671. SAS PROC MEANS, PROC FREQ, and PROC 
GLIMMIX procedures were performed to conduct these statistical analyses. The 
GLIMMIX procedure was used to model the data in the estimate of the OR for drinking 
and smoking to adjust for the random effect of geographic area as well as confounding 
effect of covariates [380]. All significance tests assumed two-tailed P values or 95% Cis. 
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Chapter 5 Assessing non-participation bias of cases and controls 
5 .1. Introduction 
A trend of decreasing participation rates in population surveys is a growmg 
concern in epidemiological research due to the increased likelihood of non-participation 
bias [3131. Low participation rates may compromise the generalizability of population 
survey data [3141, especially when the percentage of non-participants is large, and when 
non-participants differ greatly from participants [3871. Non-participation is an important 
source of inaccurate reporting of alcohol and illicit drug use in population surveys [3 l3,316l, 
and the resulting underestimates of consumption may change the association between 
important variables and prevalence estimates [3131. 
Unfortunately, non-participation bias is usually difficult to determine because 
researchers rarely have information about non-participants. Few studies on non-
participation bias in surveys in the alcohol and drug field have provided a clear answer to 
the issues raised. While some studies found no significant non-participation bias in 
estimating population attributes [317-3191, others have indicated that bias exists [3201; and it 
has been suggested there is a serious chance of bias when a participation rate is below 70 
percent [3211. The degree of non-participation bias is likely related to the focus of the study 
[3201. Several studies about direction of non- participation bias in surveys provide 
conflicting results. Some studies showed that non-participants were more likely to abstain 
from alcohol than participants [322'3231, whereas others indicated non-participants who 
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drank were more likely to be heavier drinkers than participants [3241 . In the population-
based case-control study of CRC conducted in NL, of 1,171 eligible CRC cases who 
consented to participate in the CRC study, accounting for approximately 84.4% of the 
provincial eligible cases, 702 completed and returned the questionnaires, a participation 
rate of 59.9%. Of 1,602 controls meeting eligibility criteria and verbally consenting to 
participate in the study, accounting for 78.9% of eligible controls identified using RDD, 
717 returned completed questionnaires and the participation rate was 44.7%. Therefore, 
non-participation is the main source of potential bias for assessing exposure to risk 
factors such as cigarette smoking and alcohol consumption for developing CRC. The aim 
of the study is to investigate the non-participation bias of cases and controls in this NL 
population-based case-control study. 
5 .2. Assessing methods and statistical analyses 
Several demographic variables for eligible cases and controls and pathological 
characteristics for eligible cases were available from the existing database, and these 
variables are associated with many chronic conditions including cancer. Therefore, 
comparative studies on characteristics between participants and non-participants of cases 
and controls were conducted to assess non-participation bias [365•3661. Differences in the 
characteristics between the eligible population and the participant population are of great 
importance as they may influence both the internal and the external validity of the study 
[3651; therefore, an examination of these differences is an important part of study 
evaluation. 
91 
This study compared the differences in demographic characteristics between 
participating and non-participating controls, and the differences in demographic and 
clinical characteristics between participating and non-participating cases in order to 
determine non-participation bias. The study also compared the differences in age gender, 
rural-urban area and census division between the eligible cases and controls, and between 
participating cases and controls (other epidemiological factors on participating cases ad 
controls have been collected and analyzed in Chapters 7 and 8). Chi-square technique 
was used to examine any differences in the characteristics between participants and non-
participants of cases and controls. Statistical analyses were completed using SAS 9.1 [3671 . 
SAS PROC FREQ was used to perform chi-square analyses. 
5.3. Results 
5.3 .1. Eligible colo rectal cancer cases and controls 
When the study was carried out, 1,171 cases and 1 ,602 controls met the eligibility 
criteria and consented to participate in the study. The mean age of the cases and controls 
was 61.2 and 59.9 years old. Table 9 displays the frequency distribution of all eligible 
cases and controls by the variables known. While the chi-square analysis did not show 
any differences in the distribution of age and sex between eligible cases and controls, the 
analysis suggested more cases lived in rural area and more controls were selected from 
Census Divisions (CD) No. 4, 5, 6 and 7 compared to those eligible cases. 
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Table 9. The characteristics of eligible cases of colorectal cancer and controls in the case-control 
stud 
Characteristics Eligible cases Eligible controls 
N %6 N %6 
Age group (years) 
20-49 131 11.19 222 13.86 
50-59 318 27.16 441 27.53 
60-69 474 40.48 614 38.33 
70-75 248 21.18 325 20.29 
Sex 
Female 477 40.73 639 39.89 
Male 676 59.27 963 60.1 I 
Residence area *** 
Urban 495 42.27 792 49.44 
Rural 676 57.73 810 50.56 
CD§ ** 
CDNo.l 562 47.99 743 46.38 
CD No.2 81 6.92 98 6.12 
CD No.3 18 1.54 21 1.31 
CD No. 4 47 4.01 99 6.18 
CD No.5 73 6.27 155 9.68 
CD No.6 98 8.37 144 8.99 
CD No. 7 36 3.07 54 3.37 
CD No.8 143 12.21 157 9.80 
CD No.9 70 5.98 72 4.49 
CDNo. 10 43 3.67 59 3.68 
Total 1,171 100.00 1,602 100.00 
Note: § CD: census division (see Table 8). 6 Column%. X2: *P<0.05 **P<O.O I ***P<O.OO 1. 
5.3.2. Participating colorectal cancer cases and controls 
While the chi-square analysis based on participating cases and controls was 
conducted, the study found no significant differences in age, sex and census division 
between the cases and the controls (Table 10). However, the analyses showed that more 
participating cases lived in rural area compared to those participating controls. 
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Table 10. The characteristics of participating cases of colorectal cancer and controls in the case-
control study 
Characteristics ParticiEating cases 
ParticiEating controls 
N %Ll N % Ll 
Age group (years) 
20-49 88 12.68 83 13.86 
50-59 211 30.06 209 27.53 
60-69 274 38.89 282 38.33 
70-75 129 18.38 143 19.94 
Sex 
Female 273 38.89 293 40.86 
Male 429 61.11 424 59.14 
Residence area * 
Urban 302 43 .02 355 49.51 
Rural 400 56.98 362 50.49 
CD§ 
CDNo. I 329 46.87 327 45.61 
CD No.2 53 7.55 48 6.69 
CD No.3 9 1.28 8 1.12 
CD No. 4 26 3.70 37 5.16 
CD No.5 43 6.13 78 10.88 
CD No.6 65 9.26 60 8.37 
CDNo. 7 27 3.85 28 3.91 
CD No.8 82 11.68 78 10.88 
CD No.9 43 6.13 30 4.18 
CD No. 10 25 3.56 23 3.21 
Total 702 100.00 717 100.00 
Note: § CD: census division. Ll Column%. X2: *P<0.05 **P<O.Ol ***P<O.OOl. 
5.3 .3. Case participants and non-participants 
Table 11 shows the participation rate of CRC cases and the frequency distribution 
of case participants and non-participants. The study did not find any significant 
relationship between participation and sex, urban-rural residence, census division, year of 
diagnosis, CRC site, and method of diagnosis. However, the analysis showed that 
younger people were more likely to respond to the request to participate in the survey; 
94 
and more deceased cases tended to be included m the study compared to those 
participants still living during the study period. 
Table 11. Participation rate and the characteristics of study participants and non-participants of 
colorectal cancer cases in the case-control stud;r 
Characteristics Rate & 95% CI --./ ParticiEant Non-ParticiEant 
N %~ N %~ 
Age group (years) ** 
20-49 67.18 (± 8.04) 88 12.54 43 9.17 
50-59 66.35 (± 5.19) 2 11 30.06 107 22.8 1 
60-69 57.81 (± 4.45) 274 39.03 200 42.64 
70-74 52.02 (± 6.22) 129 18.38 119 25.37 
Sex 
Female 57.23 (± 4.44) 273 38.89 204 43.50 
Male 61.82 (± 3.61) 429 61.11 265 56.50 
Residence area 
Urban 61.0 I (± 4.30) 302 43 .02 193 41.15 
Rural 59.17 (± 3.71) 400 56.98 276 58.85 
CD§ 
CDNo. l 58.54 (± 4.07) 329 46.87 233 49.68 
CD No.2 65.43 (± I 0.36) 53 7.55 28 5.97 
CD No.3 50.00 (± 23 .1 0) 9 1.28 9 1.92 
CD No.4 55.32 (± 14.21) 26 3.70 2 1 4.48 
CD No.5 58.90 (± 11.29) 43 6.13 30 6.40 
CD No. 6 66.33 (± 9.36) 65 9.26 33 7.04 
CD No.7 75.00 (± 14.15) 27 3.85 9 1.92 
CD No.8 57.34 (± 8.11) 82 11.68 61 13.0 1 
CD No.9 61.43 (± 11.40) 43 6.13 27 5.76 
CDNo. 10 58.14 (± 14.75) 25 3.56 18 3.84 
Year of diagnosis 
1999 59.39 (± 6.36) 136 19.37 93 19.83 
2000 66.17 (± 6.54) 133 18.95 68 14.50 
2001 64.00 (± 5.95) 160 22.79 90 19.19 
2002 57.46 (± 6.42) 131 18.66 97 20.68 
2003 53.99 (± 6.02) 142 20.23 121 25.80 
CRC site 
Colon 61.12 (± 3.45) 470 66.95 299 63.75 
Rectum 57.71 (± 4.83) 232 33.05 170 36.25 
Diagnosis method 
Biopsy 62.29 (± 4.15) 327 46.92 198 42.40 
Pathology 57.90 (± 3.83) 370 53.08 269 57.60 
Other (7 cases) 
Death ** 
No 56.20 (± 3.46) 444 63.25 346 73.77 
Yes 67.72 {± 4.692 258 36.75 123 26.23 
Total 59.95 (± 2.81) 702 100.00 469 100.00 
Note: §CD: Census Division. 'J Participation rate(%).~ Column%. X2: *P<0.05 **P<0.01 ***P<O.OO 1. 
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5.3.4. Control participants and non-participants 
Table 12 shows the participation rate of controls and the characteristics of control 
participants and non-participants. The chi-square analysis did not find any significant 
relationship between participation and age, sex, urban-rural residence or census division. 
Table 12. The characteristics of control participants and non-participants in the case-control study 
Characteristics Rate & 95% CI ..,J N Participan~ tJ. %on-Partic~~t 
Age group (years) 
20-49 37.39 (± 6.36) 83 11.58 139 15.7 I 
50-59 47.39 (± 4.66) 209 29.15 232 26.2 1 
60-69 45.93 (± 3.94) 282 39.33 332 37.51 
70-74 44.00 (± 5.40) 143 19.94 182 20.56 
Sex 
Female 45.85 (± 3.86) 293 40.86 346 39.10 
Male 44.03 (± 3.14) 424 59.14 539 60.90 
Residence area 
Urban 43 .83 (± 3.42) 355 49.51 455 51.41 
Rural 45.71 (± 3.47) 362 50.49 430 48.59 
CD§ 
CDNo.1 44.01 (± 3.57) 327 45.61 416 47.01 
CD No.2 48.98 (± 9.90) 48 6.69 50 5.65 
CD No. 3 38.10 (± 20.77) 8 1.12 13 1.47 
CD No. 4 37.37 (± 9.53) 37 5.16 62 7.01 
CD No.5 50.32 (± 7.87) 78 10.88 77 8.70 
CD No.6 41.67 (± 8.05) 60 8.37 84 9.49 
CD No.7 51 .85 (± 13.58) 26 3.91 26 2.94 
CD No.8 49.68 (± 7.82) 78 10.88 79 8.93 
CD No.9 41.67 (± 11.39) 30 4.18 42 4.75 
CDNo. 10 39.98 (± 12.50) 23 3.21 36 4.07 
Total 44.76 (± 2.43) 717 100.00 885 100.00 
Note: § CD: Census Division. 'J Participation rate(%). tJ. Column%. X2: *P<0.05 **P<O.O I ***P<O.OO I. 
5.4. Discussion 
Participation bias arising from differences in characteristics between participants 
and non-participants is always a concern in epidemiological studies when participation 
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rates are low, as it may lead to biased estimates of prevalence and association [3651. 
Effects depend on selection criteria, defined by the investigator, and the extent of 
participation in a case-control study. Selection bias might affect the generalizability or 
the external validity of the results [3651. Differences in selection processes between the 
groups being compared may also affect the validity of the comparison (i.e. the internal 
validity of the study). The definitions of the different levels of population may also 
modify the hypothesis which is being tested in the study l365l. 
Cases in this study were obtained from the provincial population-based cancer 
registry (NCR). The study population was resident in NL, who had CRC diagnosed and 
reported to the registry between 1999 and 2003, and were aged 20-7 4 years old. A list of 
1,171 NL residents aged 20-74 years old with a CRC diagnosis during the period from 
1999 to 2003, who consented to participate in the study, was obtained through NCR to 
conduct the study of genetic and environmental factors of CRC. Cancer reporting is 
considered virtually complete in NL, since each Canadian province and territory has a 
legislated responsibility for cancer collection and control [3881• This is likely true, since 
these cases were obtained through the NCTRF which serves the whole province; almost 
all cases of CRC would come into hospital for diagnosis or treatment. Controls were 
randomly selected from the general population within the same age range using RDD l3541. 
In a case-control study, the cases should truly be cases and be newly incident with 
the outcome such as CRC; the cases should also be a total or representative series of 
cases from a defmed eligible and source population [3651. The inclusion of some 
individuals who do not have the outcome in question within the case group will tend to 
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dilute the case group and bias the results of the study towards the null value. However, in 
this study, as described earlier, all the records of the NCR were reviewed in order to 
identify cases, pathology reports were sought to confirm the diagnosis, and pathological 
reviews for all cases were done. Over 99.9% of all 1,171 CRC cases were diagnosed for 
the first time between 1999 and 2003 using the methods of biopsy and pathology. 
Therefore all CRC cases identified can truly be considered eligible cases and would not 
dilute the fmal results. 
Subjects in the control group were chosen to be true controls without the outcome 
of interest at the time the study was performed [3651; the control group was also chosen to 
be representative of the entire population at risk, and was matched to the cases in terms of 
five-year age group and sex. By comparing representative samples of CRC cases to 
controls who did not have the outcome, the study provided an estimate of the OR in 
underlying population. Misclassification, whereby some who were actually cases were 
included in the control group, would have a dilution effect and bias the results of the 
study towards the null value. It is possible that some controls developed a case after the 
survey. Where the estimated age-standardized incidence rate for CRC was 0.76%o for 
males and 0.51 %o for females in NL in 2003 [3881, the risk of this misclassification is 
likely to be too small to be important and this effect could not be considerable. Therefore, 
both case and control non-participation would be unlikely to bias the internal validity of 
research based on these participants; otherwise the research results tend to be more 
conservative. 
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The characteristics of eligible cases and controls who did not consented may 
differ from that of those who consented to participate in the study and potential biases 
may exist. While eligible cases and controls who consented to participate in the study 
accounted for 84.4% of eligible cases and 78.9% of eligible controls, the samples of cases 
and controls who consented to participate should be the representative of eligible 
respondents when a participation rate is over 70 percent [3211. However, low participation 
rates of eligible cases and controls may have affected the generalizability of the results. 
Although the cases were identified in the provincial cancer registry and the 
controls were randomly selected from the provincial population, the generalizability of 
the results was still a concern because of low participation in this study. Since there is no 
information on tobacco smoking and alcohol consumption for non-participants, the study 
cannot evaluate any differences in exposure between participants and non-participants 
directly. A study on non-response bias in the use of alcohol and other drugs based on the 
2004 Canadian Addiction Survey (CAS) showed non-response bias on some estimates of 
substance use, but the effects were small [3891. 
In this study, the analyses of control participation showed that there were no 
statistically significant differences in age, sex, and residence between participants and 
non-participants, suggesting no substantial selection bias. The analyses of cases did not 
show a significant difference in sex, year of diagnosis, residence of diagnosis, subsites of 
CRC (colon or rectum), or diagnosis method between participants and non-participants. 
The analyses found that more participant cases than non-participant cases were younger 
than 60 years old and in terminal stages at diagnosis, and this may bias the results. 
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However, the estimates of cigarette smoking and alcohol drinking in the national surveys 
(see Table 14 and 16 in Chapter 6) did not suggest more cigarettes smoked and alcohol 
consumed among younger than older Canadians. Furthermore, the estimates of the 
adjusted OR of living and deceased CRC cases for smoking and drinking in Chapter 7 
and 8 (see Table 31 and 44) of this thesis did not demonstrate any substantial effects on 
the associations. 
One concern was that more eligible cases lived in rural areas, and more cases who 
lived in rural areas tended to participate in the study. Several studies conducted in Canada 
found a significantly higher smoking prevalence in rural areas [390'3911, and this may result 
in some degree of overestimation with respect to smoking among cases compared to 
controls. However, 59.2% of participating cases versus 57.0% participating controls 
living in rural areas is not too large and no substantial effect can be assumed. Another 
issue was that more controls were selected from census divisions 4, 5, 6 and 7 compared 
to cases. While the number of participating controls from these four census divisions 
accounted for a small proportion of total controls in the study, no substantial effect can be 
assumed. 
In summary, while low participation rates among both cases and controls and 
significant differences in participation rates of cases between rural and urban residences, 
and different census divisions, non-participation bias cannot be excluded and therefore 
the results may not be generalized to the eligible population and other populations. 
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Chapter 6 Assessing reporting bias of self-reported tobacco 
smoking and alcohol intake 
6.1. Introduction 
The population-based case-control study of CRC conducted among NL residents 
to investigate the relationship between developing CRC, tobacco smoking and alcohol 
intake was based on self-reporting of participants. As described in depth in Chapter 4, 
cases and controls were asked about exposure in the past, and the validity of self-reported 
tobacco smoking and alcohol consumption was a concern because the accuracy of recall 
is usually related to the amount of time elapsed between the exposure and the recall [3261. 
Lifetime measures might be inaccurate because of the concern about the adequacy of 
long-term recall after 18 years [3271• For a variety of reasons, including issues of social 
desirability or sensitivity, subjects may not be willing to report an exposure accurately. 
When studies gather exposure data, subjects may underestimate the number of cigarettes 
they smoke and the amount of alcohol they drink [3281. 
Inaccurate report of exposure may produce bias away from the null [392-3951 
although, in general, inaccurate reporting biases the association toward the null value [396-
3991. The validity of self-reported tobacco smoking and alcohol consumption may differ 
between cases and controls since the cases and controls by definition are people who 
differ with respect to their disease experience, and this difference may affect recall [3251. 
The bias caused by differential misclassification can either exaggerate the relative risk of 
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disease when cases overestimate and/or controls underestimate exposure or lessen an 
effect if cases underestimate and/or controls overestimate exposure [3251. Few studies have 
been conducted to investigate the accuracy of self-reported lifetime tobacco smoking and 
alcohol intake. Thus, the aim of this chapter is to examine the accuracy of self-reported 
lifetime tobacco smoking and alcohol consumption, and investigate the differences in the 
accuracy of self-reported tobacco smoking and alcohol consumption between cases and 
controls in the NL case-control study of CRC. 
6.2. Assessment methods 
Details on assessing methods and estimate procedures of self-reported tobacco 
smoking and alcohol consumption have been described in Chapter 4. This section briefly 
describes these assessment methods and analytical procedures. 
6.2.1 . Validity of self-reported tobacco and alcohol consumption 
Annual per capita tobacco and alcohol consumption were estimated using the 
weighted sample of controls in the case-control study as controls were disproportionately 
selected from the general population to allow the study to match controls with cases on 
five-year and sex [374'4001. The results were compared to the sales data of tobacco and 
alcohol in NL. Per capita tobacco consumption was estimated for cigarettes and total 
cigarettes (cigarettes, one cigar = 4 cigarettes and one pipe = 2.5 cigarettes). Annual 
packs of cigarettes and total cigarettes were also estimated based on the weighted sample 
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of controls in the case-control study. The results were compared to the sales data of 
tobacco to assess the accuracy of self-reported tobacco consumption. 
Per capita alcohol consumption was also estimated for the three major categories 
of alcoholic beverages (beers, wines and spirits). Percentage of annual alcohol 
consumption from beers, wines and spirits to total alcohol consumption was also 
estimated based on the weighted sample of controls in the case-control study. The results 
were compared to the sales data to assess the accuracy of self-reported beer, wine and 
spirit drinking. 
Per capita tobacco and alcohol consumption and the percentage by subgroups 
were estimated using the weighted sample of controls from the case-control study. The 
results were compared to the estimates from the CCHS data to examine any difference in 
the patterns of tobacco and alcohol consumption between the case-control study and the 
national survey data. Tobacco and alcohol consumption by subgroups among cases and 
controls in the case-control study were estimated to examine the patterns of tobacco and 
alcohol consumption among cases and controls, and so found any differences in the 
validity of self-reported tobacco smoking and alcohol consumption between cases and 
controls. 
6.2.2. Data analyses 
Annual per capita tobacco and alcohol consumptions and percentages of tobacco 
and alcohol consumption were estimated using the weighted sample of controls in the 
case-control study, CCHS 1.1 and 3.1 , the sales data of tobacco and alcohol. The results 
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were compared between these data sources to assess the accuracy of self-reported tobacco 
and alcohol consumption in the case-control study. The same analyses were also 
conducted among cases and controls to examine any differences in the reporting tobacco 
and alcohol consumption because of case status. The statistical analyses were performed 
using SAS 9.1 [3671. 
6.2.2.1. Analyses for the case-control study 
Tobacco and alcohol consumption in the population aged 20-74 years old were 
estimated using the weighted sample of controls in the case-control study [350•3741. 
Average annual tobacco per smoker and alcohol consumption per drinker, and 
percentages of tobacco smoked by smokers and alcohol consumed by drinkers were also 
estimated for subgroups of the population. The results were compared to the sales data of 
tobacco and alcohol in NL. The analyses were also conducted between cases and controls 
in the case-control study. 
6.2.2.2. Sales data analyses 
The cigarettes and total cigarettes (cigarettes + cigars and pipe equivalent) 
smoked by smokers aged 20-74 was estimated based on the proportion of cigarettes 
consumed by those 20-74, using the proportion (0.9331) of cigarettes smoked by daily 
and occasional smokers aged 20-74 in CCHS 1.1. More information on CCHS 1.1 can be 
found elsewhere [3571. The annuallitres of alcohol consumption for drinkers aged 20-74 
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were estimated using a proportion (0.8956) of alcohol consumption for population aged 
20-7 4 to population aged 12 years and older in CCHS 1.1. 
6.2.2.3. Analyses of the Canadian Community Health Surveys 
The number of cigarettes smoked yearly was estimated based on the number of 
cigarettes per day as reported daily smokers multiplied by 365 days. The number of 
cigarettes smoked by occasional smokers was estimated based on the answer to the 
question: "On the days that you smoke, about how many cigarettes do you usually have?" 
and "In the past month, on how many days have you smoked one or more cigarettes?" 
The last seven days method was used to estimate alcohol use based on CCHS 1.1 and 3.1 
[3711; a method that requires people to complete a retrospective ' diary' showing how much 
alcohol they drank on each of the last seven days [37 11 . The overall volume of ethanol for 
the week is the sum over all days of the number of drinks times the litres of ethanol 
assumed to be in a standard drink [3711. In Canada, a standard drink equals to 0.0172 litres 
[3701. The respondents were required to report the number of drinks of beer, wine, liquor 
or any other alcoholic beverage each day in one week prior to the interview day. The 
number of drinks in the past year was thus estimated by taking the number of drinks 
consumed in one week and multiplying this by 52 weeks. The rescaled weights were 
incorporated in the calculations to adjust for sampling method in the surveys [3751. 
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6.3. Results 
6.3.1. Accuracy of self-reported tobacco smoking and alcohol consumption 
6.3 .1.1. Estimate of tobacco smoking 
Table 13 presents the estimates of tobacco smoked yearly based on the weighted 
sample of controls in the case-control study and the sales data. The estimated annual 
packs of cigarettes were 209 per smoker aged 20-74 years old in the NL case-control 
study which accounted for 71% of the estimate from the sales data (296). The estimates 
from the sales data in NL were not within 95% CI of the estimates from the case-control 
study, and the case-control study significantly underestimated tobacco smoking compared 
to the sales data. 
Table 13. The estimates of per capita packs of cigarettes and total cigarettes yearly based on the 
weighted sample of controls in the case-control study compared to the sales data 
Beverages 
Cigarette packs 
Total cigarette packs 
N 
454 
454 
Average Annual Per Capita Cigarettes and Pack Years 
Controls 95% CI (1935-2003) r Sales Data (1980-2003) 'V 
209 166 - 252 296 
214 170- 257 
Note: r 2001 Canada census population aged 20-74 by age and sex to correct overrepresentation of males 
and older aged people in the weighted control sample in NL. 'V The sales data obtained from Health 
Canada, Wholesales sales data: cigarette and fine-cut sales charts 1980-2008 and cigarettes smoked by 
those aged 20-74 estimated based on proportion of cigarettes smoked for population 20-74 in CCHS 1.1 
(2001 ), and population data obtained from Statistics Canada, downloaded from http://estat.statcan.gc.ca 
/cgi-win/CNSMCG I .EXE. 
Table 14 presents the percentage and annual cigarette packs per smoker by 
subgroups in NL in CCHS 1.1 and 3.1 , and in the weighted sample of controls in the 
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case-control study. The results showed that cigarette packs per smoker estimated from the 
case-control study for most of subgroups were similar to that from CCHS 1.1 and 3 .1 . 
The two CCHS datasets and the case-control study dataset showed similar patterns of 
cigarette smoking among Canadian smokers aged 20-74 years old. For example, those 
who had at least some post-secondary school education smoked 42.01% of cigarettes in 
CCHS 1.1 , 50.94% in CCHS 3.1 and 50.48% in the case-control study, which represented 
the largest proportion of total cigarettes by education. However, the cigarette smoking 
was obviously underestimated by some groups such as females. 
Table 14. Percentage and annual per capita cigarette packs pe r smoker by subgroups among 
Canadians aged 20-74 in Newfoundland and Labrador in the 2001 and 2005 Canadian Community 
Health Surveys and in the weighted sample of controls in t he case-control study 
Demographics 
CCHS 1.1 CCHS 3. 1 amele of Controls 
Nr % '1' Mean 'I' Nr %'1' Mean 'I' Nr % '1' Mean 'I' 
Age 
20-49 729 75.98 262(± 15) 579 69.83 245 (±32) 46 60.82 21 1 (±72) 
50-59 159 16.42 308 (±32) 156 20.56 293 (±38) 12 1 21.56 23 1 (±32) 
60-69 72 5.71 257 (±43) 87 7.80 248 (±38) 192 13.60 207 (±26) 
70-74 22 1.88 259 (±68) 31 1.82 2 18 (±80) 88 4.02 190 (±36) 
Sex 
Male 480 59.23 308 (± 19) 399 55.83 286 (±44) 300 70.48 284 (±65) 
Female 502 40.77 226 (± 15) 454 44.18 222 (±19) 147 29.52 134 (±38) 
Marital status 
Married 634 68.18 280(± 15) 490 66.48 265 (±36) 362 81.92 208 (±50) 
Wid/sep/div 143 9.49 270 (±31) 129 12.09 294(±41) 72 10.35 193 (±59) 
Single 205 22.33 239 (±28) 234 21.43 208 (±26) 13 7.73 398(±264) 
School 
<high 352 39. 11 314(±23) 270 29.87 280 (±27) 163 31.68 292 (±43) 
=High 165 18.88 290 (±26) 14 1 19.19 256 (±43) 78 17.84 22 1 (±73) 
>high 465 42.01 230 (± 17) 442 50.94 239 (±4 1) 206 50.48 18 1 (±37) 
Total 982 100.00 269 (± 13) 853 100.00 253 (±24) 447 100.00 214 (±44) 
Note: r: unweighted CCHS 1.1-200 I survey, CCHS 3.1-2005 survey and control sample. '1': weighted estimates. 
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6.3 .1.2. Estimate of alcohol consumption 
Table 15 presents the percentage of each beverage consumed yearly and average 
annual litres of alcohol of beverages per drinker estimated in the weighted sample of 
controls in the case-control study and based on the alcohol sale data. Per capita litres of 
total alcohol consumption estimated in the case-control study were close to the estimates 
of the sales data. Each drinker consumed 13.20 litres of ethanol yearly (95% CI: 10.4 7 -
15 .93) based on the case-control study data. The estimates of average annual litres of 
alcohol consumption per drinker (11.35) from the sales data were within 95% CI of the 
estimate from the weighted sample of controls. 
Table 15. Percentage of each beverage consumed yearly and average annual per capita litres of 
ethanol per drinker estimated in the weighted sample of controls in the case-control study and based 
on the alcohol sales data 
Alcohol Consumption in Litres Per Drinker 
Beverages Sales Data t Control Sample (95% CI) 
(1992-2003) (1940-2003) 
Beer 6.52 N=453 6.84 5.17- 8.50 
Wine 0.70 N=453 1.45 0.87-2.04 
Spirit 4.13 N=453 4.91 3.56- 6.24 
Total alcohol 11.35 N=453 13.20 10.47-15.93 
Percentage of Each Beverage % t 
Sales Data t Control Sample 
(1992-2003) (1940-2003) 
57.42 51 .80 
6.16 11.04 
36.42 37.16 
100.00 100.00 
Note: t litres for each beverage to total alcohol consumption on average yearly. t The sales data of alcohol 
obtained from Statistics Canada, downloaded from http://estat.statcan.gc.ca/cgi-win/CNSMCGI.EXE and 
alcohol consumed by those aged 20-74 estimated based on proportion of alcohol consumption for 
population aged 20-74 in CCHS 1.1 (2001), and population data obtained from Statistics Canada, 
downloaded from http://estat.statcan.gc.ca/cgi-win/CNSMCGI.EXE. 
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Beer consumption accounted for 51.80% of total alcohol consumption, and wine 
and spirit consumption accounted for 11.04% and 37.16% respectively, based on the 
weighted sample of controls. Beer consumption tended to be underestimated and wine 
and spirit consumption tended to be overestimated based on the case-control study data 
compared to the sales data. The estimates of per capita alcohol consumption from beers 
and spirits from the sales data were within 95% CI of the estimates in the case-control 
study, but alcohol consumption for wines was significantly overestimated in the case-
control study compared to the sales data. 
Table 16 presents the percentage and annual per capita alcohol consumption by 
subgroups among Canadians aged 20-74 in NL in CCHS 1.1 and 3.1, and in the weighted 
sample of controls in the case-control study. The results show that per capita alcohol 
consumption was significantly underestimated in CCHS 1.1 and 3.1 for almost all 
subgroups. However, the drinking patterns generally remained unchanged in three 
samples. For example, the ratio of per capita litres of alcohol consumption for males 
versus females was 2.5 in the control sample, 1.9 in CCHS 3.1 and 2.4 in CCHS 1.1. The 
percentages of alcohol consumption within the subgroups varied in three samples in NL, 
but they showed similar patterns. For example, men consumed 77.75% of totallitres of 
alcohol and women consumed 22.25% in the case-control study of CRC compared to 
74.20% and 25.80% in CCHS 1.1 , and 71.49% and 28.51% in CCHS 3.1. 
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Table 16. Percentage and annual per capita litres of absolute alcohol consumption per drinker by subgroups 
among Canadians aged 20-74 in Newfoundland and Labrador in the 2001 and 2005 Canadian C ommunity 
Health Surve~s and in the weighted sample of controls in the case-control stud~ 
Demographics 
CCHS 1.1 CCHS 3.1 Sarnele of Controls 
Nr %\11 Mean \11 Nr %\11 Mean \11 Nr % \11 Mean \11 
Age 
20-49 1, 180 71.12 6.60(±0.41) 1238 69.54 6. 79 (±0.44) 65 66.57 12.60 (±3.80) 
50-59 361 19.94 6.62(±0.87) 4 10 19.98 6.68 (± 1.25) 140 2 1.1 2 15.43 (±4.37) 
60-69 150 6.93 6.20(±1.81) 240 8.16 5.4 7 (±0.57) 174 9.78 13.58 (±2.79) 
70-74 47 2.0 1 5.42(±1.63) 95 2.31 4.82 (±0.94) 74 2.53 12.55 (±3.48) 
Sex 
Male 996 74.20 8.16(±0.55) 1,07 1 71.49 8.08 (±0.62) 339 77.75 17.88 (±4.06) 
Female 742 25.80 4.18(±0.29) 9 12 28.51 4.49 (±0.32) 11 4 22.25 6.89 (±2.60) 
Marital status 
Married 1,207 65.03 5.98(±0.36) 1,331 66.34 6.02 (±0.35) 384 83.27 12.75 (±3.0 1) 
Wid/sep/div 206 7.87 6.85(±1.61) 234 9.01 8.16 (±3.06) 56 10.35 14. 15 (±4.04) 
ingle 325 27. 11 8.36(± 1.03) 4 18 24.65 8.02 (±0.93) 13 6.39 20.34(± 19.07) 
chool 
<high 423 20.84 6.59(±0.64) 38 1 17.00 7.00 (±0.97) 128 18.38 17.46 (±2.42) 
=High 272 17.99 6.88(±0.92) 294 17.32 7.29 (±1.56) 73 12.35 13.85 (±5.30) 
>high 1,043 61.17 6.44(±0.48) 1,308 65.68 6.32 (±0.39) 252 69.27 12.30 (±3.36) 
Total 1,738 100.00 6.55(±0.36) I 983 100.00 6.58 (±0.39) 453 100.0 13.20 (±2.73~ 
Note: r : unweighted CCHS 1.1-200 I survey, CCHS 3. 1-2005 survey and control sample. \11: weighted estimates. 
6.3.2. Tobacco smoking and alcohol intake and case-control status 
6.3.2.1. Tobacco smoking and case-control status 
Table 17 presents annual numbers and packs of cigarettes and total cigarettes 
(cigarettes, cigars and pipes) per smoker for cases and controls in the case-control study. 
While the control smokers smoked 218 packs of cigarette, and cigars and pipes 
equivalent to six packs of cigarettes on average per year prior to the survey, case smokers 
smoked 262 packs of cigarette, and cigars and pipes equivalent to four packs of cigarettes 
on average per year prior to their diagnosis of CRC. Cases smoked 40 more cigarette 
packs or total cigarette packs yearly than did controls (95% Clctiff: 42-45 and 41-44). 
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Table 17. Annual number and packs of cigarettes and total cigarettes for cases ad controls in the 
case-control study 
Tobacco smoking Case Control 
N Mean 95%CI N Mean 95%CI 
Cigarettes 504 5230 4859-5601 454 4352 4000-4705 
Total cigarettes oo 504 5325 4950-5701 454 4473 4115-4830 
Cigarette packs 504 262 243-280 454 218 200-235 
Total packs oo 504 266 248-285 454 224 206-242 
Note: oo I cigar = 4 cigarettes and 1 pipe = 2.5 cigarettes. 
Table 18 presents the average annual cigarette packs per smoker by subgroups in 
the case and control samples in the case-control study. The results show similar patterns 
of cigarette smoking reported by smokers in both the case and control samples in NL. For 
example, cigarettes smoked by age groups of cases and controls accounted for 11.53% 
and 11.07% for aged 20-49, 29.30% and 28.54% for aged 50-59, 40.86% and 42.56% for 
aged 60-69, and 18.31% and 17.83% for aged 70-74. 
Table 18. Average annual per capita cigarette packs per case and control smoker by subgroups in the 
case-control stud~ 
Demographics Case Control 
N % Mean 95%CI N % Mean 95%CI 
Age 
20-49 62 11.52 245 196-294 46 11.07 238 168-308 
50-59 152 29.29 254 223-285 12 1 28.55 233 199- 267 
60-69 196 40.86 275 241-308 192 42.55 219 191- 247 
70-74 91 18.32 265 224- 307 88 17.83 200 166- 234 
Sex 
Male 345 75.34 288 263-3 13 300 76.13 25 1 227-274 
Female 156 24.66 208 188-229 147 23.87 160 139- 182 
Marital status 
Married 400 79.00 260 240-281 362 77.66 2 12 194- 229 
Wid/sep/div 78 16.24 274 220-329 72 15.77 2 17 179-255 
Single 23 4.77 273 189-357 13 6.56 499 199-798 
Education 
<high school 242 50.45 275 247- 303 163 39.43 239 205- 274 
=High school 80 16.19 267 212-322 78 17.09 2 16 180- 252 
>hi~h school 179 33.36 246 219-272 206 43.48 208 185 -232 
Total 501 100.00 263 244-282 447 100.00 221 203-239 
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6.3.2.2. Alcohol consumption and case-control status 
Table 19 presents the percentages of alcohol consumption (ethanol in litres) from 
each beverage to total alcohol consumption and per capita litres of alcohol from 
beverages consumed for cases and controls estimated in the case-control study. Case 
drinkers tended to consume more beer and fewer wines and spirits than control drinkers 
in NL. Case drinkers on average consumed 16.94 litres of ethanol per year prior to the 
CRC diagnosis, and controls consumed 14.34- a significant difference between cases and 
controls (95% Cldiff: 2.45-2.69). While case drinkers consumed more beer (95% Cldiff: 
2.21-2.36) and spirits (95% Cldiff: 0.26-0.41) than control drinkers did, control drinkers 
consumed more wine than case drinkers did (95% Cldiff: 0.03-0.06). 
Table 19. Per capita litres of ethanol of beverages per case drinker and control drinker estimated in 
the case-control study 
Beverages Case Control 
N %t Mean 95%CI N %t Mean 95%CI 
Beer 432 56.38 9.55 8.33 - 10.77 453 50.60 7.27 6.27- 8.28 
Wine 432 5.63 0.95 0.73- 1.17 453 6.94 1.00 0.79- 1.21 
Liquor 432 37.99 6.44 5.43-7.43 453 42.45 6.10 4.89- 7.32 
Total alcohol 432 100.00 16.94 15.12-18.76 453 100.00 14.37 12.53 - 16.22 
Note: t litres for each beverage to total alcohol consumption. 
Table 20 presents average annual litres of absolute alcohol consumption and 
percentage of alcohol consumption by subgroups in the case and control samples in NL. 
Case drinkers consumed more alcohol than control drinkers did for almost all subgroups 
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in NL. The percentages of alcohol consumption by subgroups show similar patterns of 
drinking reported by the drinkers in the case and control samples in NL. For example, 
male case drinkers consumed 90.41% of total alcohol consumed by case drinkers, and 
male control drinkers consumed 91.28% of total alcohol consumed by control drinkers. 
Table 20. Annual I litres of absolute alcohol consumption per case and control drinker and 
percentage of alcohol consumption by subgroups in the case-control samples in the case-control study 
Demographics 
Case Control 
N %t Litres 95%CI N %t Litres 95%CI 
Age 
20-49 63 16.74 19.44 13.16-25.73 66 13.13 12.95 9.28-16.62 
50-59 137 32.13 17.16 13.83-20.49 143 32.44 14.77 10.90- 16.63 
60-69 161 36.02 16.37 13.43- 19.11 174 38.48 14.40 11.39- 17.41 
70-74 72 15.11 15.36 12.09 - 18.62 75 15.95 13.84 10.19- 17.50 
Sex 
Male 335 90.41 19.75 17.60-21.91 341 91.28 17.43 15.09-19.76 
Female 97 9.59 7.24 4.89-9.57 117 8.72 4.85 3.81-5.89 
Marital status 
Married 349 76.13 15.96 14.00- 17.85 384 80.16 13.67 11.82 - 15.52 
Wid/sep/div 62 18.32 21.62 15.95-27.29 56 15.84 17.86 10.16-25.56 
Single 21 5.55 19.36 6.50-32.21 13 4.00 20.02 9.89-30.15 
Education 
<high school 188 42.05 16.37 13.87- 18.87 128 36.27 18.45 14.78-22.13 
=High school 63 16.63 19.31 13.92-24.70 73 14.70 13.12 9.56- 16.66 
>high school 181 41.32 16.71 13.74- 19.68 252 49.03 12.67 10.14- 15.20 
Total 432 100.00 16.94 15.13- 18.76 453 100.00 14.37 12.53 - 16.22 
Note: t litres for each subgroup to the sample. 
6.4. Discussion 
In the NL population-based case-control study of CRC, data on tobacco smoking 
and alcohol consumption were collected by means of self-administered questionnaires 
and thus potentially susceptible to reporting bias [365•4011. A general problem in measuring 
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tobacco smoking and alcohol intake, particularly over a lifetime, is the absence of a "gold 
standard" such as direct observation of smoking and drinking behaviours [3711. Self-
reports are the simplest method of gathering the data but are prone to reporting bias since 
accuracy of recall is affected by the elapsed time since the event occurred, as well as the 
saliency of the event and its frequency of occurrence. Extending the reference period to a 
lifetime probably will affect the accuracy of such self-reports [4021. In the case-control 
study, the main protection against bias was the standardization of methods, so the 
questions were identical and presented in an identical fashion to both cases and controls. 
However, cases might have acknowledged smoking and drinking as a cause of CRC, and 
so more likely to remember more about tobacco smoking and alcohol consumption than 
controls, thus resulting in the overestimation of these exposures which can exaggerate the 
association [3651. 
In this thesis, the accuracy of self-reporting lifetime tobacco smoking and alcohol 
intake measures was estimated by a comparison of self-report versus sales statistics 
versus survey reports of tobacco smoking and alcohol consumption. The accuracy of self-
reported lifetime alcohol consumption and tobacco smoke was assessed by a comparison 
with two external sources: alcohol and tobacco sales statistics, and self-reported alcohol 
consumption and tobacco use from CCHS. The study also compared the differences in 
the accuracy of self-reported alcohol and tobacco use between cases and controls to 
assess the differential misclassification bias because of case-control status. 
The estimated annual numbers and packs of cigarettes and total cigarettes 
(including cigars and pipes) smoked were lower in the case-control study than the sales 
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data in NL. If including illegal tobacco products, the estimates of tobacco smoking from 
the case-control study might be greatly lower than actual tobacco smoking - about 22 
percent of cigarettes smoked in Canada are illegal every year [4031. Per capita tobacco 
consumption in the case-control study tended to be underestimated compared to the 
national surveys. The results in this thesis are consistent with another study based on the 
NL case-control study which also shows an underestimate of cigarette smoking [354]. 
Although the estimates of tobacco smoking based on the two CCHS datasets and the 
case-control study dataset varied by subgroups, the estimates did not show any systematic 
changes. The results showed that the cigarette smoking appeared to obviously differ in 
some groups in three samples, but the three samples showed similar patterns of cigarette 
smoking. The results tended to show no systematic changes in the reporting of tobacco 
smoking in the case-control study of CRC and thus no substantial bias on the association 
can be assumed. These analyses also did not provide any evidence of inaccurate and 
differential report of tobacco smoking for cases and controls which might bias the 
association ofCRC with drinking and smoking substantially. 
The results of this thesis show a more accurate estimate of alcohol consumption in 
the case-control study than the cross-sectional surveys. Cross-sectional studies found 
alcohol coverage rates ranging from 40-60% in general populations [3301. The 
underestimates may reflect a general memory failure that afflicts all self-report methods 
[4041. Different questions on lifetime alcohol consumption designed in the NL case-control 
study may be the reason that the case-control study produced more valid estimates of 
alcohol consumption. In this study, the self-reported lifetime alcohol consumption in the 
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weighted sample of controls was relatively accurate compared to the sales data and two 
national surveys. Annual alcohol consumption of 13.20 litres per drinker, estimated based 
on the weighted sample of controls was higher than the estimates of 11.35 litres of 
alcohol from the alcohol sale data in NL, but estimate from the sales data was within 95% 
CI of the estimate from the case-control study data. This may be because the self-
reporting of alcohol intake may include alcohol consumption from all sources including 
the retail sales, U-brew and U-vint production, home brewing, cross-border shopping and 
illegal channels; and the sale estimates were based on only the retail sales data [3461. The 
consumption of absolute alcohol from those unrecorded sources is now estimated to be 
about 19.5% in ON [4051 . Ifthe unrecorded alcohol consumption in NL is the same as that 
reported in ON, the estimate of alcohol consumption from the case-control study is 
relatively valid. In this study, beer consumption tended to be underestimated, and wine 
and spirits consumption tended to be overestimated in the case-control study compared to 
the sales data. Previous studies have shown that coverage rates of alcohol sales also 
varied by type of beverage although the rates were not totally consistent [3161. Several 
studies found that wine and spirits consumption can be more accurately estimated than 
beer because wine and distilled liquors drinkers may have more stable drinking patterns 
which can be more easily recalled [372•406.4°71. 
Although the case-control sample produced a relatively higher wine and spirits 
and lower beer estimates compared to the sales data, the patterns of three types of 
beverage consumption remained unchanged. These patterns are the same as that in other 
cross-sectional surveys (i.e., the surveys generally produce relatively higher estimates of 
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wmes and relatively lower estimates of beers) [370'371'4081 . While only the wine 
consumption was significantly overestimated in the case-control study compared to the 
sales data and it accounted for a small proportion of total alcohol consumption, the 
overestimation of wine consumption did not produce a substantial effect on the estimate 
of total alcohol consumption and the association studied in this thesis. Therefore, alcohol 
consumption reports in the case-control study of CRC were valid. 
The analyses on tobacco smoking and alcohol consumption by subgroups among 
cases and controls did not suggest any substantial differences in the reporting of tobacco 
smoking and alcohol consumption between cases and controls in the case-control study of 
CRC. Therefore, it was unlikely that inaccurate reporting of tobacco smoking and alcohol 
consumption have greatly biased the association. It was assumed that the 
misclassification of cigarette smoking is non-differential, which means that sensitivity 
and specificity of self-reported smoking was the same for cases and controls. Now 
suppose that self-reported smoking resulted in a smoking estimate that had 1 00% 
specificity but only 85% sensitivity. In other words, all the truly non-smokers were 
correctly classified as non-smokers, but there was an 85% chance that a smoker will be 
correctly classified as smoker and thus a 15% (95% CI: 13-17%) chance a smoker will be 
incorrectly classified as non-smoker. Under this circumstance, the relative risk of CRC 
due to smoking was underestimated (from 1.90 to 1.51). Similarly, as shown in Table 21 , 
when all the truly smokers were correctly classified as smokers and 85% of non-smokers 
were correctly classified as non-smokers, a 15% (95% CI: 13-17%) chance that a non-
smoker will be incorrectly classified as smoker. In such circumstances, the relative risk of 
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CRC due to smoking was also underestimated (from 1.57 to 1.51). Underestimated 
effects of misclassification for cigarettes daily can be also found. 
Table 21. Effect of non-differential misclassification of cigarette smoking on colo rectal cancer risk 
Smoking measure Case Controls OR&95%CI 
NL CRC data t Non-smoker 201 270 1.00 
Smoker 501 447 1.51 1.20- 1.88 
Cigarettes daily 
01-19 234 2 16 1.46 1.1 2-1.89 
20-29 193 175 [ .48 1.1 3-1.95 
30+ 74 56 1.78 1.20-2.63 
Sensitivity = 0.95 Non-smoker 175 246 1.00 
Specificity = 1.00 Smoker 527 471 1.58 1.26-1 .99 
Cigarettes daily 
01-19 246 227 1.53 1.1 0-1.99 
20-29 203 184 1.56 1.18-2.06 
30+ 78 59 1.87 1.26-2.75 
Sensitivity = 0.85 Non-smoker 11 3 191 1.00 
Specificity = 1.00 Smoker 589 526 1.90 1.47-2.47 
Cigarettes daily 
01 -19 275 254 1.84 1.38-2.45 
20-29 227 206 1.87 1.39-2.53 
30+ 87 66 2.24 1.51 -3.33 
Sensitivity = 1.00 Non-smoker 2 12 284 1.00 
Specificity = 0.95 Smoker 490 433 1.52 1.22-1.90 
Cigarettes daily 
01-19 223 202 1.49 1.1 5-1.93 
20-29 181 164 1.48 1.13-1.96 
30+ 86 67 1.72 1.19-2.48 
Sensitivity = 1.00 Non-smoker 236 3 18 1.00 
Specificity = 0.85 Smoker 466 399 1.57 1.26-1.94 
Cigarettes daily 
01-19 199 168 1.58 1.21-2.07 
20-29 152 137 1.49 1.12- 1.98 
30+ 115 94 1.65 1.19-2.27 
Note: t assuming that there was s misclassification of cigarette smoking in the NL data. 
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When assuming that the misclassification of cigarette smoking is differential, 
which means that sensitivity and specificity of self-reported smoking was not the same 
for cases and controls. Table 22 presents the effect of misclassification of cigarette 
smoking on CRC risk. If more case smokers were incorrectly classified as non-smokers 
or more control non-smokers were incorrectly classified as smokers, the relative risk of 
CRC due to smoking will be underestimated slightly (see Panels C and D). 
Underestimated effects of misclassification for cigarettes daily can be also found. 
When more control smokers were incorrectly classified as non-smokers, or more 
case non-smokers were incorrectly classified as smokers, the relative risk will be 
exaggerated or even reverse the relationship and make the results misleading. As shown 
in Panel A and B in Table 22, a statistically significant relationship appeared because 7% 
(95% CI: 5-9%) of control smokers were incorrectly classified as non-smokers or 13% 
(95% CI: 11-16%) of case non-smokers were incorrectly classified as smokers. When 
19% (95% CI: 16-22%) of control smokers were incorrectly classified as non-smokers or 
33% (95% Cl: 30-37%) of case smokers were incorrectly classified as non-smokers, the 
relationship will be reversed. The same effect of misclassification for cigarette daily can 
also be observed. However, the comparative analyses in this chapter show that it was 
unlikely that any misclassification of smoking for cases and controls appeared. 
119 
Table 22. Effect of differential misclassification of cigarette smoking on colo rectal cancer risk 
Cigarettes Sensitivity/ Case/ OR&95%CI Sensitivity/ Case/ OR&95%CI Specificity Control Specificity Control 
Non-smoker NL data t 201 /270 1.00 NL data t 201 /270 1.00 
Smoker 501 /447 1.51 1.20-1 .88 501 /447 1.51 1.20-1.88 
Cigs daily 
01-19 234/216 1.46 1.12-1.89 234/216 1.46 1.12-1.89 
20-29 193/ 175 1.48 1.13-1.95 193/ 175 1.48 1.13-1.95 
30+ 74/56 I. 78 1.20-2.63 74/56 I. 78 1.20-2.63 
Panel A Panel C 
Control Case 
Non-smoker Sens = 0.94 201 /241 1.00 Sens = 0.95 175/270 1.00 
Smoker Spec = 1.00 501 /476 1.27 1.01-1.59 Spec = 1.00 527/447 1.82 1.45-2.29 
Cigs daily 
01-19 234/230 1.22 0.94-1.59 246/216 1.76 1.35-2.30 
20-29 193/186 1.25 0.95-1.64 203/ 175 1.79 1.36-2.37 
30+ 74/60 1.49 1.01-2.20 78/56 2.15 1.45-3.18 
Non-smoker Sens = 0.93 201/236 1.00 Sens = 0.90 145/270 1.00 
Smoker Spec = 1.00 501 /481 1.23 0.98-1.54 Spec = 1.00 557/447 2.31 1.83-2.93 
Cigs daily 
01-19 234/232 1.18 0.91-1.54 260/216 2.24 I. 71-2.93 
20-29 193/188 1.21 0.92-1.59 2141175 2.28 1.71-3.02 
30+ 74/60 1.45 0.98-2.13 82/56 2.73 1.84-4.05 
Non-smoker Sens = 0.81 201 / 165 1.00 Sens = 0.85 113/270 1.00 
Smoker Spec = 1.00 501 /552 0.75 0.59-0.95 Spec = 1.00 589/447 3. 16 2.46-4.07 
Cigs daily 
01-19 234/267 0.72 0.55-0.94 275/216 3.06 2.30-4.06 
20-29 193/2 16 0.73 0.55-0.97 227/175 3. 11 2.32-4.18 
30+ 74/69 0.88 0.60-1.30 87/56 3. 73 2.50-5.57 
Panel B Panel D 
Case Control 
Non-smoker Sens = 1.00 223/270 Sens = 1.00 201/284 1.00 
Smoker Spec = 0.90 479/447 1.29 1.04-1.61 Spec = 0.95 501 /433 1.64 1.31 -2.04 
Cigs daily 
01-19 212/216 1.18 0.91-1.54 234/202 1.64 1.26-2.13 
20-29 167/175 1.15 0.88-1.52 93/164 1.67 1.27-2.20 
30+ 100/56 2.16 1.49-3.13 74/67 1.55 1.07-2.26 
Non-smoker Sens = 1.00 231/270 Sens = 1.00 201 /300 1.00 
Smoker Spec = 0.87 471 /447 1.23 0.99-1.53 Spec = 0.90 501/417 1.79 1.44-2.24 
Cigs daily 
01-19 204/216 1.10 0.85-1.43 234/ 186 1.88 1.44-2.44 
20-29 158/175 1.06 0.80-1.39 193/151 1.91 1.44-2.52 
30+ 109/56 2.27 1.58-3.28 74/80 1.38 0.96-1.99 
Non-smoker Sens = 1.00 300/270 Sens = 1.00 201/318 1.00 
Smoker Spec = 0.67 402/447 0.81 0.65-1.00 Spec = 0.85 5011399 1.98 1.59-2.4 7 
Cigs daily 
01-19 135/216 0.56 0.43-0.74 234/ 168 2.20 1.68-2.86 
20-29 781175 0.40 0.29-0.55 193/ 137 2.23 1.68-2.95 
30+ 189/56 3.04 2.16-4.28 74/94 1.24 0.87 -I. 77 
Note: t assuming that there was s misclassification of cigarette smoking in the NL data. 
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Some limitations of these comparisons should be kept in mind. Purchasing and 
consumption are not the same phenomenon, as other sources of tobacco and alcohol 
consumption such as home production and goods smuggled across borders are possible 
[3711 • Although the self-reported tobacco smoking and alcohol consumption in the case-
control study were valid, the average annual estimates over 55 years from the case-
control study may not equal the average annual estimates over 1 0 or 20 years from the 
sales data, or from the past year in cross-sectional surveys. However, the samples 
randomly selected from the same population, and some smoking and drinking years, were 
overlapped and more likely to produce close estimates or similar patterns of tobacco 
smoking and alcohol consumption. 
Secondly, in general, retail sales data offer the most accurate means of estimating 
how much alcohol was consumed by the population in a given year - even though data 
may not necessarily reflect consumption, since tobacco and beverages purchased in a 
given year may not be consumed in that year. However, the results produced from all the 
datasets have been averaged for decades, and the effects could be greatly reduced. 
Thirdly, estimates of consumption based on interviews may be subject to bias due to 
response errors caused by proxy reporting [4091. However, the analyses on CRC risk and 
smoking and drinking by survival status in Chapter 7 and 8 did not show a substantial 
effect due to use of proxies. Therefore, it is concluded that self-reports of tobacco 
smoking and alcohol intake would be unlikely to greatly modify the results. 
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Chapter 7 Colorectal cancer and tobacco smoking 
7 .1. Introduction 
While research has shown that the incidence of CRC has been associated with 
d. t -l'. [41331332] d h . 1 . . . [41204] .d th 1 . . 1e ary 1actors ' · an p ystca mact1v1ty · , ev1 ence on e re atwnship 
between CRC and tobacco smoking has been conflicting. A number of epidemiological 
studies have investigated the relationship between tobacco smoking and CRC in the last 
three decades but few found a significant risk for CRC among smokers. Earlier studies 
found that greater risk of CRC was associated with smoking cigars and pipes, but not 
smoking cigarettes [255•333•3341. Among studies that reported an increased risk of CRC with 
cigarette smoking, the magnitude of risk was only 1.20-1.40 [198•226-2321. Inadequate 
adjustment for various potential confounders such as alcohol consumption, physical 
activity, body weight, dietary factors, and possibly unidentified confounders could 
account for the small increase in risk found with smoking in some studies. In fact, few 
potential confounders were adjusted for in most of the cohort studies. One-third of the 
published studies considered only age or other relevant demographic factors 
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282l. Some studies adjusted only for demographic factors and alcohol 
consumption [226•265•2741, and less than half of the studies considered two or more of the 
potential confounders [198•206•227•23 1•232•262•266•281 -2861. Additionally, evidence of the 
association of CRC and smoking by sex, drinking status and subsites of CRC has been 
inconsistent. Little is known about the impact of tobacco smoking on CRC among 
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subgroups such as living and deceased cases, cases with different familial risk and cases 
by microsatellite instability (MSI) positive status. Therefore, to explore whether tobacco 
smoking is associated with the risk for CRC, whether different tobacco types influence 
risk differently, and whether tobacco smoking is associated with cancer in specific parts 
of the bowel and whether other characteristics such as sex, survival status, familial risk, 
drinking status, body weight and MSI influence risk, further studies on the relationship 
between tobacco smoking and CRC are required. 
Canada has the highest prevalence of CRC in the world [8•342•388•4101, but only one 
study specifically on tobacco smoking and CRC has been carried out. This population-
based case-control study of CRC performed in Montreal between 1979 and 1985, which 
accrued over 4,000 males aged 35-70 years old who underwent face-to-face interviews 
only found that cigar smoking was associated with the development of rectal cancer 
[264•4 111. This Montreal study did not provide any evidence for an association between 
cigarette smoking and CRC [264•4111 but cannot be generalized to other provinces such as 
NL where the population shows different lifestyle and genetic characteristics [257•342,4101. 
Newfoundland and Labrador (NL), a province of Canada, has the highest incidence of 
CRC in the world [8•4121. Historically, there has been a relatively high prevalence of 
tobacco smoking in the province, with an average rate of 34% during the period of 1985-
2003 [348-350•4131. However, there have been no studies conducted in NL to investigate the 
effect of tobacco smoking on the risk of developing CRC. This thesis was to investigate 
the relationship between CRC risk and tobacco smoking in the NL population and to 
examine the association for subgroups. 
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7.2. Research methods 
Readers can read methods on recruitment of cases and controls, data collection of 
tobacco smoking and other epidemiological variables, and statistical approaches in 
Chapter 4. Briefly, cases were recruited using the NCR while controls were random 
samples of the NL population aged 20-74 [3541. Eligible CRC cases were NL residents 
between 20 and 74 years old, newly-diagnosed with CRC in 1999-2003, with 
histologically confirmed primary adenocarcinoma of the colon or rectum. Controls were 
frequency-matched according to sex and five-year age group. A total of 702 cases and 
717 controls were included in this analysis. 
Self-administered questionnaires were used to collect information on tobacco 
smoking and covariates. Tobacco smoking, including cigarettes, cigars and pipes, was 
investigated. Subjects were classified into the cigarette smoking group (smoker) if they 
had smoked one cigarette a day for three months or longer and the non-cigarette smoking 
group (non-smoker) if they had not smoked. Cigarette smokers were further classified 
into former and current cigarette smokers. Former cigarette smokers were those who 
stopped smoking cigarettes about one year before cancer diagnosis or survey, and current 
cigarette smokers were those who still smoked at least one cigarette a day during the year 
prior to diagnosis or recruitment. Derived variables of cigarette smoking included age at 
initiation of smoking; number of cigarettes smoked per day; total number of years of 
cigarette smoking; years since started smoking and cigarette pack years; pack years of 
smoking cigarettes; years of abstention from smoking cigarettes were also estimated. 
Subjects were classified into the tobacco smoking group (smoker) if they had smoked one 
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cigarette a day or one cigar/pipe a month for three months or longer, and non-tobacco 
smoking group (non-smoker) if they had not smoked. Tobacco smokers were further 
classified into former and current smokers. Former tobacco smokers were those who 
stopped smoking tobacco before cancer diagnosis or survey, and current tobacco smokers 
were those who still smoked at least one cigarette a day or cigar/pipe among during the 
year prior to diagnosis or recruitment. 
Covariates considered in the analyses were age, sex, region of urban-rural 
residence, education, marital status, alcohol consumption, physician diagnosed diabetes, 
physician diagnosed hypercholesterolemia, regular use of aspirin, intake of fruits, 
vegetables and red meats, BMI, physical activity, lifetime use of any laxatives and 
lifetime use of calcium pills or tablets and calcium-based antacids. The independent 
effect of cigarette smoking on the RR of CRC was estimated using adjusted OR 
calculated in multivariate binary and multinomial logistic multilevel regression models 
[219•2201. Analyses were performed for subgroups including men and women, drinkers and 
non-drinkers, obese and non-obese, cases of colon and rectal cancer, living and deceased 
cases during the enrollment, cases with low familial risk and intermediate/high familial 
risk and cases with MSI-H and MSI-LIMSS tumour [35 1•3791. All statistical analyses were 
completed using SAS 9.1 [3671. 
7.3. Characteristics ofthe sample and tobacco smoking 
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7.3 .1. Demographics and tobacco smoking 
A total of 702 cases and 717 controls were included in the study of the association 
of CRC risk with tobacco smoking. The mean age of cases was 60.42 years old (SD: 9.36 
range: 20-74) and that of controls was 60.40 (SD: 9.5, range: 20-75). The demographic 
characteristics of cases and controls are presented in Table 23. Compared to controls, 
Table 23. The demographic characteristics of cases of colorectal cancer and controls and the 
l!revalence rates of tobacco smoking b~ subgroUJ:!S in the case-control stud~ 
Demographics Case Control Tobacco Smoking ~ N %~ N %~ N % 95%CI 
Age group n 
20-54 186 26.50 185 25.80 230 61.99 57.05- 66.94 
55-64 242 34.47 264 36.82 344 67.98 63.91 -72.05 
65-74 274 39.03 268 37.38 374 69.00 65.91-72.05 
Sex n 
Female 276 39.32 293 40.86 303 53.25 49.15-57.36 
Male 426 60.68 424 59.14 645 75.88 73.00- 78.76 
Race 
Other 29 4.13 46 6.42 53 70.67 60.35 - 80.98 
Caucasians 673 95.87 671 93.58 895 65.59 64.07- 69.11 
Birth place ** 
Other 32 4.56 58 8.09 55 61.11 51.03-71.19 
Canada 670 95.44 659 91.91 893 67.19 64.67- 69.72 
Region * 
Urban 302 43.02 355 49.51 432 65.95 62.32- 69.58 
Rural 400 56.98 362 50.49 516 67.54 64.22 - 70.86 
Education *** n 
High school or less 446 63.53 349 48.68 563 70.82 67.65- 73 .98 
College+ 256 36.47 368 51.32 385 61 .70 57.88- 65.52 
Household income ($) *** 
0-29,999 395 56.27 334 46.58 498 68.31 64.93- 71.69 
30,000+ 307 43.73 383 53.42 450 65.21 61.65-68.76 
Marital status 
Married 540 76.92 579 80.75 757 67.65 64.91 -70.39 
Single/div/seE/wid 162 23.08 138 19.25 191 63.67 58.22- 69.12 
Total cigarette 702 100.00 717 100.00 948 67.02 64.57- 69.47 
Total cigar 61 4.29 3.24- 5.36 
Total EiEe 141 9.93 8.38- 11.50 
Note:~ Column% and X1: *P<0.05 **P<0.01 ***P<O.OOl. t Number, percentage of smokers and 95% CI 
of the percentage. n shows a significant difference in the percentage of cigarette smoking between 
subgroups. 
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cases tended to be those who were Canadian-born, lived in rural areas and had a high 
school education or less. In the sample of cases and controls, more people aged 65-74 
years old smoked tobacco than those aged 20-54 years old (95% Clctiff: 1.3 7-12.65% ); 
more males smoked tobacco than females (95% Clctiff: 17.62-27.64%); more people who 
had a high school education or less smoked tobacco than those who had a college 
education or higher (95% Clctiff: 4.17-14.07%). 
7.3 .2. Chronic condition, medication and lifestyle and tobacco smoking 
Table 24 presents the measures for chronic condition, medication and lifestyle for 
cases and controls and cigarette smoking status for subgroups in the case-control study of 
CRC. Cases tended to be those who had polyps, family history of CRC, diabetes, and no 
high cholesterol level. Fewer cases took aspirin and calcium pills and tablets compared to 
controls. They tended to eat fewer fruits and be obese. 
In the case and control sample, the high prevalence rate of tobacco smoking 
appeared among those with a diagnosis of other cancer history (95% Clctiff: 1.68-13.82%), 
polyps (95% Clctiff: 2.25-12.83%), diabetes (95% Clctiff: 2.85-15.15%), high cholesterol 
level (95% Clctiff: 1.09-11.29%), and among those who took aspirin (95% Clctirr: 4.63-
15.03%) and calcium pills and tablets (95% Clctiff: 5.81-19.35%), ate less fruits (95% 
Clctiff: 0.48-11.30%) and were obese (95% Clctiff: 0.76-11.70%). Alcohol drinkers smoked 
more tobaccos than non-drinkers did (95% Clctiff: 14.55-21.69%). 
127 
Table 24. Comparison of chronic conditions, medications and lifestyles of cases of colorectal cancer 
with controls and the Erevalence rates of tobacco smoking b;r subgrouE in the case-control stud;r 
Chronic conditions, Case Control Tobacco Smoking i 
medications, lifestyles N %~ N %~ N % 95%CI 
CRC family history 
No 540 76.92 614 85.63 765 66.29 63.56- 69.02 
Yes 162 23.08 103 14.37 183 69.05 63.48- 74.62 
Other cancer history n 
No 600 85.47 625 87.17 808 65.96 63.30- 68.62 
Yes 102 14.53 92 12.83 143 73.71 67.51 -79.91 
Polyp *** n 
No 400 56.98 627 87.45 636 65.16 62.17-68.16 
Yes 302 43.02 90 12.55 285 72.70 68.29-77.12 
Diabetes *** n 
No 555 79.06 623 86.89 769 65.28 62.56 - 68.00 
Yes 147 20.94 94 13.11 179 74.28 68.74- 79.80 
High cholesterol level ** n 
No 494 70.37 451 62.90 612 64.70 61.71-67.81 
Yes 208 29.63 266 37.10 336 70.89 66.79- 74.98 
Aspirin * n 
No 522 74.62 492 68.62 649 64.00 61.05 - 66.96 
Yes 180 25.38 225 31.38 299 73 .83 69.54- 78.11 
Any laxatives use *** 
No 573 81.62 657 91 .63 823 66.91 64.28- 69.54 
Yes 129 18.38 60 8.37 125 66.14 59.38- 72.89 
Fruits daily 
1-2 servings 519 73.93 471 65.69 679 68.59 65 .69- 71.48 
3+ servings 183 26.07 246 34.31 269 62.70 58.12- 67.29 
Vegetables daily 
1-2 servings 436 62.11 430 59.97 583 67.32 64.19- 70.95 
3+ servings 266 37.89 287 40.03 365 66.00 62.05 - 69.96 
Red meats daily 
1-2 servings 384 54.70 409 57.04 515 64.94 61.62 - 68.23 
3+ servings 318 45.30 308 42.96 433 69.17 65.55- 72.79 
Calcium pills/tablets *** n 
No 608 86.61 568 79.22 811 68.96 66.31 - 7 1.61 
Yes 94 13.39 149 20.78 137 56.38 50.14- 62.62 
Obesity * n 
No (BMI<30) 503 71.65 556 77.55 693 65.44 62.57 - 68.31 
Yes (BMI~30) 199 28.35 161 22.45 255 71.67 67.0 I - 76.33 
Physical activity 
Active 226 32.19 220 30.68 302 67.71 63.37- 72.06 
Inactive 476 67.81 497 69.32 646 66.70 63 .74- 69.67 
Alcohol consumption n 
No 270 38.46 264 36.82 260 48.69 44.44- 52.93 
Yes 432 61.54 453 63.18 688 77.74 75.00- 80.48 
Total cigarette 702 100.00 717 100.00 948 66.81 64.35 - 69.26 
Total cigar 61 4.29 3.24- 5.36 
Total EiEe 141 9.93 8.38 - 11.50 
Note:~ Column% and X2: *P<0.05 **P<0.01 ***P<O.OOI. t Number, percentage of smokers and 95% CI 
of the percentage. n shows a significant difference in the percentage of cigarette smoking between 
subgroups. 
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7.4. Relative risk of developing colorectal cancer with tobacco smoking 
7.4.1. Colorectal cancer and total tobacco smoking 
The study examined the association of CRC with smoking tobacco including 
cigarette, cigar (1 cigar = 4 cigarettes) and pipe (1 pipe = 2.5 cigarettes). Table 25 
presents the unadjusted and adjusted ORs for total tobacco smoking in the case-control 
Table 25. The odds ratio of colorectal cancer and the corresponding 95% confidence interval for 
total tobacco smoking in the case-control stud~ 
Tobacco measure Case Control Unadjusted Adjusted t 
N % N % OR & 95%Cl OR & 95%CI 
Tobacco smoking *** 
Non-smoker 198 28.21 263 36.68 1.00 1.00 
Smoker 504 71.79 454 63.32 1.47 1.18- 1.84 *** 1.47 1.14- 1.89 *** 
Smoke status *** 
Former 353 50.21 356 49.65 1.32 1.04- 1.67 * 1.33 1.02 - 1.73 * 
Current 151 21.51 98 13.67 2.05 1.49- 2.80 *** 1.91 1.36 - 2.69 *** 
Initiation age ** 
< 16 169 24.07 145 20.22 1.55 1.16- 2.07 ** 1.52 1.10 - 2. 11 * 
16+ 335 47.72 309 43.10 1.44 1.13 - 1.83 ** 1.44 1.11 - 1.88 ** 
Smoke years *** 
1-19 120 17.09 154 2 1.48 1.04 0.77- 1.40 1.12 0.81 - 1.55 
20-29 136 19.37 114 15.90 1.58 1.16-2.16** 1.60 1.14-2.24 * 
30+ 248 35.33 186 25.94 1.77 1.36 - 2.3 1 *** 1.69 1.25 - 2.27 ** 
P-trend ** 
Cigarettes daily ** 
1-19 237 33.76 222 30.96 1.42 1.09 - 1.84 ** 1.42 1.07- 1.89 * 
20-29 193 27.49 176 24.55 1.46 1.11 - 1.92 ** 1.48 1.09-2.02 * 
30+ 74 10.54 56 7.81 1.76 1.18- 2.60 ** 1.65 1.06-2.56 * 
P-trend * 
Pack years ** 
1-19 199 28.35 204 28.45 1.30 0.99- 1.70 1.34 1.00- 1.79 * 
20-39 171 24.36 146 20.36 1.56 1.17 - 2.07 ** 1.57 1.15 - 2. 15 * 
40+ 134 19.09 104 14.50 1.71 1.25- 2.35 *** 1.61 1.12-2.31* 
P-trend * 
Note: t OR estimates for tobacco smoking from multilevel binary models adjusted for age, sex, ruraVurban, 
education, marriage, family history of co1orectal cancer, diabetes, cholesterol, aspirin, alcohol, fruits, BMl, 
laxatives and calcium and random effect of census area. X2 or Wald test or Cochran-Armitage test for 
trend: *P<0.05 **P<0.01 ***P<0.001. Cocbran-Armitage test for trend: ns=not significant at 5%. 
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study. While 71% of CRC cases have ever smoked at least one cigarette a day for three 
months or longer in lifetime, only 63% of controls have smoked. The adjusted OR of 
CRC for tobacco smoking status suggested a 4 7% higher risk of developing CRC among 
all tobacco smokers, a 33% and a 91% higher risk of developing CRC among former and 
current smokers than non-smokers. The study showed a statistically significant 
relationship between CRC and age of smoking initiation. The adjusted OR of CRC for 
age of initiation of smoking suggested a 52% and a 44% higher risk of developing CRC 
among those who started smoking prior to 16 years old and at the age of 16 years and 
older than among those who have never smoked, thus indicating that starting smoking 
prior to 16 years old or 16 years or older had a higher risk of developing CRC. The risk 
of CRC significantly increased with tobacco smoking years, number of total cigarettes 
daily and cigarette pack years. 
7.4.2. Colorectal cancer and types of tobacco smoking 
Table 26 presents the OR of CRC and the corresponding 95% CI for tobacco 
smoking in the case-control study. The majority of CRC cases and controls had smoked 
cigarettes; approximately 5% had smoked cigars and approximately 10% had experienced 
pipe smoking in their lifetime. Other measures of smoking cigar and pipe are not 
presented here since there were small numbers of subjects who smoked cigars and pipes 
with no statistically significant relationship between CRC, and smoking cigars and pipes. 
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Table 26. The odds ratio of colorectal cancer and the corresponding 95% confidence interval for 
cigarette smoking in the case-control stud~ 
Tobacco measure Case Control Unadjusted Adjusted t 
N % N % OR & 95%CI OR & 95% CI 
Cigarette smoke *** 
Non-smoker 201 28.63 270 37.66 1.00 1.00 
Smoker 501 71.37 447 62.34 1.51 1.20- 1.88 *** 1.49 1.16 - 1.92 *** 
Cigarette status *** 
Former 352 50.14 351 48.95 1.35 1.06- 1.70 * 1.36 1.04- 1.77 * 
Current 149 21.23 96 13.39 2.08 1.52 - 2.86 *** 1.96 1.40 - 2.76 *** 
Cigarette age ** 
<16 172 24.50 153 21.34 1.51 1.14-2.01 ** 1.47 1.07-2.03 * 
16+ 329 46.87 294 41 .00 1.50 1.18 - 1.92 *** 1.50 l. 15 - 1.66 * * 
Cigarette years *** 
1-19 119 16.95 150 20.92 1.07 0.79-1.44 1.15 0.83 - 1.59 
20-29 136 19.37 11 3 15.76 1.62 1.20 - 2.20 ** 1.62 1.16-2.28 ** 
30+ 246 35.04 184 25.66 1.80 1.38- 2.34 *** 1.71 1.27- 2.30 ** 
P.trend ** 
Years since smoke ** 
1-25 36 5.13 26 3.63 1.86 1.09-3.18 * 1.67 0.95-2.95 
26-35 89 12.68 72 10.04 1.66 1.16 -2.38 ** 1.62 1.07-2.47 * 
36+ 376 53.56 349 48.68 1.45 1.15 - 1.83 ** 1.44 1.10- 1.89 * 
P-trend ns 
Cigarettes daily ** 
1-19 234 33.33 216 30.13 1.46 1.12- 1.89 ** 1.45 1.10- 1.92 * 
20-29 193 27.49 175 24.41 1.48 1.13- 1.95 ** 1.51 1.11 - 2.05 * 
30+ 74 10.54 56 7.81 1.78 1.20 - 2.63 ** 1.67 1.07-2.58 * 
P-trend * 
Pack years *** 
1-19 198 28.21 201 28.03 1.32 1.01- 1.73 * 1.36 1.03- 1.82 * 
20-39 172 24.50 146 20.36 1.58 1.19-2.11 ** 1.60 1.11-2.19 ** 
40+ 131 18.66 100 13.95 1.76 1.28- 2.42 *** 1.64 1.14- 2.36 * 
P-trend ** 
Years of abstain *** 
0 149 2 1.23 96 13.39 2.08 1.52 - 2.86 *** 1.97 1.40- 2.77 *** 
1-19 193 27.49 156 21.76 1.66 1.26 - 2.20 *** 1.61 1.19 - 2.19 * 
20-29 96 13.68 94 13.11 1.37 0.98 - 1.92 1.37 0.95 - 1.99 
30+ 63 8.97 101 14.09 0.84 0.58 - 1.21 0.90 0.60- 1.33 
P-trend *** 
Cigar smoke 
Non-smoker 677 96.44 681 94.98 1.00 1.00 
Smoker 25 3.56 36 5.02 0.70 0.41-1.18 0.55 0.32-0.96 * 
Pipe smoke 
Non-smoker 636 90.60 642 89.54 1.00 1.00 
Smoker 66 9.40 75 10.46 0.89 0.63 - 1.26 0.89 0.61 - 1.30 
Note: t OR estimates for cigarette smoke from multilevel binary models adjusted for age, sex, rural/urban, 
education, marriage, family history of colorectal cancer, diabetes, cholesterol, aspirin, alcohol, BM1, fruits, 
laxatives and calcium and random effect of census area. X2 or Wald test or Cochran-Armitage test for 
trend: *P<O.OS **P<O.O I ***P<O.OO 1. Cochran-Armitage test for trend: ns=not significant at 5%. 
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There was a significant relationship between CRC risk and cigarette smoking. The 
adjusted OR of CRC for cigarette smoking status suggested a 49%, 36% and 96% higher 
risk of developing CRC among all cigarette smokers, former and current cigarette 
smokers than those who have never smoked. The estimated population attributable risk 
(PAR) of CRC associated with cigarette smoking was 13.18% (95% CI: 6.80-19.58%), 
i.e., 13% of incidence of CRC can be attributed to cigarette smoking in the population. 
There was also a significant relationship between CRC and age of cigarette smoking 
initiation; there was a 4 7% higher risk of developing CRC among those who started 
smoking cigarette at the age of 16 years and older than those who have never smoked, 
and a 50% increased risk of developing CRC when starting smoking cigarette prior to 16 
years old. The adjusted OR suggests that the risk of developing CRC significantly 
increased with smoking cigarette years, number of smoking cigarettes daily, and cigarette 
pack years and decreased with years of abstention from smoking. 
7.4.3. Colorectal cancer and cigarette smoking by sex 
Table 27 presents the adjusted OR of CRC and the corresponding 95% CI for 
cigarette smoking in men and women in the case-control study of CRC. Cigarette 
smoking demonstrated a stronger effect on CRC in men than women. As can be seen in 
Table 27, in men, the adjusted ORs suggested a 73%, 64% and 106% higher risk of 
developing CRC among all smokers, former and current cigarette smokers than those 
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Table 27. The adjusted odds ratio of colorectal cancer and the corresponding 95% confidence 
interval for cigarette smoking in men and women in the case-control stud~ 
Cigarette smoke Men Women 
Case Control OR & 95% CIt Case Control OR & 95% CI ... 
Cigarette status *** 
Non-smoker 81 124 1.00 120 146 1.00 
Smoker 345 300 1.73 I .22 - 2.46 ** 156 147 1.26 0.87 - 1.81 
Smoker type *** ** 
Former 254 238 1.64 1.13-2.36 * 98 113 1.06 0.71 - 1.58 
Current 91 62 2.06 1.30- 3.27 *** 58 34 1.87 1.11-3.17* 
Cigarette age ** ** 
< 16 137 126 1.61 1.07-2.42 * 35 27 1.46 0.79- 2.68 
16+ 208 174 1.81 1.24 - 2.65 ** 121 120 1.21 0.83 - 1.78 
Cigarette years ** *** 
1-19 91 91 1.61 1.04- 2.47 * 28 59 0.60 0.35 - 1.05 
20-29 88 77 1.73 1.10-2.72 * 48 36 1.52 0.88 - 2.62 
30+ 166 132 1.84 1.23 - 2.76 ** 80 52 1.63 1.02- 2.60 ** 
P-trend * * 
Years since smoke ** 
1-25 15 14 1.54 0.67-3.54 2 1 12 1.77 0.79- 3.97 
26-35 53 42 1.67 0.94-2.98 36 30 1.43 0.76- 2.68 
36+ 277 244 1.76 1.21 - 2.56 ** 99 105 1.07 0.71 - 1.62 
P-trend * ns 
Cigarettes daily ** 
1-19 127 115 1.72 1.15-2.59 ** 107 101 1.21 0.82- 1.81 
20-29 149 133 1.71 1.15- 2.56 * 44 42 1.30 0. 77 - 2 .21 
30+ 69 52 1.79 1.09-2.95 * 5 4 2.10 0.49 - 8.95 
P-trend * ns 
Pack years ** 
1-19 121 115 1.70 1.13 - 2.55 * 77 86 1.01 0.66- 1.57 
20-39 Ill 98 1.64 1.07 -2.52 * 61 48 1.53 0.94 - 2.5 1 
40+ 113 87 1.89 1.21-2.93* 18 13 1.22 0.54 - 2.78 
P-trend * ns 
Years of abstain *** *** 
0 91 62 2.07 1.31 - 3.29 *** 58 34 1.82 1.07- 3.10 * 
1-19 124 106 1.71 1.13- 2.61 * 69 50 1.61 0.99- 2.61 
20-29 77 64 1.88 1.18-3.01 ** 19 30 0.71 0.36- 1.40 
30+ 53 68 1.27 0. 77 - 2.10 10 33 0.39 0.17- 0.89 * 
P-trend *** ns 
Note: t OR for cigarette smoke from multilevel binary models adjusted for age, rural/urban, education, 
marriage, family history of colorectal cancer, diabetes, cholesterol, aspirin, alcohol, BMI, fruits, laxatives 
and calcium and random effect of census area. X2 or Wald test or Cochran-Armitage test for trend: *P<0.05 
**P<O.O I ***P<O.OO I. Cochran-Armitage test for trend: ns=not significant at 5%. 
who have never smoked; the risk of developing CRC significantly increased with age of 
smoking initiation, smoking cigarette years, years since starting smoking cigarettes, 
cigarettes smoked daily and cigarette pack years and decreased with years of abstention 
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from smoking. The adjusted OR suggested a significantly increased risk of developing 
CRC in current smokers compared to non-smokers in women (OR: 1.87 and 95% CI: 
1.11-3.17). 
7.4.4. Colorectal cancer and cigarette smoking by drinking status 
Table 28 presents the adjusted OR of CRC and the corresponding 95% CI for 
smoking cigarettes among drinkers and non-drinkers in the case-control study. The 
adjusted ORs of CRC for cigarette smoking status suggested a 82%, 67% and 133% 
higher risk of developing CRC among all cigarette smokers, former and current cigarette 
smokers than those who have never smoked. The risk of developing CRC significantly 
increased with age of smoking initiation, smoking cigarette years, and decreased with 
years of abstention from smoking among drinkers. 
Among non-drinkers, the study only found a weak relationship between smoking 
cigarettes and the risk of developing CRC. The adjusted OR of CRC suggested a 99% 
higher risk of developing CRC among those who smoked 20-29 cigarettes daily than 
those who have never smoked among non-drinkers (OR: 1.99 and 95% CI: 1.14-3.48). 
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Table 28. The adjusted odds ratio of colorectal cancer and the corresponding 95% confidence 
interval for cigarette smoking among drinkers and non-drinkers in the case-control study 
Cigarette smoke Drinkers Non-Drinkers 
Case Control OR & 95%CI t Case Control OR & 95% crt 
Cigarette status *** 
Non-smoker 70 127 1.00 131 143 1.00 
Smoker 362 326 1.82 1.28 - 2.58 ** 139 121 1.18 0.81 - 1.70 
Smoker type *** * 
Former 259 257 1.67 1.16-2.58 * 93 94 1.05 0.57- 1.69 
Current 103 69 2.33 1.49- 3.65 ** 46 27 1.57 0.89-2.75 
Cigarette age *** 
< 16 136 124 1.68 1.11 - 2.54 36 29 1.36 0. 75 - 2.45 
16+ 226 202 1.89 1.31 - 2.74 ** 103 92 1.12 0.76- 1.67 
Cigarette years *** * 
1-19 89 106 1.47 0.96-2.25 30 44 0.77 0.44- 1.34 
20-29 98 83 2.07 1.33 - 3.21 ** 38 30 1.23 0.69 - 2.19 
30+ 175 137 1.96 1.32- 2.93 ** 71 47 1.51 0.94-2.41 
P.rrend ** ns 
Years since smoke *** 
1-25 24 19 1.99 0.97- 4.04 12 7 1.38 0.50 - 3.80 
26-35 68 58 1.87 1.12-3.14* 21 14 1.48 0.66- 3.33 
36+ 270 249 1.78 1.22- 2.59 ** 106 100 1.09 0.73- 1.64 
P.rrend ns ns 
Cigarettes daily *** 
1-19 159 134 2.03 1.37-3.00 * 75 82 0.89 0.58 - 1.36 
20-29 141 146 1.58 1.06-2.36 * 52 29 1.99 1.14- 3.48 * 
30+ 62 46 1.89 1.11-3.19* 12 10 1.47 0.56-3.85 
P.rrend ns ns 
Pack years *** 
1-19 143 139 1.79 1.21-2.66 * 55 62 0.89 0.56- 1.41 
20-39 120 106 1.90 1.25-2.89 * 52 40 1.39 0.83 - 2.32 
40+ 99 81 1.73 1.10-2.74 * 32 19 1.78 0.90- 3.50 
P.rrend ns ns 
Years of abstain *** ** 
0 103 69 2.34 1.50- 3.67 ** 46 27 1.55 0.88-2.72 
1-19 141 119 1.87 1.25-2.81 * 52 37 1.43 0.85-2.41 
20-29 72 70 1.71 1.07- 2.73 * 24 24 1.09 0.56 - 2.1 I 
30+ 46 68 l.l9 0.71-2.00 17 33 0.55 0.28 - 1.09 
P.rrend *** ns 
Note: t OR for cigarette smoke from multilevel binary models adjusted for age, sex, rural/urban, education, 
marriage, family history of colorectal cancer, diabetes, cholesterol, aspirin, alcohol BMI, fruits, laxatives 
and calcium and random effect of census area. X2 or Wald test or Cochran-Armitage test for trend: *P<0.05 
**P<0.01 ***P<0.001. Cochran-Arrnitage test for trend: ns=not significant at 5%. 
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7.4.5. Colorectal cancer and cigarette smoking by obesity 
Table 29 presents the adjusted OR of CRC and the corresponding 95% CI for 
smoking cigarettes among non-obese and obese men in the case-control study of CRC. 
Among non-obese, there was a 57% increased risk of developing CRC among cigarette 
smokers than non-smokers. The risk of developing CRC significantly increased with age 
of smoking initiation, smoking cigarette years, cigarettes daily and cigarette pack years 
among non-obese and significantly decreased with years of abstaining from smoking 
cigarette. While the study did not found a significant effect of cigarette smoking on CRC 
among obese women (not shown in the table), the study showed a Ill% higher risk of 
developing CRC (OR: 2.11 and 95% CI: 1.04-4.27) among smokers than non-smokers 
among obese men (shown in Table 29). While the adjusted OR showed two times higher 
effect for current smokers than non-smokers, there was a 95% higher, but not significant 
risk for former smokers than non-smokers. There was a significantly stronger effect if a 
respondent started smoking prior to the age of 16 years old. The risk of CRC significantly 
increased with smoking years, years since starting smoking cigarettes, the number of 
cigarettes smoked daily, and pack years and significantly decreased with years of 
abstaining from smoking among obese. The results showed a stronger effect for obese 
than non-obese, but the adjusted OR was unstable because of the small sample size. 
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Table 29. The adjusted odds ratio of colorectal cancer and the corresponding 95% confidence 
interval for cigarette smoking among non-obese and obese in the case-control study 
Cigarette smoke Non-Obese (BMJ<302 Obese Men (BMI2:302 
Case Control OR & 95%CJ t Case Control OR & 95%CI t 
Cigarette status ** * 
Non-smoker 152 2 14 1.00 19 25 1.00 
Smoker 351 342 1.57 1.18-2.10** 116 67 2.11 1.04-4.27 * 
Smoker type *** 
Former 235 266 1.39 1.03- 1.89 89 56 1.95 0.95-4.00 
Current 116 76 2.11 1.44-3.10 *** 27 II 3.00 l.l5- 7.84 ** 
Cigarette age * 
<16 Ill 112 1.50 1.03-2.18* 54 30 2. 19 1.00-4.83 * 
16+ 240 230 1.60 1.18-2.17** 62 37 2.05 0.97-4.35 
Cigarette years *** * 
1-19 78 109 2.30 l.l9 - 4.47 ** 32 26 1.43 0.63 - 3.26 
20-29 101 90 2.14 1.29- 3.56 ** 24 15 2.02 0.82-4.98 
30+ 172 143 1.72 1.03 - 1.91 * 60 26 3.16 1.38- 7.23 ** 
P.trend ** * 
Years since smoke *** * 
1-25 29 18 1.19 0.81 - 1.75 3 4 0.93 0.17-5.01 
26-35 64 47 1.74 1.19-2.55 * 18 16 1.10 0.41 -2.95 
36+ 258 277 1.78 1.27- 2.49 ** 95 47 2.77 1.30-5.89 * 
P-trend ** * 
Cigarettes daily *** 
1-19 174 170 1.53 1.11-2.10** 36 23 1.88 0.83-4.29 
20-29 135 135 1.59 1.12 - 2.27 ** 50 27 2.25 1.02-5.00 * 
30+ 42 37 1.80 1.05-3.08 * 30 17 2.22 0.92- 5.35 
P-trend ** * 
Pack years * 
1-19 139 155 1.41 1.01-1.96 * 37 29 1.52 0.68- 3.39 
20-39 126 Ill 1.75 1.22- 2.50 ** 38 18 2.58 1.10-6.03 ** 
40+ 86 76 1.71 1.12- 2.60 * 41 20 2.72 1.13 - 6.54 ** 
P-trcnd * * 
Years of abstain *** * 
0 116 76 2.13 1.45-3.13 *** 27 II 2.90 1.11 - 7.58 ** 
1-19 128 112 1.73 1.21 -2.48 ** 47 30 1.95 0.88-4.31 
20-29 57 74 1.25 0.81 - 1.94 31 13 2.83 1.15-6.99 ** 
30+ 50 80 1.01 0.65- 1.58 11 13 0.88 0.30-2.57 
P-trend *** * 
Note: t OR for cigarette smoke from multilevel binary models adjusted for age, sex, rural/urban, education, 
marriage, family history of colorectal cancer, diabetes, cholesterol, aspirin, alcohol, fruits, laxatives and 
calcium and random effect of census area. t OR adjusted for age, marriage, alcohol and census area. X2 or 
Wald test or Cochran-Armitage test for trend: *P<0.05 **P<O.Ol ***P<O.OOI. Cochran-Armitage test for 
trend: ns=not significant at 5%. 
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7.4.6. Colon and rectal cancer and cigarette smoking 
Table 30 resents the adjusted ORs of colon and rectal cancer and the 
corresponding 95% CI for cigarette smoking in the NL study. The adjusted OR showed a 
Table 30. The adjusted odds ratio of colon and rectal cancer and the corresponding 95% confidence 
interval for cigarette smoking in the case-control stud~ 
Cigarette smoke Control Colon Cancer Rectal Cancer Case OR & 95% CI t Case OR & 95% CI t 
Cigarette status *** 
Non-smoker 270 140 1.00 61 1.00 
Smoker 447 330 1.49 1.12-1.97 * 171 1.56 1.09-2.25 * 
Smoker type *** 
Former 351 243 1.41 1.01 -2.05 * 109 1.31 0.89- 1.93 
Current 96 87 1.70 1.15-2.98 * 62 2.41 1.52 - 3.83 *** 
Cigarette age ** 
< 16 153 116 1.54 1.07 -2.20 * 56 1.36 0.86 - 2. 15 
16+ 294 214 1.47 1.09- 1.98 * 115 1.66 1.13-2.43 ** 
Cigarette years *** 
1-19 150 73 1.08 0.76- 1.83 46 1.36 0.85-2.16 
20-29 113 94 1.72 1.17 - 2.87 ** 42 1.53 0.94- 2.48 
30+ 184 163 1.70 1.09 -2.45 * 83 1.78 1.16- 2.72* 
P-trend ** * 
Years since smoke *** 
1-25 26 24 1.65 0.88 - 3.09 12 1.67 0.77 - 3.64 
26-35 72 52 1.52 0.95-2.44 37 1.83 1.05-3.19 * 
36+ 349 254 1.44 1.06- 1.94 * 122 1.48 0.99 - 2.20 
P-trend ns ns 
Cigarettes daily ** 
1-19 216 161 1.44 1.05 - 1.98 * 73 1.46 0.97 - 2.20 
20-29 175 122 1.48 1.05-2.10 * 71 1.67 1.08 - 2.58 * 
30+ 56 47 1.66 1.01-2.71 * 27 1.75 0.96- 3. 18 
P-trend * * 
Pack years ** 
l-19 201 124 1.27 0.92 - 1.76 74 1.58 1.04- 2.39 * 
20-39 146 117 1.70 1.20- 2.40 * 55 1.56 0.99 - 2.44 
40+ 100 89 1.72 1.15- 2.58 * 42 1.54 0.92 - 2.57 
P-trend ** ns 
Years of abstain *** 
0 96 87 1.76 1.20- 2.58 ** 62 2.43 1.53 - 3.86 *** 
1-19 156 142 1.81 1.29- 2.54 ** 51 1.29 0.82 - 2.03 
20-29 94 56 1.22 0.80 - 1.85 40 1.79 1.08 -2.95 * 
30+ 101 45 0.95 0.61 - 1.49 18 0.86 0.46 - 1.59 
P-trend ** *** 
Note: t OR for cigarette smoke from multilevel multinomial models adjusted for age, sex, rural/urban, 
education, marriage, family history of colorectal cancer, diabetes, cholesterol, aspirin, alcohol, BMI, fruits, 
laxatives and calcium and random effect of census area. X2 or Wald test or Cochran-Armitage test for 
trend: *P<0.05 **P<O.O I ***P<O.OO 1. Cochran-Armitage test for trend: ns=not significant at 5%. 
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49% higher risk of colon cancer and a 56% higher risk of rectal cancer among smokers 
than non-smokers. The risk of colon cancer significantly increased with smoking 
cigarette years, cigarettes smoked daily and cigarette pack years. The risk of rectal cancer 
significantly increased with age of smoking initiation, smoking cigarette years, and 
number of smoking cigarettes daily. The risk of both colon and rectal cancers 
significantly decreased with years of abstention from smoking. The results demonstrated 
a stronger effect of smoking cigarette on rectal cancer than colon cancer. 
7.4.7. Colorectal cancer and cigarette smoking by survival status 
Table 31 resents the adjusted OR of living and deceased CRC patients and the 
corresponding 95% CI for cigarette smoking in the case-control study. Cigarette smoking 
significantly increased the risk of developing CRC among living (OR: 1.48 and 95% CI: 
1.12-1.96) and deceased CRC cases (OR: 1.55 and 95% CI: 1.10-2.20) compared to 
controls. The risk significantly increased with smoking years and cigarettes smoked daily 
and significantly decreased with years of abstaining from smoking among living cases. 
The risk of CRC among deceased cases significantly increased with age of smoking 
initiation, smoking years, cigarettes daily and pack years, and the risk significantly 
decreased with years of abstaining from smoking. The results demonstrated no obvious 
differences in the effect of smoking on CRC between deceased and living cases. 
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Table 31. The adjusted odds ratio of living and deceased colorectal cancer patients and the 
corresponding 95% confidence interval for cigarette smoking in the case-control study 
Cigarette smoke Control Living CRC Deceased CRC 
Case OR & 95% CIt Case OR & 95%CI t 
Cigarette status ** 
Non-smoker 270 127 1.00 74 1.00 
Smoker 447 317 1.48 1.12- 1.96 * 184 1.55 1.10 - 2.20 ** 
Smoker type *** 
Former 351 224 1.36 0.92 - 1.89 128 1.59 1.00-2.53 * 
Current 96 93 1.88 1.29- 2.74 ** 56 2.07 1.31 - 3.27 ** 
Cigarette age ** 
< 16 153 116 1.58 1.11-2.26** 56 1.52 0.85-2.07 
16+ 294 201 1.44 1.07- 1.94 * 128 1.65 1.15 - 2.38 ** 
Cigarette years *** 
1-19 150 84 1.26 0.88 - 1.81 35 0.98 0.6 1 - 1.58 
20-29 113 76 1.41 0.96-2.06 60 2.05 1.32- 3.21 ** 
30+ 184 157 1.73 1.25-2.41 * 89 1.74 1.16-2.60 ** 
P-trend * ** 
Years since smoke ** 
1-25 26 23 1.66 0.89- 3.09 13 1.68 0. 79 - 3.59 
26-35 72 58 1.64 1.04-2.60 * 76 1.59 1.05- 2.82 * 
36+ 349 236 1.42 1.05- 2.75 * 31 1.53 1.33- 3.32 ** 
P-trend ns ns 
Cigarettes daily *** 
1-19 216 157 1.51 1.10-2.06 * 77 1.35 0.91 - 2.0 I 
20-29 175 117 1.41 1.00- 2.00 * 76 1.74 1.14-2.65 * 
30+ 56 43 1.58 0.97-2.58 31 2.00 1.12-3.55* 
P-trend * * 
Pack years *** 
1-19 201 140 1.48 1.08-2.05 * 58 1.14 0.75- 1.73 
20-39 146 101 1.44 1.01-2.05 * 71 1.98 1.30- 3.02 ** 
40+ 100 76 1.56 1.04- 2.34 * 55 1.91 1.18 - 3.08 ** 
P-trcnd ns ** 
Years of abstain *** 
0 96 93 1.89 1.30- 2.75 * 56 2.10 1.33 - 3.32 *** 
1-19 !56 121 1.59 1.13- 2.24 * 72 1.75 1.15 -2.66 * 
20-29 94 58 1.33 0.88- 2.01 38 1.54 0.94 - 2.54 
30+ 101 45 1.01 0.65- 1.57 18 0.68 0.37- 1.25 
P-trend *** *** 
Note: t OR for cigarette smoke from multilevel multinomial models adjusted for age, sex, ruraVurban, 
education, marriage, family history of colorectal cancer, diabetes, cholesterol, aspirin, alcohol, BMI, fruits, 
laxatives and calcium and random effect of census area. X2 or Wald test or Cochran-Armitage test for 
trend: *P<0.05 **P<O.O 1 ***P<O.OO I. Cochran-Armitage test for trend: ns=not significant at 5%. 
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7 .4.8. Colorectal cancer and cigarette smoking by familial risk 
Table 32 presents the adjusted OR of CRC with low, and intermediate or high 
familial risk and the corresponding 95% CI for cigarette smoking in the case-control 
Table 32. The adjusted odds ratio of colo rectal cancer with low familial risk and intermediate or high 
familial risk and the corresponding 95% confidence interval for cigarette smokers in the case-control 
stud 
Cigarette smoke Control Low Familial Risk CRC Inter-High Familial Risk CRC Case OR & 95%CI! Case OR & 95% CI! 
Cigarette status 
Non-smoker 270 109 1.00 92 1.00 
Smoker 447 258 1.36 1.01- 1.84 * 243 1.68 1.22- 2.31 ** 
Smoker type *** 
Former 351 186 1.25 0.91- 1.71 166 1.53 1.09-2.13 ** 
Current 96 72 1.75 1.17-2.62 * 77 2.17 1.43- 3.28 *** 
Cigarette age ** 
<16 153 85 1.31 0.89- 1.93 87 1.71 1.15-2.54 * 
16+ 294 173 1.38 1.0 I - 1.89 * 156 1.67 1.19 - 2.33 ** 
Cigarette years *** 
1-19 150 56 1.01 0.68- 1.52 63 1.35 0.90 - 2.03 
20-29 113 69 1.48 0.99-2.22 * 67 1.76 1.16 - 2.67 ** 
30+ 184 133 1.57 1.1 I- 2.23 ** 113 1.93 1.33 - 2.80 *** 
P.rrend ** *** 
Years since smoke ** 
1-25 26 12 1.19 0.56 - 2.51 24 2.08 1.10- 3.95 * 
26-35 72 27 1.23 0.70-2.15 62 1.97 1.22-3.16 ** 
36+ 349 219 1.40 1.02- 1.92 * 157 1.52 1.07-2.16 ** 
P.rrend * ns 
Cigarettes daily * 
1-19 216 123 1.35 0.96- 1.88 Ill 1.58 1.11 - 2.45 * 
20-29 175 98 1.35 0.93 - 1.96 95 1.72 1.17 - 2.53 ** 
30+ 56 37 1.44 0.86 - 2.43 37 2.09 1.23-3.55* 
P-rrend * ** 
Pack years ** 
1-19 201 96 1.22 0.86- 1.74 102 1.54 1.07-2.22 * 
20-39 146 87 1.45 1.00- 2.11 * 85 1.80 1.22- 2.66 ** 
40+ 100 75 1.54 1.01 -2.34 * 56 1.83 1.16- 2.89 ** 
P.rrend ** ** 
Years of abstain *** 
0 96 72 1.77 1.18 - 2.65 *** 77 2.18 1.44 - 3.29 *** 
1-19 156 97 1.50 1.04-2.17 * 96 1.80 1.23 - 2.63 ** 
20-29 94 51 1.28 0.83 - 1.99 45 1.54 0.97 - 2.43 
30+ 101 38 0.82 0.52 - 1.31 25 0.98 0.57- 1.68 
P.rr n *** *** 
Note: t OR for cigarette smoke from multilevel multinomial models adjusted for age, sex, rural/urban, 
education, marriage, family history of colorectal cancer, diabetes, cholesterol, aspirin, alcohol, BMI, fruits, 
laxatives and calcium and random effect of census area. X2 or Wald test or Cochran-Armitage test for 
trend: *P<0.05 **P<0.01 ***P<O.OOI. Cochran-Armitage test for trend: ns=not significant at 5%. 
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study. Smoking cigarettes had a stronger effect on CRC risk among those who had 
intermediate or high familial risk than those with low risk. There was a 36% higher risk 
of developing CRC with low familial risk versus a 68% higher risk of developing CRC 
with intermediate or high familial risk among smokers. The risk of developing CRC with 
low familial risk increased with increasing age of smoking initiation, smoking years, 
years since started smoking and pack years. The risk of developing CRC with 
intermediate or high familial risk increased with age of smoking initiation, smoking 
cigarette years, cigarettes daily and cigarette pack years. The risk of developing CRC 
significantly decreased with years of abstention of smoking cigarette among cases with 
both low and intermediate or high familial risk compared to controls. 
7.4.9. Colorectal cancer and cigarette smoking by microsatellite instability 
Table 33 presents the adjusted OR of MSI-L/MSS and MSI-H CRC and the 
corresponding 95% CI for cigarette smoking in the case-control study. Cigarette smoking 
significantly increased the risk of developing CRC among both MSI-L/MSS and MSI-H 
CRC cases compared to controls. The risk of developing MSI-L/MSS and MSI-H CRC 
significantly decreased with years of abstention of smoking. There were no obvious 
differences in the risk between MSI-L/MSS and MSI-H CRC. 
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Table 33. The adjusted odds ratio of colorectal cancer cases with microstallite instability status and 
the corresponding 95% confidence interval for cigarette smoking in the case-control study 
Cigarette smoke Control MSI-LIMSS CRC MSI-H CRC 
N OR & 95%CI t N OR & 95% CT t 
Cigarette status ** 
Non-smoker 270 182 1.00 19 1.00 
Smoker 447 452 1.46 1.13 - 1.89 ** 49 1.90 1.05 - 3.45 * 
Smoker type ** 
Former 351 319 1.33 1.02- 1.75 ** 33 1.73 0.92- 3.25 
Current 96 133 1.89 1.33 - 2.68 *** 16 2.43 1.15-5.12 * 
Cigarette age ** 
< 16 153 160 1.49 1.08 - 2.07 ** 12 1.36 0.60-3.04 
16+ 294 292 1.45 1.10 - 1.90 *** 37 1.75 1.15 - 3.93 
Cigarette years ** 
1-19 150 109 1.16 0.83- 1.62 10 1.21 0.53- 2.75 
20-29 113 121 1.57 1.11-2.22 ** 15 2.14 1.01 -4.54 * 
30+ 184 222 1.68 1.24- 2.27 *** 24 2.13 1.20-4.67 * 
P.trend *** * 
Years since smoke *** 
1-25 26 32 1.65 0.92-2.96 4 1.74 0.53-5.73 
26-35 72 75 1.23 1.00-2.39 * 14 2.34 1.02 - 5.36 ** 
36+ 349 345 1.43 1.08- 1.88 * 31 1.77 0.91-3.44 
P-trend * ns 
Cigarettes daily ** 
1-19 216 205 1.39 1.04 - 1.86 ** 29 2.10 I. II - 3.98 ** 
20-29 175 175 1.48 1.08 - 2.03 ** 18 1.85 0.89- 3.83 
30+ 56 72 1.78 1.14-2.78 ** 2 0.67 0.16-3.13 
P-trend *** ns 
Pack years ** 
1-19 201 172 1.30 0.97- 1.76 26 2.09 1.08-4.02 * 
20-39 146 157 1.58 1.15-2.18*** 15 1.71 0.81-3.60 
40+ 100 123 1.65 1.14-2.38 *** 8 1.68 0.66 - 4.27 
P-trend *** ns 
Years of abstain *** 
0 96 133 1.90 1.34- 2.70 *** 16 2.45 1.16-5.15 * 
1-19 156 172 1.57 1.15-2.15 *** 2 1 2.24 1.12 - 4.49 * 
20-29 94 88 1.38 0.94 - 2.00 8 1.56 0.64- 3.85 
30+ 101 59 0.90 0.60- 1.35 4 0.87 0.16-2.75 
P-trend *** ** 
Note: t OR for cigarette smoke from multilevel multinomial models adjusted for age, sex, ruraVurban, 
education, marriage, family history of colorectal cancer, diabetes, cholesterol, aspirin, alcohol, BMT, fruits, 
laxatives and calcium and random effect of census area. X2 or Wald test or Cochran-Armitage test for 
trend: *P<0.05 **P<O.OI ***P<0.001. Cocbran-Armitage test for trend: ns=not significant at 5%. 
7.5. Discussion 
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This study reports the results of a large population-based Canadian 
epidemiological study that explicitly examines the relationship between tobacco smoking 
and CRC in men and women in NL. The results suggest that cigarette smoking 
significantly increases the risk of CRC. The observed association was persistent 
regardless of how tobacco smoking was defined and can not be explained by known 
potential confounding factors. Given the inconsistency in existing literature around this 
issue, this study provides new and important evidence supporting the positive association 
between cigarette smoking and CRC. The results in this thesis also suggest that the 
effects of cigarette smoking on CRC seem to be stronger in males and alcohol drinkers. 
The study also shows a stronger effect of cigarette smoking on CRC risk in obese men 
than non-obese men and/or women. This thesis shows a stronger effect of smoking on 
rectal cancer than colon cancer. The risk of developing CRC slightly varied by survival 
status with a stronger effect among deceased than living CRC cases, by familial risk level 
with a stronger effect on CRC risk among cases with intermediate/high familial risk of 
cancer than low familial risk, and by MSI with a stronger effect on MSI-H CRC risk than 
MSI-L/MSS CRC risk. 
This thesis suggests that cigarette smoking increased CRC risk. The results are 
consistent with previous similar studies [198•226-2321. The present study demonstrated a clear 
dose-response relationship, showing that the risk of CRC increased with cigarette 
smoking years, the number of cigarettes smoked per day and smoking cigarette pack 
years. This is consistent with other studies that reported statistically significant dose-
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response trends with the number smoked daily for CRC and its subsites [198•226• 
232,250,256,2571 
Studies on CRC have varied in their assessment of duration of smoking. Some 
evidence exists to suggest that the risk for CRC increase with earlier age at initiation 
[227•2311. However, this observation was not made in the current study. While other studies 
found a statistically significant increase of CRC incidence after 30 years of smoking [4141, 
this thesis showed a significantly increased risk after 20 years or more of smoking. Other 
studies found that cigarette smoking was unrelated to CRC risk until 35 years after 
smoking began, and that the relationship became progressively more strongly related with 
time [2841 . However, this thesis showed that the risk of CRC increased after 25 years since 
smoking began, and the risk did not increase with time. 
The benefit of smoking cessation was also evaluated in this thesis. The results 
showed that the risk of CRC significantly decreased with years of abstention from 
smoking and there was no significant difference in the risk between smokers who stopped 
smoking for 20 years or more and non-smokers. Other studies also reported a reduced 
risk of CRC after years of smoking cessation, but the risk remained substantially elevated 
even after 20 years of smoking cessation [1981. 
Possible biological mechanisms relating to the cause of CRC may involve the 
exposure of the epithelium of the large bowel to carcinogens either via the blood 
circulation after absorption of these chemicals in the lung, or after ingestion of saliva 
contaminated by tobacco smoke [284•41 51. Tobacco smoke contains at least 50 carcinogenic 
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components, the most genotoxic of which are thought to be the polycyclic aromatic 
hydrocarbons, heterocyclic aromatic amines, and N-nitroso compounds [4161. 
Several cohort studies have reported that the association between smoking and 
CRC is stronger in men than in women [198'228.2711. However, one study reported a 
significantly increased risk associated with smoking only in women and not in men [2721 
and another showed the association between smoking and CRC was equally strong in 
both sexes [2311 . While two case-control studies showed smoking was a risk factor only in 
men [252'2551, three showed no clear gender differences [257-2591. This thesis found the effect 
to be stronger among males than females. The elevated risk related to smoking among 
men may be because of fewer cigarettes smoked by women or more years of abstention 
from smoking. It is possible that there may be hormone-related differences in 
susceptibility to smoking. 
This thesis found that smoking cigarettes demonstrated a stronger risk of CRC 
among drinkers than non-drinkers. This combined effect may be because tobacco 
smoking is a major source of a wide variety of carcinogens including heterocyclic amines, 
polycyclic hydrocarbons and nitrosamines, and alcohol might serve as a solvent for 
polycyclic aromatic hydrocarbons and similar organic compounds from cigarettes, 
transporting these chemicals to sites they otherwise would not reach [122,4 171. 
This thesis also observed a significantly increased risk of CRC among both non-
obese and obese male smokers, but a stronger effect was observed among obese men. No 
other studies have reported this fmding. Studies including ours reported that the 
association between smoking and CRC is stronger in men than in women (1 98,228,27 11. The 
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reason is unknown. It may be because fewer cigarettes were smoked by women or more 
years of abstention from smoking. There may also be hormone-related differences in 
susceptibility to smoking. Obesity is characterized by a low-grade chronic inflammatory 
state [2171. Adipocytes produce pro-inflammatory factors and obese individuals have 
elevated concentrations of circulating tumour necrosis factor (1NF)-alpha [2181 
interleukin (IL)-6 and C-reactive protein compared with lean people [2191, as well as of 
leptin which also functions as an inflammatory cytokine [2201. Chronic inflammation can 
result in DNA damage and cancer promotion because a chronic inflammatory 
environment can increase proliferation and differentiation, inhibit apoptosis and induce 
angiogenesis [2211 . Tobacco smoke is a major source of a wide variety of carcinogens 
including heterocyclic amines, polycylic hydrocarbons and nitrosamines [122,3331. The 
combination of both smoking and obesity might increase the risk of CRC in the obese. 
This effect may be further combined with alcohol consumption. Further analyses and 
discussion on combined drinking, smoking and obesity can be found in Chapter 8. 
Smoking cigarettes resulted in a slightly stronger effect on the risk of rectal 
cancer than colon cancer consistent with case-control studies [246-249,256,2641 and cohort 
studies [200,228,282,418,4191 in other populations. The biological mechanism behind this 
subsite specificity is unknown. It is possible that nicotine may have a differential effect 
on colon and rectum or enhancing motility in the colon reduces transit time of 
carcinogens in the colon, but not in the rectum [2811. 
This study found that smoking demonstrated a stronger effect on CRC among 
deceased than living CRC cases. The reason is unknown. This might be due to genetic 
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cause of the difference observed in this study. Studies conducted in the United States 
showed that the higher frequency of the Pro/Pro phenotype of p53 in African American 
patients with colorectal adenocarcinoma is associated with an increased incidence of p53 
mutations, and with short survival [420l. 
This thesis demonstrates a stronger effect of cigarette smoking on MSI-H CRC 
than MSI-L/MSS CRC. This fmding is somewhat consistent with two previous studies. 
One case-control study conducted in the United States found that cigarette smoking 
increased the risk of both colon cancer with MSI-positive and MSI-negative compared to 
controls, but the risk was significantly higher for MSI-positive tumour than MSI-negative 
tumour [268l. Another study also found that the risk of MSI colon cancer was increased in 
patients who smoked [269l. The reason is unknown. 
This study is subject to several limitations. First, the participation rates of both 
cases and control subjects were relatively low (59.6% and 44.7%). Participation rates are 
as good as other population based studies [42 1l. It is possible that study respondents and 
non-respondents had different certain characteristics (e.g. smoking and drinking). While 
this thesis was unable to accurately estimate the magnitude of the possible bias, given the 
strength of the reported association, it is unlikely to be fully explained by participation 
bias. An analysis of the differences in demographic characteristics between the eligible 
cases and controls, between participating cases and controls, and between participating 
and non-participating controls, and the differences in demographic and clinical 
characteristics between participating and non-participating cases in this thesis did not 
show evidence that non-participation greatly affects the results of the study. 
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Second, the results in this thesis were not free from recall bias that may lead to 
exposure misclassification. The main protection against bias in this study was the 
standardization of methods, so the questions were identical, and presented in an identical 
fashion to both cases and controls. Analyses in Chapter 6 conducted to assess the 
reliability and validity of self-reporting lifetime tobacco smoking for this study did not 
suggest that cigarette smoking tended to be underestimated in the case-control study 
compared to several studies and data, but no obvious differential reporting of smoking for 
cases and controls [354•4031 . The underestimate of cigarette smoking would lead to the 
underestimate of the risk due to cigarette smoking. 
Third, this thesis included 258 deceased cases during the survey was conducted. 
The response from proxies of these deceased cases might differ from those of living cases, 
possibly biasing the results. However, examination of the estimates of the risk of living 
and deceased cases did not show a substantial difference. For example, as can be seen in 
Table 31 of this Chapter, the OR of deceased CRC cases was 1.55 and the OR of living 
CRC cases was 1.48. Furthermore, this minor difference could not be explained by the 
overreporting of cigarette smoking from the proxies. Finally, while this study could not 
assess how other unknown confounders affected the observed association, a recent review 
suggests that confounding is not important [4221. 
In summary, the study investigated the effects of tobacco smoking on CRC risk in 
the NL population. Smoking cigarettes increases the risk of CRC. There was a 49%, 36% 
and 96% higher risk of CRC among all cigarette smokers, former and current smokers 
than non-smokers. The risk of CRC tended to increase significantly with cigarette 
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smoking years, number of cigarettes smoked daily, cigarette pack years and the risk 
significantly decreased with years of abstention from smoking cigarettes. Smoking 
cigarettes demonstrated a stronger cancer risk among males than females, among drinkers 
than non-drinkers and among obese men than obese women. Smoking demonstrated a 
slightly stronger effect on rectal than colon cancer, deceased cancer than living cancer 
patients, on cases with intermediate/high familial risk than those with low familial risk of 
cancer, and on MSI-H CRC cases than MSI-L/MSS CRC cases. Further studies are 
needed to investigate why the association between cigarette smoking and CRC varied by 
sex, drinking status and weight. As well, more research is required to help clarify 
differences observed in the risk of colon and rectal cancer, living and deceased cases, 
cases with low and intermediate/high familial risk of cancer, and cases with MSI-L/MSS 
and MSI-H with cigarette smoking. 
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Chapter 8 Colorectal cancer and alcohol consumption 
8.1. Introduction 
In Canada, there is a wide variation in CRC incidence and mortality rates among 
provinces [9,10'3421. Very high incidence and mortality rates have been observed in the 
Atlantic provinces, particularly in NL, where CRC incidence and mortality rates are 
approximately twice as high as they are in British Columbia and Alberta [3421. It is unclear 
why such variation exists, but it has been speculated that differences in exposure to 
modifiable risk factors may explain some of the variation in incidence and mortality [91 . 
Alcohol has been linked to cancers of the colon and rectum, but results of studies 
and meta-analyses have been inconsistent regarding whether an association exists, and 
whether associations vary according to CRC subsite and beverage type [122,294,4231. While 
some studies found that alcohol consumption was significantly associated with an 
increased risk of colon cancer [295'2971, others found a decreased risk [4241. Some studies 
found that the single determinant of alcohol intake correlated with a modest relative 
elevation in CRC rate, mainly at the highest levels of intake [2971. However, others found 
that the consumption of even one or more alcoholic beverages a day at baseline was 
associated with approximately 70% greater risk of colon cancer [2951. There was a more 
than twofold increased risk of CRC reported in people who drank spirits and beers 
compared to people who drank wine [4241. While several studies have found that the most 
important risk factor for colon cancer is liquor consumption [2951, other studies showed no 
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clear difference in relative risks found among specific alcoholic beverages [2971. 
Furthermore there are some limitations in those studies. For example, some studies 
included only one measure of alcohol consumption at baseline and could not investigate 
lifetime alcohol consumption including alcohol consumption at younger ages and 
changes in alcohol consumption over time [2971 . A further issue is whether the effects seen 
elsewhere can be demonstrated in Canada since almost all studies have been conducted in 
other countries and the alcohol content in alcoholic beverages made in Canada differs 
from that in other countries [3431. Canada has had the highest incidence rate in the world 
and NL has had the highest incidence rate in the country [9,3421. However, only one study 
specifically on alcohol and CRC incidence has been carried out among men in Montreal, 
Quebec [425'4261 and the fmdings cannot be generalized to other provinces such as NL 
where the population shows different lifestyle and genetic characteristics [10'342'4101. No 
studies have been conducted to investigate the effect of alcohol intake on CRC in NL. To 
explore whether alcohol intake is associated with the risk of developing CRC, whether 
different alcoholic beverages influence risk differently, and whether alcohol consumption 
is associated with cancer in particular parts of the bowel and whether other characteristics 
such as sex, smoking status, obesity, survival status, familial risk and microsatellite 
instability (MSI) influence risk, further studies need to be conducted in a large Canadian 
population. 
8.2. Materials and methods 
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Detailed information on recruitment of cases and controls, data collection and 
statistical approaches is presented in Chapter 4. In brief, CRC cases diagnosed in 1999-
2003 were obtained from the NCR. Records of the NCR were reviewed to identify cases, 
and pathology reports were sought to confirm the diagnosis. Controls were selected 
randomly from the NL population using RDD. Controls were frequency-matched 
according to sex and five-year age group. A total of 702 cases and 717 controls were 
included in this analysis. 
All participants were asked to complete self-administered questionnaires which 
collect information on alcohol consumption and other various variables. Information on 
participants' alcohol consumption in each decade of life before diagnosis/enrollment date 
was collected. Cases and controls were asked questions to determine whether they were a 
beer, wine or spirit drinker. This thesis defines beer drinkers if they ever consumed beer 
once a week for 6 months or longer or beer non-drinkers; wine drinkers if they ever 
consumed wine once a week for 6 months or longer or wine non-drinkers; spirits drinkers 
if they ever consumed spirits once a week for 6 months or longer or spirits non-drinkers; 
Subjects were classified as alcohol drinkers if they ever consumed any alcoholic 
beverages once a week for 6 months or longer. Otherwise they were classified as alcohol 
non-drinkers. 
Derived variables on specific beverages were number of drinking years (0, 1-19, 
20+), number of drinks daily/weekly (0, 1-2, 3+) and number of litres of absolute alcohol 
yearly (0, 1-4, 5+ ). Derived variables on total alcohol consumption in the analysis 
included types of beverage (0, 1, 2+), number of drinking years (0, 1-19, 20+), number of 
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drinks daily (0, 1-2, 3+) and number of litres of absolute alcohol yearly (0, 1-4, 5-14, 
15+). Drinkers were required to report how many years and how many drinks of 12 ounce 
cans or bottles of beer, four ounce glasses of wine, one ounce serving of fortified wine or 
one ounce shots liquor or spirits they consumed per day or week. 
Covariates included in the model were age, sex, marital status, education 
attainment, rural-urban area, census division, physician diagnosed diabetes, physician 
diagnosed hypercholesterolemia, regular use of aspirin, intake of fruits, lifetime use of 
any laxatives and lifetime use of calcium pills or tablets and calcium-based antacids, BMI 
and cigarette smoking. The independent effect of alcohol intake was estimated using the 
OR as the estimate of the RR of CRC for alcohol intake calculated in multivariate 
multilevel logistic regression models, adjusted for potential clustering and confounding 
effects [376•382-3841. The OR was also estimated by sex, cigarette smoking and body weight 
(obese and non-obese), types of CRC (colon and rectal cancer), survival status of cases 
(living and deceased), familial risk level of cases (low familial risk and intermediate or 
high familial risk), and MSI of cases (MSI-L/MSS and MSI-H) [351 •3791. The combined 
effects of drinking, smoking and weight on CRC were also analyzed. Statistical analyses 
were completed using SAS 9.1 [367•3801. 
8.3. Characteristics of the sample and alcohol consumption 
8.3.1. Demographics and alcohol consumption 
A total of 702 CRC cases and 717 controls were included in the study of the 
association of CRC with alcohol consumption. The mean age of cases was 60.4 years old 
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(SD: 9.3, range: 20-74) and that of the controls was 60.4 (SD: 9.5, range: 20-75) with no 
statistically significant difference between cases and controls (F-test, P = 0.6801). Table 
34 presents the demographic characteristics of cases and controls and the prevalence rate 
of alcohol consumption in the sample. Compared to controls, cases tended to be those 
who were Canadian-born, lived in rural area, had a high school education or less, and had 
no household income or less than $30,000 of income. 
Table 34. The demographic characteristics of cases of colorectal cancer and controls and the 
~revalence rates of alcohol consum~tion b~ subgrou~ in the case-control stud~ 
Demographics Case Control Alcohol ConsumEtion 1 
N %t N %t N % 95%CI 
Age group n 
20-54 186 26.50 185 25.80 257 69.27 64.57- 73.97 
55-64 242 34.47 264 36.82 328 64.82 60.66- 69.99 
65-74 274 39.03 268 37.38 300 55.35 51.16-59.54 
Sex n 
Female 276 39.32 293 40.86 211 37.08 33.11 -41.06 
Male 426 60.68 424 59.14 674 79.29 76.57- 82.02 
Race 
Other 29 4.13 46 6.42 42 56.00 44.75- 67.25 
Caucasians 673 95.87 671 93.58 843 62.72 60.14-65.3 1 
Birth place ** 
Other 32 4.56 58 8.09 49 54.44 44.14-64.75 
Canada 670 95.44 659 91.91 836 62.90 60.30- 65.50 
Region * n 
Urban 302 43.02 355 49.51 433 66.11 62.48 - 69.74 
Rural 400 56.98 362 50.49 452 59.16 55.67- 62.65 
Education *** n 
High school or less 446 63 .53 349 48.68 452 56.86 53.41 - 60.30 
College+ 256 36.47 368 51.32 433 69.39 65.77- 73 .01 
Household income ($) *** n 
0-29,999 395 56.27 334 46.58 380 52.13 48.50- 55.76 
30,000+ 307 43.73 383 53.42 505 73.19 69.88 - 76.50 
Marital status n 
Married 540 76.92 579 80.75 728 65.06 62.26- 67.86 
Single/div/seE/wid 162 23.08 138 19.25 157 52.33 46.67 - 57.99 
Total 702 100.00 717 100.00 885 62.37 59.84- 64.89 
Note: t Column % and X2: *P<0.05 **P<O.O I ***P<O.OO l. t Number, percentage of drinkers and 95% C1 
of the percentage in the sample of cases and controls. n shows a significant difference between subgroups. 
155 
The prevalence rate of alcohol consumption was significantly higher among those 
aged 20-54 and aged 55-64 than those aged 65-74 (95% Cldiff: 8.21-19.63% and 3.57-
15.37%). Significantly more men than women consumed alcohol (95% Cidiff: 37.40-
47.02%). The prevalence rate of alcohol consumption was significantly higher in urban 
residents than rural residents (95% Cldiff: 1.92-11.98%) and among those who had some 
post-secondary school education or higher (95% Cldiff: 7.54-17.52%). The prevalence rate 
of alcohol consumption was also significantly higher among those who had a household 
income of $30,000 or higher than those who had a household income of lower than 
$30,000 or no income (95% Cldiff: 16.15-25.97%) and among those who were married 
(including common-law) than those who were single, separated, divorced or widowed 
(95% Cidiff: 6.43-19.03%). 
8.3.2. Chronic condition, medication and lifestyle and alcohol consumption 
Table 35 presents the characteristics of chronic condition, medication and lifestyle 
and the prevalence rate of alcohol consumption of the sample. Cases in total tended to be 
those who had polyps, diabetes, and no high cholesterol level. More controls took aspirin 
and calcium pills and tablets and ate fruits daily than cases. More cases tended to be 
obese than controls. The prevalence rate of alcohol consumption was significantly higher 
among those without family history of CRC than those with family history (95% Cidiff: 
0.96 -14.14%), among those without other cancer diagnosis than those with other cancer 
diagnosis (95% Cidiff: 1.03-14.47%), among those who took aspirin (95% Cidiff: 1.58-
12.52%) than those who never took and among those who did not take calcium 
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supplement than those who did (95% Clditf: 10.81-24.49%). More smokers tended to be 
drinkers (95% Clditf: 16.94-24.14%). 
Table 35. Comparison of chronic condition, medication and lifestyle of cases of colo rectal cancer with 
controls and the prevalence rates of alcohol consumption by subgroup in the case-control study 
Chronic condition, Case Control Alcohol Consumption ;j; 
medication, lifestyle N % t N % t N % 95% CI 
CRC family history 0 
No 540 76.92 614 85.63 736 63.77 
Yes 162 23.08 103 14.37 149 56.22 
Other cancer history 0 
No 600 85.47 625 87.17 777 63.42 
Yes 102 14.53 92 12.83 108 55.67 
Polyp *** 
No 400 56.98 
Yes 302 43.02 
Diabetes *** 
No 555 79.06 
Yes 147 20.94 
High cholesterol level ** 
No 494 70.37 
Yes 208 29.63 
A~~~ * 
No 522 74.62 
Yes I 80 25.38 
Any laxatives use *** 
No 573 81.62 
Yes 129 18.38 
Fruits daily *** 
1-2servings 519 73.93 
3+ servings 183 26.07 
Vegetables daily 
I -2 servings 
3+ servings 
Red meats daily 
I -2 servings 
3+ servings 
Calcium pills/tablets 
No 
Yes 
Obesity 
No (BMI<30) 
Yes (BMI~30) 
Physical activity 
436 
266 
384 
318 
608 
94 
503 
199 
62.11 
37.89 
54.70 
45.30 
*** 
86.61 
13.39 
* 
71.65 
28.35 
627 
90 
623 
94 
451 
266 
492 
225 
657 
60 
471 
246 
430 
287 
409 
308 
568 
149 
556 
161 
87.45 
12.55 
86.89 
13.11 
62.90 
37.10 
68.62 
31.38 
91.63 
8.37 
65.69 
34.31 
59.97 
40.03 
57.04 
42.96 
79.22 
20.78 
77.55 
22.45 
625 
260 
745 
140 
589 
296 
612 
272 
776 
109 
607 
278 
533 
352 
465 
420 
769 
116 
654 
231 
60.86 
66.33 
63.24 
58.09 
62.33 
62.45 
n 
60.36 
67.41 
63.09 
57.67 
6 I .31 
64.80 
61.55 
63.65 
n 
58.63 
67.09 
n 
65.39 
47.74 
61.76 
64.17 
Active 226 32.19 220 30.68 272 60.99 
Inactive 476 67.81 497 69.32 613 63.00 
Cigarette smoking *** 0 
61 .00 - 66.55 
50.24- 62.20 
60.73- 66.33 
48.67 - 62.67 
57.87- 63 .85 
61.64-71.01 
60.49- 66.00 
51.85 - 64.33 
59.23 - 65.42 
58.09 - 66.8 I 
57.34-63.37 
62.84 - 71.98 
60.39 - 65.79 
50.62- 64.72 
58.28- 64.72 
60.28- 69.33 
58.30- 64.79 
59.64- 67.67 
55.21 - 62.07 
63.41 -70.78 
62.67 - 68.11 
41.45- 54.02 
58.83 - 64.69 
59.21 -69.13 
56.45 - 65.52 
59.96- 66.04 
No 201 28.63 270 37.66 197 41.83 37.37-46.29 
Yes 501 71.37 447 62.34 688 72.57 69.73 -75.42 
Total 702 100.00 717 100.00 885 62.37 59.84-64.89 
Note: t Column% and X2: *P<0.05 **P<O.Ol ***P<O.OOI. t Number, percentage of drinkers and 95% CT 
of the percentage~ the sample of cases and controls. n shows a significant difference between subgroups. 
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8.4. Relative risk of colorectal cancer with alcohol consumption 
8.4.1. Colorectal cancer and total alcohol consumption 
Table 36 presents the OR of CRC and the corresponding 95% CI for total alcohol 
consumption (beer, wine and spirits) in the case-control study. Chi-square analysis and/or 
Table 36. The odds ratio of colorectal cancer and the corresponding 95% confidence interval for 
total alcohol consumption in the case-control study 
Alcohol use 
Drink status 
Non-drinker 
Drinker 
Types 
1-2 
3+ 
Drinking years 
1-19 
20-39 
40+ 
P-trend 
Drinks daily 
1-2 
3-4 
5+ 
P-rrend 
Litres yearly 
1-4 
5-14 
15+ 
Case Control 
N % 
270 38.46 
432 61.54 
* 
335 47.72 
97 13.82 
78 11.11 
247 35.19 
107 15.24 
* 
241 34.33 
60 8.55 
131 18.66 
* 
134 19.09 
137 19.52 
161 22.93 
N % 
264 36.82 
453 63 .18 
339 47.28 
114 15.90 
Ill 15.48 
246 34.31 
96 13.39 
287 40.03 
68 9.48 
98 13.67 
144 20.08 
180 25.10 
129 17.99 
Unadjusted 
OR & 95%CI ... 
1.00 
0.93 0.75- 1.16 
0.97 0.77- 1.21 
0.83 0.60 - 1.15 
0.69 0.49- 0.96 * 
0.98 0.77 - 1.25 
1.09 0.79 - 1.51 
0.82 0.65 - 1.05 
0.86 0.59 - 1.27 
1.31 0.96- 1.79 
0.91 0.68- 1.22 
0.74 0.56- 0.98 * 
1.22 0.92 - 1.63 
Adjusted t 
OR & 95%CI t 
1.00 
0.99 0.76-1.29 
1.00 0. 76 - 1.31 
0.96 0.65 - 1.40 
0.74 0.51- 1.08 
1.08 0.80 - 1.46 
1.15 0.78-1.69 
ns 
0.93 0. 70 - 1.23 
0.87 0.56 - 1.35 
1.33 0.91 - 1.95 
ns 
1.06 0.77- 1.46 
0.78 0.56-1.10 
1.18 0.82 - 1.68 
ns 
Note: t OR estimates for alcohol use from multilevel binary models adjusted for cigarette smoking, age, 
sex, rural/urban, education, marriage, family history of colorectal cancer, diabetes, cholesterol, aspirin, 
fruits, obesity, laxatives and calcium and random effect of census area. X2 or Wald test or Cochran-
Armitage test for trend: *P<0.05 **P<0.01 ***P<O.OO I. Cochran-Armitage test for trend: ns=not 
significant at 5%. 
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the unadjusted OR showed a significant relationship between CRC and alcohol types 
(X2(2dt) = 8.56 and P = 0.0138), drinking years, drinks daily (X2(3dt) = 9.89 and P = 0.0195) 
and drinking litres yearly (X2(3dt) = 9.63 and P = 0.0220), but the adjusted OR of CRCs 
did not suggest any significant relationship between CRC and alcohol consumption. 
8.4.2. Colorectal cancer and types of beverage 
Table 37 presents the unadjusted and adjusted OR of CRC and the corresponding 
95% CI for drinking beer, wine, and spirits in the case-control study. The study found a 
protective effect of drinking beer on CRC. The adjusted OR of 0.65 (95% CI: 0.45-0.96) 
of CRC for drinking beer years suggested a 35% lower risk of developing CRC among 
those who drank beer for fewer than 20 years than those who never drank beer. There 
was a 27% decreased risk of CRC for drinking fewer than three drinks of beer compared 
to non-drinkers. The study also found a protective effect of drinking spirit on CRC. The 
adjusted OR of 0.67 (95% CI: 0.47-0.93) of CRC for drinking spirit suggested a 33% 
lower risk of developing CRC among those who drank spirit fewer than 20 years than 
those who never drank spirit. The adjusted OR did not suggest any significant 
relationship between drinking wine and CRC. 
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Table 37. The odds ratio of colorectal cancer and the corresponding 95% confidence interval for 
t~Ees of beverage in the case-control stud~ 
Alcohol Case Control Unadjusted Adjusted! 
consumption N % N % OR & 95% CI OR & 95%CI 
Beer 
Non-drinker 359 51.14 356 49.65 1.00 1.00 
Drinker 343 48.86 361 50.35 0.94 0. 76 - 1.16 0.81 0.61 - 1.08 
Drinking years 
1-19 76 10.83 103 14.37 0.73 0.53- 1.02 0.65 0.45-0.96 * 
20+ 267 38.03 258 35.98 1.03 0.82- 1.29 0.90 0.66- 1.22 
P-rrcnd ns 
Drinks daily ** 
1-2 221 31.48 270 37.66 0.81 0.64- 1.02 0.73 0.54- 0.98 * 
3+ 122 17.38 91 12.69 1.33 0.98 - 1.81 1.10 0.75-1.60 
P-trend ns 
Litres yearly * 
1-4 132 18.80 155 21.62 0.84 0.64- 1.11 0.79 0.57- 1.10 
5+ 211 30.06 206 28.73 1.02 0.80- 1.29 0.83 0.60- 1.1 5 
P-trend ns 
Wine ** 
Non-drinker 560 79.77 523 72.94 1.00 1.00 
Drinker 142 20.23 194 27.06 0.68 0.53 - 0.88 ** 0.85 0.65- 1.12 
Drinking years 
1-19 79 11 .25 102 14.23 0.72 0.53-0.99 * 0.85 0.60- 1.20 
20+ 63 8.97 92 12.83 0.64 0.45-0.90 * 0.86 0.59- 1.24 
P-trend ns 
Drinks weekly ** 
1-2 66 9.40 97 13.53 0.64 0.45 - 0.89 * 0.79 0.55-1.13 
3+ 76 10.83 97 13.53 0. 73 0.53 - 1.0 I 0.91 0.64- 1.29 
P-trend ns 
Litres yearly ** 
1-4 59 8.40 86 11.99 0.64 0.45 - 0.91 * 0.82 0.56 - 1.20 
5+ 83 11.82 108 15.05 0. 72 0.53 - 0.98 * 0.88 0.63 - 1.23 
P-trend ns 
Spirits 
Non-drinker 378 53.85 366 50.05 1.00 1.00 
Drinker 324 46. 15 351 49.95 0.89 0.73- 1.10 0.93 0.73 - 1.18 
Drinking years 
1-19 83 11 .82 121 16.08 0.66 0.48- 0.91 ** 0.67 0.47- 0.93 ** 
20+ 241 34.33 230 32.08 1.01 0.81 - 1.28 1.06 0.80- 1.39 
P-trend ns 
Drinks daily 
1-2 238 33.90 277 38.63 0.83 0.66- 1.04 0.90 0.70- 1.16 
3+ 86 12.25 74 10.32 1.13 0.80- 1.59 1.24 0.82 - 1.88 
P-trend ns 
Litres yearly 
1-4 162 23.08 193 26.91 0.81 0.63- 1.05 0.87 0.66- 1.16 
5+ 162 23.08 158 22.04 0.99 0.76- 1.29 1.00 0 .74 - 1.36 
P-rrend ns 
Note: t OR for beverage from multilevel binary models adjusted for age, sex, education, marriage, 
rural/urban, diabetes, aspirin, fruits, BMI, laxatives, calcium and cigarette and random effect of census 
area. X2 or Wald test or Cochran-Armitage test for trend: *P<0.05 **P<0.01 ***P<O.OOI. Cochran-
Armitage test for trend: ns=not significant at 5%. 
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8.4.3. Colorectal cancer and total alcohol consumption by sex 
Table 38 presents the adjusted OR of CRC and the corresponding 95% CI for total 
alcohol consumption in women and men in the case-control study. Chi-square analyses 
showed a significant relationship between CRC and types of drinking, drinks daily and 
litres consumed yearly in women but the adjusted ORs did not suggest any significant 
effect of total alcohol use on CRC in women. No significant effect was found in men. 
Table 38. The adjusted odds ratio of colorectal cancer and the corresponding 95% confidence 
interval for total alcohol consumEtion in women and men in the case-control stud~ 
Alcohol Women Men 
Consumption Case Control OR & 95%CI Case Control OR & 95%Cl t 
Alcohol 
Non-drinker 179 179 1.00 91 85 1.00 
Drinker 97 114 1.12 0.75- 1.68 335 339 0.90 0.62- 1.31 
Types * 
1-2 87 95 1.23 0.81 - 1.88 248 244 0.89 0.61-1.31 
3+ 10 19 0.74 0.31- 1.77 87 95 0.94 0.59- 1.49 
Drinking years 
1-19 34 53 0.85 0.49- 1.46 44 58 0.70 0.41- 1.21 
20-39 55 53 1.47 0.89-2.44 192 193 0.89 0.59- 1.32 
40+ 8 8 1.34 0.46-3.94 99 88 1.05 0.66- 1.65 
P-trend ns ns 
Drinks daily * 
1-2 74 96 1.06 0.69- 1.63 167 191 0.83 0.56- 1.24 
3-4 9 11 1.01 0.38-2.66 51 57 0.75 0.44- 1.27 
5+ 14 7 1.87 0.68-5.13 117 91 1.18 0. 75 - 1.85 
P-trend ns ns 
Litres yearly * 
1-4 62 70 1.26 0.80 - 1.99 72 74 0.98 0.61 - 1.58 
5-14 22 35 0.73 0.39- 1.39 115 145 0.74 0.48- 1.13 
15+ 13 9 1.64 0.64-4.23 148 120 1.05 0.69- 1.61 
P-trend ns ns 
Note: t OR estimates for alcohol use from multilevel binary models adjusted for cigarette smoking, age, 
rural/urban, education, marriage, family history of colorectal cancer, diabetes, cholesterol, aspirin, fruits, 
BMI, laxatives and calcium and random effect of census area. X2 or Wald test or Cochran-Armitage test for 
trend: *P<0.05 **P<O.Ol ***P<O.OO I . Cochran-Armitage test for trend: ns=not significant at 5%. 
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8.4.4. Colorectal cancer and total alcohol consumption by smoking status 
Table 39 presents the adjusted OR of CRC and the corresponding 95% CI for total 
alcohol use among non-smokers and smokers in the case-control study. Among non-
smokers, chi-square analyses showed a significant relationship between CRC and the 
number of litres yearly, but the adjusted ORs did not suggest a significant relationship 
between CRC and alcohol consumption. Among smokers, no significant relationship 
between drinking and CRC was found. 
Table 39. The adjusted odds ratio of colorectal cancer and the corresponding 95% confidence 
interval for total alcohol consumetion among non-smokers and smokers in the case-control stud~ 
Alcohol Non-Smoker Smoker 
Consumption Case Control OR & 95% CIt Case Control OR & 95%CI t 
Alcohol 
Non-drinker 131 143 1.00 139 121 1.00 
Drinker 70 127 0.89 0.57 - 1.40 362 326 1.06 0.76- 1.49 
Types 
1-2 58 89 1.0 I 0.63- 1.62 277 250 1.05 0.74- 1.48 
3+ 12 38 0.51 0.23-1.13 85 76 1.13 0.71- 1.79 
Drinking years 
1-19 19 41 0.76 0.40- 1.46 59 70 0.76 0.47-1.21 
20-39 38 65 0.97 0.56- 1.68 209 181 1.13 0.78- 1.64 
40+ 13 2 1 0.93 0.40-2.16 94 75 1.29 0.82-2.03 
P-trend ns ns 
Drinks daily 
1-2 52 104 0.84 0.52- 1.35 189 183 1.01 0.71- 1.45 
3-4 7 12 0.68 0.23- 1.98 53 56 0.90 0.54- 1.49 
5+ II II 2.01 0.75- 5.43 120 87 1.33 0.86-2.04 
P-trend ns ns 
Litres yearly * 
1-4 32 61 0.85 0.50- 1.46 102 83 1.25 0.83 - 1.88 
5-14 21 47 0.77 0.40- 1.47 116 133 0.81 0.54- 1.21 
15+ 17 19 1.39 0.61-3.14 144 110 1.17 0.77- 1.78 
P-trend ns ns 
Note: t OR estimates for alcohol consumption from multilevel binary models adjusted for age, sex, 
rural/urban, education, marriage, family history of colorectal cancer, diabetes, cholesterol, aspirin, fruits, 
BMI, laxatives and calcium and random effect of census area. X2 or Wald test or Cochran-Armitage test for 
trend: *P<0.05 **P<O.O I ***P<O.OO I. Cochran-Armitage test for trend: ns=not significant at 5%. 
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8.4.5. Colorectal cancer and total alcohol consumption by obesity 
Tills section presents the analyses on CRC and total alcohol consumption, the 
combined effect of drinking, smoking and obesity in the case-control study of CRC. 
Table 40 presents the adjusted OR of CRC and the corresponding 95% CI for total 
alcohol consumption among non-obese (BMI < 30) and obese (BMI 2: 30) in the case-
control study. Total alcohol consumption showed a weak protective effect ofCRC among 
non-obese, but significantly increased the risk of developing CRC among obese. 
Drinking fewer than 20 years, 1-2 drinks daily or 5-14 litres of alcohol significantly 
reduced the risk of CRC among non-obese. 
Table 40. The adjusted odds ratio of colorectal cancer and the corresponding 95% confidence 
interval for total alcohol consum~tion in non-obese and obese in the case-control studl: 
Alcohol Non-Obese {BM1<302 Obese {BMI>30} 
Consumption Case Control OR & 95%CI! Case Control OR & 95% CIt 
Alcohol * * 
Non-drinker 208 197 1.00 62 67 1.00 
Drinker 295 359 0.79 0.58- 1.07 137 94 2.25 1.24-4.08 * 
Types ** 
1-2 233 262 0.82 0.60- 1.12 102 77 2.09 1.13-3.86* 
3+ 62 97 0.68 0.44- 1.06 35 17 3.40 1.43- 8.10 * 
Drinking years * 
1-19 53 82 0.62 0.40- 0.95 ** 25 29 1.69 0.77- 3.73 
20-39 166 197 0.84 0.59 - 1.19 81 49 2.59 1.33 - 5.06 * 
40+ 76 80 0.92 0.59- 1.43 31 16 2.62 1.05-6.53 * 
P-trend ns * 
Drinks daily * 
1-2 167 236 0.74 0.53- 1.00 * 74 55 2.30 1.21 -4.36 * 
3-4 36 47 0.72 0.42- 1.24 24 21 1.37 0.58- 3.22 
5+ 92 80 1.03 0.67 - 1.59 39 18 3.77 1.57- 9.05 * 
P-rrend ns * 
Litres yearly ** 
1-4 94 115 0.86 0.60 - 1.24 40 29 2.56 1.25- 5.24 * 
5-14 94 147 0.61 0.42 - 0.90 ** 43 33 1.80 0.83 - 3.90 
15+ 107 97 0.97 0.64- 1.47 54 32 2.24 1.05 - 4.78 * 
P-trend ns ns 
Note: t OR estimates for alcoholic drink from multilevel binary models adjusted for cigarette smoke, age, 
sex, education, marriage, rural/urban, family history of colorectal cancer, diabetes, cholesterol, aspirin, 
fruits, laxatives and calcium and random effect of census area. X2 or Wald test or Cochran-Arrnitage test 
for trend: *P<0.05 **P<O.OJ ***P<O.OOI. Cochran-Arrnitage test for trend: ns=not significant at 5%. 
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There was a 2.25 times increased risk of developing CRC for alcohol drinkers 
compared to non-drinkers among obese (OR: 2.25 and 95% CI: 1.24-4.08). The estimated 
population attributable risk (PAR) of CRC associated with alcohol consumption was 
49.87% (95% CI: 35.42-64.32%), i.e. , 49% of incidence of CRC can be attributed to 
alcohol consumption among the obese. Drinkers who had one to two (OR: 2.09 and 95% 
CI: 1.13-3.86) or three types (OR: 3.40 and 95% CI: 1.43-8.10) of beverage had a 
significantly increased the risk of CRC compared to non-drinkers among the obese. The 
risk of developing CRC increased with drinking years and drinks daily among the obese. 
Table 41 presents the combined effects of drinking, cigarette smoking and obesity 
on CRC. In this analysis, subjects were classified into eight groups regarding their 
drinking, smoking and obese status (see Table 41). The ORs of CRC for combined 
drinking, smoking and obesity were estimated when different referent groups were used 
in the model. Among non-drinkers (Model 1: Referent group = non-drinkers, non-
smokers and non-obese), neither smoking nor obesity increased the risk of CRC and 
combined smoking and obesity did not increase the risk of CRC. Among drinkers (Model 
2: Referent group = Drinkers, non-smokers and non-obese), cigarette smoking 
significantly increased the risk ofCRC compared to not smoking (OR: 1.81 and 95% CI: 
1.22-2. 70), but obesity did not. However, obesity can strengthen the effect of smoking on 
CRC (OR: 2.99 and 95% CI: 1.87-4.78), i.e., the risk ofCRC due to smoking increased to 
2.99 from 1.81 when obese was present. The observed OR (2.99) for obesity and smoking 
was larger than the expected additional OR (2.66 = 1.85 + 1.81 - 1) among drinkers. 
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Table 41. The adjusted odds ratio of colorectal cancer and the corresponding 95% confidence 
interval for alcohol intake, cigarette smoking and obesitl: in the case-control studl: 
Alcohol Smoke Obesity Case Control Unadjusted Adjusted! OR & 95%CI OR & 95%CI 
Modell *** 
No No No 99 105 1.00 1.00 
No No Yes 30 34 0.91 0.52 - 1.60 0.77 0.43 - 1.40 
No Yes No 104 85 1.28 0.87 - 1.90 1.21 0.80 - 1.84 
No Yes Yes 32 32 1.06 0.61 - 1.87 0.86 0.47- 1.57 
Yes No No 53 109 0.51 0.34- 0.79 ** 0.61 0.38- 0.87 * 
Yes No Yes 19 19 0.96 0.49- 1.90 1.14 0.55- 2.33 
Yes Yes No 247 257 1.03 0.74- 1.42 1.1 2 0.77- 1.62 
Yes Yes Yes 118 76 1.72 1.16- 2.57 * 1.84 1.18-2.88 * 
Model2 
Yes No No 53 109 1.00 1.00 
Yes No Yes 19 19 1.88 0.92- 3.80 1.85 0.88 - 3.86 
Yes Yes No 247 257 2.00 1.37 - 2.92 *** 1.81 1.22- 2.70 ** 
Yes Yes Yes 118 76 3.35 2.15 - 5.23 *** 2.99 1.87-4.78 *** 
Model3 
No No Yes 30 34 1.00 1.00 
No Yes Yes 32 32 1.05 0.47- 2.32 1.10 0.53 - 2.29 
Yes No Yes 19 19 1.12 0.67- 1.89 1.46 0.63 - 3.35 
Yes Yes Yes 118 76 1.88 1.06 - 3.32 * 2.37 1.28 - 4.36 ** 
Model4 
No Yes No 104 85 1.00 1.00 
No Yes Yes 32 32 0.83 0.47 - 1.46 0. 71 0.39 - 1.29 
Yes Yes No 247 257 0.80 0.57 - 1.11 0.92 0.63 - 1.32 
Yes Yes Yes 118 76 1.34 0.89 - 2.0 I 1.51 0.97- 2.36 
Model5 
No Yes Yes 32 32 1.00 1.00 
Yes Yes Yes 118 73 3.35 2.15-5.23 ** 2.99 1.87- 4.78 * 
Note: t OR estimates for alcoholic drink, tobacco smoke and weight from multilevel binary models 
adjusted for age, sex, birth place, race, education, marriage, family history of co1orectal cancer, diabetes, 
other cancer, cholesterol, aspirin, fruits, vegetables, activity, laxatives and calcium and random effect of 
census area. X2 or Wald test: *P<0.05 **P<O.OI ***P<O.OOl. 
In relation to drinking, the effect of drinking on CRC was to significantly 
decrease the risk of CRC (see Model 1) compared to not drinking if not smoking and not 
obese (OR: 0.61 and 95% CI: 0.38-0.87) and was to increase the risk of CRC compared 
to not drinking when smoking and obese appeared (OR: 1.84 and 95% CI: 1.18-2.88). 
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Among the obese (Model 3: Referent group = non-drinkers, non-smokers and obese) 
neither drinking nor smoking increased the risk of CRC significantly, but combined 
drinking and smoking significantly increased the risk of CRC (OR: 2.37 and 95% CI: 
1.28-4.36). The observed OR (2.37) for drinking and smoking was larger than the 
expected additional OR (1.56 = 1.10 + 1.46 - 1) and multiplicative OR (1.60 = 1.10 x 
1.46). 
Among smokers (Model 4: Referent group = non-drinkers, smokers and non-
obese), neither drinking nor obesity solely increased the risk of CRC significantly and 
combined drinking and obesity tended to increase the risk of CRC, but not significantly 
(OR: 1.51 and 95% CI: 0.97-2.36). Among obese smokers (Model 5: non-drinkers, 
smokers and obese), drinking significantly increased CRC risk (OR: 2.99 and 95% CI: 
1.87-4. 78). 
8.4.6. Colon and rectum cancer and total alcohol consumption 
Because the body weight modified the effect of alcohol consumption on CRC 
shown above, further analyses by BMI were conducted. Table 42 presents the adjusted 
OR and the corresponding 95% CI of colon and rectal cancer for total alcohol 
consumption in non-obese. The results showed a slightly reduced effect of alcohol 
consumption on both colon cancer and rectal cancer among non-obese. The adjusted OR 
of colon cancer of 0.60 (95% CI: 0.38-0.92) suggested a 40% lower risk of colon cancer 
among those who drank 4-14 litres yearly than those who did not drink. The adjusted OR 
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of rectal cancer of 0.43 (95% CI: 0.22-0.85) suggested a 57% lower risk of rectal cancer 
among those who drank fewer than 20 years than those who did not drink any beverages. 
Table 42. The adjusted odds ratio of colon and rectal cancer and the corresponding 95% confidence 
interval for total alcohol consumption in non-obese 
Alcohol . Control Colon Cancer 
ConsumptiOn Case OR & 95% CI t 
Alcohol 
Non-drinker 
Drinker 
Types 
1-2 
3+ 
Drinking years 
1-19 
20-39 
40+ 
P-trend 
Drinks daily 
1-2 
3-4 
5+ 
P-trend 
Litres yearly 
1-4 
5-14 
15+ 
197 
359 
262 
97 
* 
82 
197 
80 
232 
47 
80 
* 
115 
147 
97 
146 
191 
151 
40 
39 
105 
47 
105 
23 
63 
64 
56 
71 
1.00 
0.81 0.58- 1.14 
0.84 0.59- 1.19 
0.71 0.43- 1.16 
0.71 0.44- 1.14 
0.85 0.58 - 1.25 
0.90 0.55 - 1.47 
ns 
0.73 0.51 - 1.05 
0.78 0.43- 1.43 
1.18 0.73- 1.89 
ns 
0.89 0.59- 1.34 
0.60 0.38-0.92 * 
1.08 0.68-1.71 
Case 
62 
104 
82 
22 
14 
61 
29 
62 
13 
29 
30 
38 
36 
Rectal Cancer 
OR & 95%Cl t 
1.00 
0.72 0.46- I. II 
0.74 0.47-1.16 
0.62 0.33 - 1.16 
0.43 0.22- 0.85 ** 
0.79 0.48- 1.29 
0.93 0.51 - 1.69 
ns 
0.72 0.46 - 1.15 
0.59 0.28- 1.26 
0.79 0.43- 1.44 
ns 
0.79 0.46- 1.34 
0.61 0.36- 1.04 
0.78 0.44- 1.39 
P- ns ns 
Note: t OR estimates for alcohol consumption from multilevel multinomial models adjusted for age, sex, 
education, marriage, ruraVurban, family history of colorectal cancer, diabetes, cholesterol, aspirin, fruits, 
laxatives, calcium and cigarette and random effect of census area. X2 or Wald test or Cochran-Armitage test 
for trend: *P<0.05 **P<O.O 1 ***P<O.OO I . Cochran-Armitage test for trend: ns=not significant at 5%. 
Table 43 present the adjusted OR of colon and rectal cancer for alcohol 
consumption and the corresponding 95% CI among the obese. The results showed that 
drinking significantly increased the risk of both colon and rectal cancer in the obese. The 
results seemed not to suggest any substantial differences in the effects of alcohol 
consumption on the cancer between the colon and the rectum even though more 
significant relationships between colon cancer and the measures of alcohol consumption. 
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Table 43. The adjusted odds ratio of colon and rectal cancer and the corresponding 95% confidence 
interval for total alcohol consum~tion among the obese 
Alcohol Control Colon Cancer Rectal Cancer Consumption Case OR & 95%CI t Case OR & 95%CI t 
Alcohol 
Non-drinker 67 43 1.00 19 1.00 
Drinker 94 90 2.30 1.20 - 4.39 * 47 2.15 0.96-4.81 
Types 
1-2 77 62 1.97 1.01-3.85 * 40 2.22 0.99 - 4.99 
3+ 17 28 4.55 1.79- 11.57 ** 7 1.66 0.49 - 5.61 
Drinking years 
1-19 29 19 2.11 0.90-4.98 6 1.05 0.33- 3.39 
20-39 49 49 2.47 1.19-5.15 * 32 2.79 1.15-6.78 * 
40+ 16 22 2.67 1.01 -7.08 * 9 2.78 0.84- 9.21 
P-trend * ns 
Drinks daily 
1-2 55 48 2.27 1.13-4.56 * 26 2.32 0.98- 5.48 
3-4 21 18 1.66 0.66 - 4.15 6 0.91 0.27- 3.04 
5+ 18 24 3.63 1.40-9.38* 15 4.06 1.35-12.19* 
P-trend * ns 
Litres yearly 
1-4 29 28 2.77 1.27 - 6.05 * 12 2.40 0.90 - 6.38 
5-14 33 26 1.78 0.76-4.21 17 1.94 0.72 - 5.23 
15+ 36 36 2.42 1.05 - 5.57 * 18 1.99 0.74-5.37 
P-trend * ns 
Note: t OR estimates for alcohol consumption from multilevel multinomial models adjusted for age, sex, 
education, marriage, ruraVurban, family history of colorectal cancer, diabetes, cholesterol, aspirin, fruits, 
laxatives, calcium and cigarette and random effect of census area. X2 or Wald test or Cochran-Armitage test 
for trend: *P<0.05 **P<0.01 ***P<O.OOI. Cochran-Armitage test for trend: ns=not significant at 5%. 
8.4.7. Colorectal cancer and total alcohol consumption by survival status 
Table 44 presents the adjusted OR of CRC of living and deceased cases and the 
corresponding 95% CI for total alcohol consumption in non-obese. The values of the 
adjusted OR of cancer for both living cases and deceased cases suggested a slightly 
reduced effect of alcohol consumption in moderation of CRC among non-obese. 
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Table 44. The adjusted odds ratio of living and deceased colorectal cancer patients and the 
corresponding 95% confidence interval for total alcohol consumption in non-obese 
Alcohol 
Control 
Living CRC Cases Deceased CRC Cases 
Consumption Case OR & 95% CIt Case OR & 95%Cf t 
Alcohol 
Non-drinker 197 126 1.00 82 1.00 
Drinker 359 179 0.84 0.59- 1.19 116 0.72 0.48- 1.07 
Types * 
1-2 262 134 0.83 0.58 - 1.18 99 0.81 0.54 - 1.22 
3+ 97 45 0.92 0.56- 1.51 17 0.39 0.20-0.74 * 
Drinking years 
1-19 82 33 0.64 0.39- 1.06 20 0.58 0.32- 1.05 
20-39 197 100 0.88 0.59 - 1.32 66 0.77 0.49- 1.22 
40+ 80 46 1.04 0.63 - 1.72 30 0.77 0.43 - 1.37 
P-trend ns ns 
Drinks daily * 
1-2 232 105 0.80 0.56- 1.16 62 0.64 0.42- 1.00 * 
3-4 47 22 0.78 0.42- 1.45 14 0.62 0.30- 1.29 
5+ 80 52 1.03 0.63- 1.69 40 1.03 0.59- 1.79 
P-trend ns ns 
Litres yearly * 
1-4 115 63 0.96 0.64- 1.46 31 0.70 0.42- 1.1 7 
5-14 147 57 0.65 0.42- 1.0 I 37 0.56 0.33-0.94 * 
15+ 97 59 0.94 0.58- 1.51 48 1.00 0.59- 1.70 
P-trend ns ns 
Note: t OR estimates for alcohol consumption from multilevel multinomial models adjusted for age, sex, 
rural/urban, education, marriage, family history of colorectal cancer, diabetes, cholesterol, aspirin, frujts, 
laxatives, calcium and cigarette and random effect of census area. X2 or Wald test or Cochran-Armitage test 
for trend: *P<0.05 **P<O.O I ***P<O.OO I . Cochran-Armitage test for trend: ns=not significant at 5%. 
Table 45 presents the adjusted odds ratio of living and deceased colorectal cancer 
patients and the corresponding 95% confidence interval for total alcohol consumption 
among the obese. There was a significantly increased risk of CRC for living cases for 
drinking compared to controls among the obese (OR: 2.56 and 95% CI: 1.35-4.85). The 
risk increased with years of drinking, the number of drinks daily and litres yearly. 
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Table 45. The adjusted odds ratio of living and deceased colorectal cancer patients and the 
corresponding 95% confidence interval for total alcohol consumption among the obese 
Alcohol 
Control 
Living CRC Cases Deceased CRC Cases 
Consumption Case OR & 95% CIt Case OR & 95% CI t 
Alcohol 
Non-drinker 67 38 1.00 24 1.00 
Drinker 94 101 2.56 1.35 - 4.85 ** 36 1.58 0.69 - 3.63 
Types * 
1-2 77 72 2.27 1.18-4.38 * 30 1.62 0.70- 3.76 
3+ 17 29 4.42 1.78- 10.97 ** 6 1.24 0.34- 4.59 
Drinking years 
1-19 29 18 1.91 0.83-4.41 7 1.13 0.35-3 .67 
20-39 49 62 3.03 1.49-6.15 ** 19 1.54 0.60- 3.99 
40+ 16 21 2.69 1.03-7.06 * 10 2.48 0.74- 8.29 
P-lrend * ns 
Drinks daily 
1-2 55 56 2.65 1.34- 5.23 ** 18 1.55 0.62 - 3.84 
3-4 21 18 1.58 0.64- 3.90 6 0.94 0.28 - 3.22 
5+ 18 27 4.13 1.64- 10.41 •• 12 3.09 0.95- 10.03 
P-trend * ns 
Litres yearly 
1-4 29 30 2.87 1.35-6.13 ** 10 1.85 0.66-5.13 
5-14 33 31 2.03 0.90-4.61 12 1.36 0.46- 3.96 
15+ 32 40 2.64 1.18-5.90 * 14 1.45 0.50- 4.1 7 
P-trend * ns 
Note: t OR estimates for alcohol consumption from multilevel multinomial models adjusted for age, sex, 
rural/urban, education, marriage, family history of colorectal cancer, diabetes, cholesterol, aspirin, fruits, 
laxatives, calcium and cigarette and random effect of census area. X2 or Wald test or Cochran-Armitage test 
for trend: *P<0.05 **P<0.01 ***P<O.OOl. Cochran-Armitage test for trend: ns=not significant at 5%. 
8.4.8. Colorectal cancer and total alcohol consumption by familial risk 
Table 46 presents the adjusted OR of CRC with low and intermediate or high 
familial risk and the corresponding 95% CI for total alcohol consumption in non-obese. 
The results showed that alcohol consumption in moderation slightly decreased the risk of 
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CRC with low and intermediate or high familial risk among non-obese, but a significantly 
reduced risk for CRC cases with intermediate or high familial risk. 
Table 46. The adjusted odds ratio of colorectal cancer with low familial risk and intermediate or high 
familial risk and the corresponding 95% confidence interval for total alcohol consumption in non-
obese 
Alcohol 
Control 
Low Familial Risk CRC Inter-High Familial Risk CRC 
Consumption Case OR & 95% CIt Case OR & 95%CI t 
Alcohol 
Non-drinker 197 112 1.00 96 1.00 
Drinker 359 153 0.81 0.56- 1.16 142 0.76 0.51 - 1.12 
Types 
1-2 262 117 0.82 0.56- 1.19 116 0.80 0.54- 1.19 
3+ 97 36 0.75 0.44- 1.26 26 0.60 0.33- 1.07 
Drinking years * 
1-19 82 23 0.57 0.33 - 0.98 ** 30 0.65 0.38- 1.13 
20-39 197 83 0.88 0.58 - 1.34 83 0.78 0.50- 1.21 
40+ 80 47 0.95 0.58- 1.57 29 0.88 0.49- 1.57 
P-crend ns ns 
Drinks daily 
1-2 232 85 0.74 0.50- 1.09 82 0.73 0.48- 1.10 
3-4 47 18 0.70 0.36- 1.35 18 0.74 0.38 - 1.46 
5+ 80 50 1.12 0.68- 1.86 42 0.91 0.53- 1.58 
P-crend ns ns 
Litres yearly * 
1-4 115 47 0.86 0.55 - 1.33 47 0.86 0.54- 1.37 
5-14 147 44 0.56 0.35-0.90 * 50 0.66 0.40- 1.07 
15+ 97 62 1.16 0.71- 1.88 45 0.77 0.45 - 1.31 
P-trend ns ns 
Note: t OR estimates for alcohol consumption from multilevel multinomial models adjusted for age, sex, 
education, marriage, ruraVurban, family history of colorectal cancer, diabetes, cholesterol, aspirin, fruits, 
laxatives, calcium and cigarette and random effect of census area. X2 or Wald test or Cochran-Armitage test 
for trend: *P<0.05 **P<O.O I ***P<O.OO I. Cochran-Armitage test for trend: ns=not significant at 5%. 
Table 47 presents the adjusted OR of CRC with low familial risk and intermediate 
or high familial risk and the corresponding 95% CI for total alcohol consumption among 
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the obese. The results showed that alcohol consumption increased the risk of CRC for 
cases with low and intermediate or high familial risk among the obese, but a stronger 
effect for cases with intermediate or high familial risk. The risk of CRC with intermediate 
or high familial risk significantly increased with the number of drinking years, drinks 
daily and litres yearly. 
Table 47. The adjusted odds ratio of colo rectal cancer with low familial risk and intermediate or high 
familial risk and the corresponding 95% confidence interval for total alcohol consumption among the 
obese 
Alcohol 
Control Low Familial Risk CRC Inter-High Familial Risk CRC 
Consumption Case OR & 95%CI t Case OR & 95%CI t 
Alcohol 
Non-drinker 67 34 1.00 28 1.00 
Drinker 94 68 1.71 0.86- 3.40 69 2.07 1.48 - 6.39 ** 
Types 
1-2 77 54 1.65 0.82 - 3.33 48 2.66 1.25-5.63 * 
3+ 17 14 1.97 0.71 - 5.46 21 5.82 2.12- 15.99 * 
Drinking years * 
1-19 29 9 0.99 0.37- 2.67 16 2.74 1.08-6.95 * 
20-39 49 41 2.03 0.94- 4.37 40 3.34 1.49- 7.48 ** 
40+ 16 18 2.21 0.80-6.07 13 3.06 1.02-9.20 * 
P-trend ns * 
Drinks daily 
1-2 55 39 1.91 0.91-4.00 35 2.81 1.29 - 6.16* 
3-4 21 6 0.46 0.14-1.47 18 3.06 1.14-8.19 * 
5+ 18 23 3.36 1.27 - 8.90 ** 16 4.47 1.56 - 12.85 ** 
P-trend ns * 
Litres yearly 
1-4 29 20 1.98 0.86- 4.54 20 3.39 1.43 - 8.04 ** 
5-14 33 20 1.31 0.54- 3.22 23 2.58 1.03-6.47 * 
15+ 32 28 1.73 0.73-4.10 26 3.07 1.23- 7.67 * 
P·o-end ns * 
Note: t OR estimates for alcohol consumption from multilevel multinomial models adjusted for age, sex, 
education, marriage, ruraVurban, family history of colorectal cancer, diabetes, cholesterol, aspirin, fruits, 
laxatives, calcium and cigarette and random effect of census area. X2 or Wald test or Cochran-Armitage test 
for trend: *P<0.05 **P<O.O J ***P<O.OOl . Cochran-Armitage test for trend: ns=not significant at 5%. 
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8.4.9. Colorectal cancer and total alcohol consumption by microsatellite 
instability 
Table 48 presents the adjusted OR of MSI-L/MSS and MSI-H CRC and the 
corresponding 95% CI for total alcohol consumption in non-obese. The results showed a 
slightly reduced effect of alcohol consumption in moderation on both MSI-L/MSS CRC 
and MSI-H CRC in non-obese. There was no dose-response relationship observed in non-
obese. 
Table 48. The adjusted odds ratio of colorectal cancer cases with low-frequency microsatellite 
instability or stability and high-frequency microsatellite instability and the corresponding 95% 
confidence interval for total alcohol consum~tion in non-obese 
Alcohol Control MSI-L/MSS CRC MSI-HCRC Consumption Case OR & 95% CIt Case OR & 95% CI t 
Alcohol * 
Non-drinker 197 182 1.00 21 ·1.00 
Drinker 359 274 0.80 0.59- 1.10 26 0.48 0.23-0.99 * 
Types 
1-2 262 217 0.84 0.61- 1.16 16 0.47 0.22-0.99 * 
3+ 97 57 0.67 0.42- 1.05 5 0.57 0.19- 1.76 
Drinking years * 
1-19 82 52 0.68 0.44- 1.05 0.08 0.01-0.63 * 
20-39 197 151 0.83 0.58-1.19 15 0.64 0.28- 1.45 
40+ 80 71 0.92 0.59- 1.44 5 0.89 0.28-2.82 
P-trend ns ns 
Drinks daily * 
1-2 232 157 0.76 0.55- 1.06 lO 0.37 0.16-0.86 * 
3-4 47 34 0.71 0.41 - 1.24 2 0.38 0.08- 1.86 
5+ 80 83 1.03 0.66- 1.59 9 1.02 0.38- 2.73 
P-trend ns ns 
Litres yearly * 
1-4 115 90 0.91 0.62- 1.32 4 0.29 0.09-0.89 * 
5-14 147 86 0.61 0.41-0.90 * 8 0.51 0.20- 1.33 
15+ 97 98 0.96 0.63- 1.46 9 0.87 0.32-2.34 
P-trend ns ns 
Note: t OR estimates for alcohol use from multilevel multinomial models adjusted for age, sex, education, 
marriage, rural/urban, family history of colorectal cancer, diabetes, cholesterol, aspirin, fruits, laxatives and 
cigarette smoking and calcium and random effect of census area. X2 or Wald test or Cochran-Armitage test 
for trend: *P<0.05 **P<O.O 1 ***P<O.OO 1. Cochran-Armitage test for trend: ns=not significant at 5%. 
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Table 49 presents the adjusted OR of CRC cases with MSI-L/MSS and MSI-H 
and the corresponding 95% confidence interval for total alcohol consumption among the 
obese in the case-control study. The results showed that alcohol consumption increased 
the risk of CRC for cases with MSI-L/MSS and MSI-H among the obese, but a stronger 
effect for cases with MSI-H. The results for MSI-H and alcohol consumption are subject 
to the sample size. 
Table 49. The adjusted odds ratio of colorectal cancer cases with low-frequency microsatellite 
instability or stability and high-frequency microsatellite instability and the corresponding 95% 
confidence interval for total alcohol consumption among the obese 
Case OR & 95% CIt 
Alcohol MSI-L/MSS CRC Control 
Case OR & 95% CI t Consumption 
MSI-HCRC 
Alcohol 
Non-drinker 67 59 1.00 3 1.00 
Drinker 94 119 1.72 0.96-3.10 18 5.92 1.30 - 26.91 * 
Types 
1-2 77 89 1.58 0.87-2.88 13 5.32 1.14-24.77 * 
3+ 17 30 2.61 1.09- 6.22 ** 5 9.50 1.52 - 59.34 * 
Drinking years 
1-19 29 21 1.24 0.57- 2.71 4 5.39 0.93 - 31 .09 
20-39 49 70 1.94 1.00- 3.74 * II 6.52 1.32 - 32.37 * 
40+ 16 28 2.14 0.88- 5.22 3 5.14 0.66-39.96 
P-trend ns ns 
Drinks daily 
1-2 55 64 1.81 0.96- 3.41 10 5.92 1.23 - 28.43 * 
3-4 21 19 0.90 0.38 - 2.11 5 4.51 0.79- 25.95 
5+ 18 36 3.06 1.30-7.19 ** 3 7.10 0.95- 53.24 
P-trend ns ns 
Litres yearly 
1-4 29 34 1.93 0.95 - 3.92 6 6.55 1.28 - 33.58 * 
5-14 33 38 1.46 0.68- 3.12 5 4.87 0.81 - 29.26 
15+ 32 47 1.69 0.80- 3.58 7 5.98 1.07- 33.48 * 
P-trend ns * 
Note: t OR estimates for alcohol use from multilevel multinomial models adjusted for age, sex, education, 
marriage, rural/urban, family history of colorectal cancer, diabetes, cholesterol, aspirin, fruits, laxatives and 
cigarette smoking and calcium and random effect of census area. X2 or Wald test or Cochran-Armitage test 
for trend: *P<0.05 **P<O.O 1 ***P<O.OO I. Cochran-Armitage test for trend: ns=not significant at 5%. 
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8.5. Discussion 
The study examined the relationship between CRC and alcohol consumption. The 
adjusted OR of CRC for alcohol consumption was estimated using multivariate 
multilevel logistic regression for the purpose of adjustment for confounding and 
clustering effects. The study examined the effects of beer, wine and spirit on CRC risk. 
The study investigated the effects of alcohol consumption among subgroups including 
men and women, smokers and non-smokers, obese and non-obese, living and deceased 
cases, cases with low familial risk and cases with intermediate/high familial risk, and 
cases with MSI-L/MSS and MSI-H CRC diagnoses. The study examined the effects of 
alcohol consumption on colon cancer and rectal cancer. The study also assessed the 
combined effects of alcoholic drinking, cigarette smoking and obesity on CRC. 
The results of this population-based case-control study of CRC conducted in NL 
demonstrated that the effect of alcohol intake on odds of developing CRC differed by 
weight status. Alcohol consumption tended to reduce the odds of developing CRC among 
non-obese. However, in the obese (BMI 2: 30), the odds of CRC (OR= 2.25) were greater 
among alcohol drinkers than in non-drinkers. Drinkers who had one to two or three types 
of beverage had a significantly increased the risk of CRC compared to non-drinkers 
among the obese. The odds of developing CRC increased with number of drinking years 
and numbers of drinks daily among the obese. The effect of drinking on CRC risk was 
stronger among obese subjects who smoked. Drinking significantly reduced the risk of 
CRC among non-obese and weakened the effect of smoking on CRC among non-obese. 
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Previous studies have provided evidence that alcohol consumption may increase 
the risk of developing CRC [41 ' 122•294•342,423•4271. However, this study found that drinking 
reduced the risk of CRC when smoking and obesity were not present, but increased the 
risk of CRC in the presence of smoking and obesity. The observed decreased effect did 
not vary substantially by subsite of CRC, survival status, familial risk level and MSI 
status. Despite the fact that ethanol has been classified as a carcinogen [4281, several 
studies on other types of cancers have reported that alcohol intake reduced the risk of 
cancer. In a pooled analysis, alcohol consumption of one or more drinks daily was 
reported to reduce the risk of renal cell cancer by 28% [4291 . Drinking alcohol (beer, wine 
and spirits) has also been reported to reduce the risk of non-Hodgkin's lymphoma [4301, 
Hodgkin's lymphoma [4311 and thyroid cancer in women [4321. This evidence suggests that 
alcohol may reduce the risk of cancer including CRC in which this study has found 
among non-obese. 
Although "Food, Nutrition, Physical Activity and the Prevention of Cancer: a 
Global Perspective", also known as the Export Report, published by the the World 
Cancer Research Fund global network in 2007 has stated there is convincing evidence 
that alcohol increase the risk ofCRC in men and probably increases risk in women [411, it 
is not clear why this thesis observed a risk reduction for CRC in non-obese, non-smoking 
alcohol consumers. However, it is conceivable that antioxidants such as resveratrol and 
phenolic compounds which may help reduce the risk of cancer by removing oxidized 
carcinogenic agents, reducing lipid peroxidation, reducing cell proliferation or promoting 
apoptosis, may provide some protective effects [4324381. 
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This thesis observed that alcohol consumption combined smoking increased the 
risk of CRC in obese which is inconsistent with one pooled analysis of eight cohort 
studies on alcohol intake and CRC [2971. This study found that the association between 
alcohol consumption and the risk of CRC was stronger among persons with a lower BMI 
( < 22 kg/m2) than in those with a higher BMI [2971. It was speculated that leaner people 
have higher blood alcohol concentrations in response to a fixed dose of alcohol, resulting 
a higher risk of CRC. 
Although this thesis found that cigarette smoking, obesity and drinking together 
appeared to increase the risk of CRC, the mechanism of combined drinking, cigarette 
smoking and obesity increasing risk of CRC is not fully understood. It is possible that 
these three exposures share one or more common etiological pathways. Obesity is 
characterized by a low-grade chronic inflammatory state [2171. Chronic inflammation can 
result in DNA damage and cancer promotion because a chronic inflammatory 
environment can increase proliferation and differentiation, inhibit apoptosis and induce 
angiogenesis [4391. Tobacco smoke is a major source of a wide variety of carcinogens 
including heterocyclic amines, polycyclic hydrocarbons and nitrosamines [1221. Alcohol 
might serve as a solvent for polycyclic aromatic hydrocarbons and similar organic 
compounds from cigarettes and transport these chemicals to sites they otherwise would 
not reach [41 71. Additionally, alcohol is metabolized to acetaldehyde locally in the oral 
cavity by microbes representing normal oral flora [4401 . Heavy drinking and chronic 
smoking modify oral flora to produce more acetaldehyde [4401. Cigarette smoking contains 
acetaldehyde which becomes dissolved in saliva during smoking [440•4411 and provides 
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high concentration of acetaldehyde in the gastrointestinal tract (4421. Therefore, it is 
possible that in the state of obesity, combined drinking and smoking significantly may 
increase the risk of CRC, but more research is required to investigate this observation in 
other populations. 
While several previous studies reported that alcohol consumption increased the 
risk of both colon (58,226,251 ,273,283,298,299,443-446] and rectal cancer [58,226,273,283,443,444,446-449], 
other studies showed that alcohol intake increased the risk of neither colon cancer 
[57,238,254,447,450,451] nor the risk of rectal cancer [57,238,25 1,254,255,299,445,450-452] . This study 
found that drinking significantly increased the risk of both colon and rectal cancer in the 
obese suggesting the modified effect of body weight on the relationship between alcohol 
consumption on both colon and rectal cancer. 
This thesis also showed the modified effect of survival status on the relationship 
between alcohol consumption and CRC risk in obese. However, the reason for this 
combined effects of drinking, body weight and survival status is not fully understood. No 
studies have reported the effect of alcohol consumption on CRC for living cases and 
deceased cases. It may be due to any differences in susceptibility of living cases and 
deceased cases. 
This thesis showed that alcohol consumption increased the risk of CRC for cases 
with low and intermediate or high familial risk among the obese, but a stronger effect for 
cases with intermediate or high familial risk. This thesis found that alcohol consumption 
increased the risk of CRC for cases with MSI-LIMSS and MSI-H among the obese, but a 
stronger effect for cases with MSI-H. These results seem to suggest an interaction effect 
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of drinking, obesity and gene on CRC. However, the reason is unknown while one 
population-based case-control study has shown that alcohol consumption contributes to 
MSI [3121 and another case-control study published recently found that obesity is 
associated with MSS tumour [4531 . The results ofthis thesis are also subject to the sample 
size. 
One of the strengths of this study was its attempt to control for the effects of all 
potential confounding variables. All selected variables by univariate analysis were 
included in the models regardless of their "statistical significance". The rationale for this 
approach was to provide as much control of confounding as possible within the given 
data set [2191. This is based on the fact that it is possible for individual variables not to 
exhibit strong confounding, but when taken collectively, considerable confounding may 
be present in the data [2191. This design effectively controlled for intra-class correlations 
among census divisions within cells of the design, i.e. the tendency for observations 
adjacent within spatial units to be similar to each other. Measures from within one 
geography may be highly correlated whereas those from different areas may be more 
likely to be independent of each other [382-3841. Analysis of data needs to take into account 
such groupings, otherwise spurious statistically significant results are more likely [3811. 
The multilevel analyses conducted effectively dealt with the spatial autocorrelation by 
virtue of nesting 1 0 census divisions. 
In conclusion, the study conducted in NL, relatively isolated population, found 
that alcoholic drinking decreased the risk of CRC among non-obese and non-smokers, 
but drinking increased the risk of CRC in the presence of tobacco smoking and obesity. 
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These results have implications for exploring the association between alcohol 
consumption and tobacco smoking and obesity and possible mechanisms for their 
combined effects, and for tailoring alcohol and tobacco policies and prevention strategies 
for obese people. 
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Chapter 9 Summary and future research 
This chapter summarizes the results and contributions made by this thesis and 
provides recommendations for future work arising from this research. 
9.1. Summary of the present work 
The work presented in this thesis was designed to explore the relations between 
tobacco smoking and alcohol consumption and risk of CRC. A review of the literature 
revealed that there are various genetic and environmental factors, including tobacco 
smoking and alcohol consumption, which may have been associated with CRC risk, and 
may help explore substantial differences in the incidence of CRC among various 
subgroups by social and demographic characteristics and genetic characteristics. 
However, previous studies that explored the relations between tobacco and alcohol use 
and CRC have been inconclusive and inconsistent. One possible explanation is that 
previous studies that explored the impact of tobacco use and alcohol consumption on 
CRC risk have not adequately considered subgroup effects, and little research has 
reported on the combined effects of alcohol and tobacco and potential interactions with 
other risk factors. 
The exploration of the relations between tobacco use and alcohol consumption 
and CRC risk, described in this thesis, was carried out using data from the population-
based case-control study of CRC conducted in Newfoundland and Labrador of Canada. 
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The study also examined the extent of non-participation bias by analyzing some 
characteristics of eligible participants and non-participants. The reliability and validity of 
self-reported tobacco use and alcohol consumption in the case-control study were 
analyzed by comparing questionnaire response with the provincial data of tobacco and 
alcohol sales and the data from the Canadian Community Health Surveys. The major 
results and contributions of this thesis are summarized below. 
9 .1.1. Effect of cigarette smoking on colorectal cancer 
This thesis found that cigarette smoking significantly increased the risk of CRC. 
There was 1.4 times increased risk of CRC among former smokers and 2 times increased 
risk of CRC among current smokers. The risk of CRC tended to increase significantly 
with greater cigarette smoking years, number of cigarettes smoked daily, and cigarette 
pack years. The risk tended to significantly increase when smoking cigarettes 20 years or 
longer or after starting smoking cigarettes 25 years. 
This thesis also found that cigarette smoking produced a stronger effect on CRC 
risk among men, drinkers and male obese than women, non-drinkers and male and/or 
female non-obese. In male obese, for example, there were 2 times increased risk of CRC 
among former smokers and 3 times among current smokers compared to non-smokers. 
The study found that cigarette smoking led to a significantly higher risk of rectal 
cancer than colon cancer. The risk of CRC slightly varied by survival status with a 
stronger effect among deceased than living CRC cases, by familial risk level with a 
stronger effect on CRC risk among cases with intermediate/high familial risk of cancer 
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than low familial risk, and by MSI with a stronger effect on MSI-H CRC risk than MSI-
L/MSS CRC risk. 
Furthermore, this thesis also found that the risk of CRC significantly decreased 
with greater number of years of abstention from smoking cigarettes. After abstaining 
from cigarette smoking 20 years or more, the risk did not differ from that for non-
smokers. Among those subgroups which cigarette smoking produces a higher risk of 
CRC, the risk significantly decreased with years of abstaining from smoking cigarettes. 
Given the inconsistence in existing literature around this issue, this thesis provides 
new and important evidence supporting the positive association between cigarette 
smoking and CRC. This adds to knowledge in the etiology of CRC. In addition to the 
observed stronger effects on CRC in men, and drinkers, this study found a stronger effect 
of cigarette smoking on CRC among male obese which have not been reported in 
previous studies. The thesis also revealed that the effects of cigarette smoking on CRC 
varied by CRC site, survival status of cases, familial risk level of cases and MSI status of 
cases. 
9 .1.2. Effect of alcohol consumption on colorectal cancer 
The study first demonstrated a positive association between greater risk of CRC 
and higher lifetime alcohol intake in obese smokers, and a decreased risk of CRC among 
non-obese who never smoked in their lifetime. The results of this population-based case-
control study conducted in NL demonstrated that the effect of alcohol intake on risk of 
developing CRC differed by weight status. Alcohol consumption tended to reduce the 
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risk of developing CRC among non-obese. The observed decreased effect did not vary 
substantially by subsite of CRC, survival status, familial risk level and MSI status. 
However, in the obese, the risk of CRC was 91% higher among alcohol drinkers than in 
non-drinkers. Drinkers who consumed three or more types of alcoholic beverage had 2.9 
times greater risk of CRC relative to non-drinkers among the obese. The risk of 
developing CRC increased with the number of drinking years and the number of drinks 
daily among the obese. The effect of drinking on CRC risk was stronger among obese 
subjects who smoked. Drinking significantly reduced the risk of CRC among non-obese 
and weakened the effect of smoking on CRC among non-obese. 
This thesis also found that alcohol consumption increased the risk of CRC for 
cases with low and intermediate or high familial risk among the obese, but a stronger 
effect for cases with intermediate or high familial risk; alcohol consumption increased the 
risk of CRC for cases with MSI-L/MSS and MSI-H among the obese, but a stronger 
effect for cases with MSI-H. These results suggest the combined effects of alcohol, body 
weight and gene mutation on CRC. 
These results have implications for exploring the association between alcohol 
consumption and tobacco smoking and obesity and possible mechanisms for their 
combined effects on CRC risk. While there are no reports in the literature to investigate 
the joint effects of alcohol consumption, cigarette smoking and obesity on CRC risk, this 
thesis provides new and important evidence supporting the combined effects of alcohol 
drinking, smoking and obesity on CRC risk. 
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In the analyses, attempts were made to explore the potential impact of 
misreporting and non-participation bias. While it was concluded that these factors were 
unlikely to have had substantial impact on the results, it is possible that unknown 
confounders may have played a role. There are methodological weaknesses in many 
previous studies. Inadequate adjustment for various potential confounders (e.g. alcohol, 
physical activity, body size, dietary factors) or unidentified confounders could account 
for the small increase in risk found with smoking in some studies. For example, smokers 
are more likely than non-smokers to be physically inactive [4541, to use alcohol, to have 
poorer dietary habits (e.g. lower consumption of fruits and vegetables and higher 
consumption of fat and meat) and they are less likely to be screened for CRC [2771 . Each 
of these factors, in turn, is positively associated with CRC risk [11 71 • One of the strengths 
of this study was its attempt to control for the effects of all potential confounding 
variables. This design effectively controlled for intra-class correlations among census 
divisions within cells of the design since measures from within one geography may be 
highly correlated whereas those from different areas may be more likely to be 
independent of each other [382-3841. Therefore, the results presented in this thesis are highly 
valid. 
9.2. Implications for health practice and change of individual lifestyle 
The results of this thesis have important implications for public health practice 
and policy-making, and changes of individual smoking and drinking. Cigarette smoking 
is a notorious risk factor for cancer in organs such as lung, oropharynx, larynx and upper 
185 
digestive tract where there is direct contact with cigarette-related carcinogens [2631. This 
thesis found that cigarette smoking significantly increased CRC risk in NL. Over 13% of 
incidence of CRC can be attributed to cigarette smoking in the population. The combined 
effect of smoking with drinking and obesity can be significantly strengthened. People 
who have quit smoking are still at the elevated risk of CRC even many years later 
compared to non-smokers. Therefore, people should never start smoking and quit 
smoking in order to reduce the risk of CRC. Policy makers should incorporate quit 
smoking component into the existing prevention program of cancer. 
There is convincing evidence that alcohol increases the risk of CRC in men and 
probably increases risk in women [411 • This thesis found that alcohol consumption 
significantly increased the risk of CRC among obese. Over 42% of incidence of CRC can 
be attributed to alcohol consumption among the obese. Drinking 20 years significantly 
increased the risk of CRC in obese. Obese who drink even 1-2 drinks per day had two 
times increased risk of CRC compared to obese non-drinkers. This combined effect of 
drinking with smoking can be strengthened among obese. While this thesis also found an 
reduced risk of CRC due to drinking when smoking and obesity are not present, the 
research suggests that non-obese who do not smoke drink in moderation and obese who 
smoke quit drinking and smoking and reduce their weight. Policy makers should initiate 
quitting drinking, smoking and obesity program to minimize the risk of CRC in NL. 
9.3. Limitations of this thesis 
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The primary methodological concern has been the estimation of tobacco smoking, 
alcohol consumption and other risk factors. These exposures are difficult to estimate, 
given the complex nature of tobacco smoking and alcohol drinking behaviours and the 
limited ability of self-administered questionnaires to assess the use by study subjects 
several decades in the past. Although the assessments in this thesis suggested the impacts 
of tobacco smoking and alcohol consumption on CRC tended to be underestimated, 
further work is required to understand more about the effects of tobacco smoking and 
alcohol consumption on CRC risk. Given tobacco smoking through self-report approach 
in the case-control study has significantly been underestimated, the study instrument 
particularly about tobacco smoking is needed to be revised and validated. 
An individual's body shape and size are represented by several measures 
including height, weight, body mass index, fat deposition patterns, and weight change. 
These measures are interrelated, but some of them such as fat deposition patterns are 
better predictors of CRC [t 61. However, in the present study, only body mass index was 
calculated and the modified effect of obesity was examined based on this index. The true 
magnitude of the association between the exposures and CRC risk may not be estimated 
accurately. 
Limitations of this thesis also include exposure misclassification regarding case-
control status and inclusion of deceased cases and information collected from proxies of 
these deceased cases. Although the analyses were conducted to assess the extent of 
exposure misclassification, the true magnitude of the association could not be estimated 
accurately. This needs better procedures of data collection in the design stage. This study 
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included 258 deceased cases and their proxies were used. The response from proxies of 
these deceased cases might differ from those of living cases, possibly biasing the results. 
Thesis could not assess how other unknown confounders affected the observed 
association even though a recent review suggests that confounding is not important [4221. 
The participation rates of both cases and control subjects were relatively low and 
varied by case-control status (59.6% and 44.7%). It is possible that study respondents and 
non-respondents were different certain characteristics (e.g. smoking and drinking). This 
thesis was unable to accurately estimate the magnitude of the possible bias even though 
the analysis on the credibility of the data sources did not suggest any substantial effects. 
9.4. Future research 
9.4.1. Tobacco smoking and colorectal cancer 
This thesis observed a significant association between cigarette smoking and CRC 
risk and the association varied by sex, alcohol drinking status, body weight, colon and 
rectum, survival status, familial risk level of cases and MSI status of cases. There has 
been a lack of consideration and/or inconsistent findings in previous studies of CRC 
etiology and epidemiology. Further studies are needed to investigate why the association 
between cigarette smoking and CRC varied by sex, drinking status and body weight. As 
well, more research is required to help clarify differences observed in the risk of colon 
and rectal cancer, living and deceased cases, and cases at different familial risk levels and 
MSI status of CRC cases with cigarette smoking. 
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Future research should consider the effect of exposure to environmental tobacco 
smoking on CRC risk when examining the effect of tobacco smoking on CRC risk. 
Previous studies on the incidence of CRC in relation to passive exposure to smoking 
observed a significantly increased risk of CRC for those exposed to environmental 
tobacco smoking [455•4561. The prospective cohort study conducted in the United States 
which investigated the incidence of CRC in relation to passive exposure to smoking 
observed an increased risk of CRC for non-smoking men exposed to secondhand 
smoking in the household (RR: 3.0 and 95% CI: 1.8-5.0) [4551. The Swedish population-
based case-control study found an increased risk for colon cancer in women (OR: 1.8 and 
95% CI: 1.2-2.8) and rectal cancer in men (OR: 1.9 and 95% CI: 1.0-3.6) in association 
with passive smoking after adjustment for numerous potential confounders [4561. It can be 
hypothesized a combined effect of smoking and exposure to environmental smoking on 
CRC risk. Future research should examine combined effects of tobacco smoking and 
exposure to environment tobacco smoking on CRC. 
This thesis showed a significantly increased risk of CRC among non-obese 
smokers and obese male smokers, but a stronger effect of smoking was observed among 
obese men. No studies reported that there was a stronger effect of cigarette smoking on 
CRC by sex among obese than non-obese. Studies including this thesis observed that the 
association between smoking and CRC is stronger in men than in women [198•228•27 11. 
Although it can be speculated that fewer cigarettes were smoked by women or more years 
of abstention from smoking and/or there may be hormone-related differences in 
susceptibility to smoking [411, future research is needed to investigate this sex difference. 
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Obesity is characterized by a low-grade chronic inflammatory state. Chronic 
inflammation can result in DNA damage and cancer promotion because a chronic 
inflammatory environment can increase proliferation and differentiation, inhibit apoptosis 
and induce angiogenesis [2211 . Tobacco smoke is a major source of a wide variety of 
carcinogens including heterocyclic amines, polycyclic hydrocarbons and nitrosamines 
[3331. The combination of both smoking and obesity might result this stronger effect on 
CRC in obese. Future research need to further investigate this combined effect of 
smoking and obesity by sex. 
This thesis found that smoking demonstrated a stronger effect on CRC among 
deceased than living CRC cases, and among cases of CRC with intermediate/high 
familial risk or MSI-H. The reason is unknown. This might be due to genetic cause of the 
difference observed in this study. Studies conducted in the United States showed that the 
higher frequency of the Pro/Pro phenotype of p53 in African American patients with 
colorectal adenocarcinoma is associated with an increased incidence of p53 mutations, 
with short survival [4201. More research is needed to clarify this. 
9.4.2. Alcohol consumption and colorectal cancer 
Previous studies have provided evidence that alcohol consumption may increase 
the risk of developing CRC [9•10•41 ' 122•294•342'423•4271, but this study found that drinking 
reduced the risk of CRC when smoking and obesity were not present, and increased the 
risk of CRC in the presence of smoking and obesity. Despite the fact that ethanol has 
been classified as a carcinogen [4281, several studies on other types of cancers have 
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reported that alcohol intake reduced the risk of cancer [42943 1•4571. This evidence suggests 
that alcohol may reduce the risk of cancer including CRC in which this thesis has found 
among non-obese who did not smoke. Further research is needed to examine this 
decreased effect and future research should also investigate why drinking alcohol lead to 
a reduced risk of CRC. 
9.4.3. Methodological issues in future research 
Future research must also consider several methodological issues in study designs. 
First is the study population. There is at least a 25-fold variation in occurrence of CRC 
worldwide [8•91 . The highest incidence rates are in North America, Australia and New 
Zealand, Western Europe, and, in men especially, Japan [8•91. This international 
geographic variation in CRC risk can be explained by foods intake such as meat [131 fat 
[I 4J, fibre [I 5J and lifestyle factors such as physical inactivity, excess body weight, and a 
central deposition of adiposity have major influences on risk of colon cancer [161• There 
has been variation in CRC rates among provinces in Canada which had the highest 
incidence rates ofCRC [IOJ. Incidence rates are obviously higher in eastern provinces than 
western provinces, for both men and women. However, the factors that cause these real 
differences are not well understood. It can be speculated that several factors including 
environmental factors, socioeconomic status, and genetic factors except alcohol 
consumption and cigarette smoking identified by this thesis may be associated with. 
Future research is needed to investigate whether cigarette smoking and alcohol 
consumption play key role in the development of CRC in Canadian population or 
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cigarette smoking and/or alcohol consumption combined with other risk factors increased 
the risk of CRC. Improved study designs in future research should consider this 
geographic variation factor. 
Future research should use new and improved methods for assessing 
anthropometric factors to ensure standardized, reliable, and validated results. For 
example, abdominal fat may be a better indicator of the risk of CRC, but this measure 
was not included in this study. Studies should use all these anthropometric measurements. 
More complete examination of confounding and effect modification by other risk 
factors should be done. Studies should investigate statistical interactions between tobacco, 
alcohol and other risk factors, particularly investigations of interactions with other 
molecular biological markers such as MSI. For example, the analysis in this thesis has 
suggested MSI-H might modify the impact of alcohol consumption on CRC, but the 
observation might be affected by the sample, i.e., small number of cases with MSI-H and 
future research should recruit more cases with MSI-H to determine this potential 
modified effect. 
Research on drinking and smoking and weight control interventions, strategies 
and policies should be considered as the means for the primary prevention of CRC in NL. 
CRC prevention trials of reducing tobacco smoking and alcohol consumption 
interventions for CRC should be implemented at least among the obese who smoke and 
drink in Newfoundland and Labrador, given that evidence of this thesis has been 
provided by this thesis and evidence already exists to suggest abstaining from smoking 
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could reduce the risk of CRC and reducing the number of alcohol drinking could reduce 
the risk of CRC particularly among the obese. 
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Newfoundland 
Familial Colon Cancer Study 
Personal History Questionnaire 
This questionnaire is about factors that may relate to a person' s risk of cancer. It is 
important to have complete information for scientific reasons and we encourage you to 
answer all of the questions. But if you come to a question that don' t want to answer, put 
an "X" beside it and go on with the rest of the questions. 
Should you wish to talk to someone about this questionnaire, please call our study 
coordinator Elizabeth Dicks Toll free 1-888-908-4988 or St. John' s 777-8040. 
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Please write in your answers where space is provided, or place tick marks in circles 0 
What date are you filling out this questionnaire? __ / __ / __ 
Day Month Year 
Identifying Information 
I . Are you male or female? 
2. What is your date of birth? 
2. What is your age? 
3. Are you a twin or triplet? 
5. What is your marital status? 
Page I 
Omale 
0 female 
__ years 
0 don't know 
day 
month 
year __ 
0 don' t know day 
0 don't know month 
0 don' t know year 
0 yes, a twin 
0 yes, other multiple (triplet, quadruplet, etc.): ____ _ 
Please specify 
Ono 
0 don't know 
If yes, please read the following statement and answer the 
question. 
Non-identical twins are no more alike than ordinary brothers 
and sisters. Genetically identical twins, on the other hand, 
look so much alike *that is, they have a strong resemblance 
to each other in height, colouring, features of the face, etc.) 
that people often mistake one for the other, especially during 
their chjldhood. 
Do you have a genetically identical twin or triplet? 
0 yes 
Ono 
0 don't know 
0 currently married or living as married 
0 separated 
0 divorced 
0 widowed 
0 single or never married 
0 don't know 
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Bowel Screening and Health 
6. Have you ever had a test for blood in your 
stool, called a smear test or a hemoccult? 
This test is frequently done as part of a 
routine physical examination, or it can be 
done at home. 
0 yes 
0 no ~ Please go to # 7 
0 don't know ~ Please go to # 7 
6a. When did you first have this test? 
age when first tested __ 
or 
year of first test ___ _ 
0 don ' t know 
6b. What were the reasons for your first test? 
Please tick all that apply. 
0 to investigate a new problem 
0 fam ily history of colorectal cancer 
0 routine/yearly examination or check-up 
0 follow up of previous problem 
0 don 't know 
6c. How many times have you had a hemoccult 
test? 
number of hem occult tests 
0 don't know 
6d. If you have had a hemoccult test more than 
once, when did you last have this test? 
age when last tested __ 
or 
year of last test ___ _ 
0 don' t know 
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7. Have you ever had a sigmoidoscopy? 
sigmoidoscopy involves looking inside the 
lower bowel and rectum with a lighted 
instrument. This examination is usually 
done in a doctor's office without anesthesia. 
0 yes 
0 no ~ Please go to # 8 
0 don't know~ Please go to # 8 
7a. When did you first have this test? 
age when first tested __ 
or 
year of first test ___ _ 
0 don' t know 
7b. What were the reasons for your first 
sigmoidoscopy? Please tick all that apply. 
0 to investigate a new problem 
0 family history of colorectal cancer 
0 routine/yearly examination or check-up 
0 follow up of previous problem 
0 don' t know 
7c. How many times have you had a 
sigmoidoscopy? 
_ number of sigmoidoscopies 
0 don' t know 
7d. If you have had a sigmoidoscopy more than 
once, when did you last have this test? 
age when last tested __ 
or 
year of last test ___ _ 
0 don't know 
Page2 
8. Have you ever had a colonoscopy? 
colonoscopy is an examination of the entire 
large bowel using a long flexible 
instrument. This examination is usually 
done under sedation. 
Oyes 
0 no ~ Please go to # 9 
0 don' t know~ Please go to # 9 
8a. When did you first have this test? 
age when frrst tested __ 
or 
year of first test ___ _ 
0 don't know 
8b. What were the reasons for your frrst 
colonoscopy? Please tick all that apply. 
0 to investigate a new problem 
0 family history of colorectal cancer 
0 routine/yearly examination or check-up 
0 follow up of previous problem 
0 other: __________ _ 
Please specify 
0 don't know 
8c. How many times have you had a 
colonoscopy? 
_ number of colonoscopies 
0 don't know 
8d. If you have had a colonoscopy more than 
once, when did you last have this test? 
age when last tested __ 
or 
year of last test ___ _ 
0 don't know 
Page3 
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9. Has a doctor ever told you that you had 
polyps in your large bowel or colon or 
rectum? Polyps are growths in the lining of 
the colon which vary in size from a tiny dot 
several inches. 
0 yes 
0 no~ Please go to # 10 
0 don' t know ~ Please go to # 10 
9a. When did your doctor first tell you that you 
have had polyps? 
age when first tested __ 
or 
year offust test ___ _ 
0 don't know 
9b. Have you been told more than once that 
you had polyps? 
0 yes 
Ono 
0 don't know 
9c. When did you your doctor last tell you that 
you had polyps? 
age at last diagnosis __ 
or 
year of last diagnosis ___ _ 
0 don't know 
9d. Do you know what kind of polyps they 
were? 
0 benign 
0 adenomatous (pre-cancerous) 
0 hyperplastic 
0 other: __________ _ 
Please specify 
0 don't know 
9e. Did you have the polyps removed (by a 
procedure called a polypectomy)? (This can 
be done during a sigmoidoscopy or 
colonoscopy.) 
0 yes 
0 no --+ Please go to # 10 
0 don't know--+ Please go to # IO 
9f. When did you first have polyps removed? 
age at first polypectomy __ 
or 
year of first polypectomy ___ _ 
0 don ' t know 
9g. Have you had polyps removed more than 
once? 
0 yes 
Ono 
0 don't know 
9h. If you have had polyps removed more than 
once, when did you last have polyps 
removed? 
age at ftrst polypectomy __ 
or 
year of first polypectomy ___ _ 
0 don't know 
10. Has a doctor ever told you that you had 
familial adenmotaous polyposis, known 
also as F AP? This is a condition, 
sometimes occurring in families, in which 
numerous polyps line the inside of the large 
bowel or colon. 
0 yes 
0 no --+ Please go to # 1 I 
0 don' t know --+ Please go to # 11 
I Oa. When did your doctor first tell you that 
you had FAP? 
age at first diagnosis __ 
or 
year of diagnosis ___ _ 
0 don' t know 
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I 1. Has a doctor ever told you that you had 
Crohn's disease? This is where you have an 
inflammation that extends into the deeper 
layers of the intestinal wall. It may also 
affect other parts of the digestive tract, 
including the mouth, esophagus, stomach, 
and small intestine. 
0 yes 
0 no --+ Please go to # 12 
0 don ' t know --+ Please go to # I 2 
II a. When did your doctor first tell you that 
you had Crohn' s disease? 
age when first tested __ 
or 
year of first test ___ _ 
0 don't know 
I 2. Has a doctor ever told you that you had 
ulcerative colitis? This is an inflammation 
and ulceration of the lining of the bowel 
(colon) & rectum. It is not a stomach ulcer. 
Oyes 
0 no--+ Please go to # 13 
0 don' t know --+ Please go to # 13 
12a. When did your doctor first tell you that 
you had ulcerative colitis? 
age at ftrst diagnosis __ 
or 
year of diagnosis ___ _ 
0 don' t know 
I3. Has a doctor ever told you that you had 
irritable bowel syndrome? This is a 
disorder of the bowels leading to cramping, 
gassiness, bloating and alternating diarrhea 
and constipation. Tt is sometimes called 
lBS, or spastic colon. 
0 yes 
0 no --+ Please go to # 14 
0 don't know --+ Please go to # 14 
Page 4 
13a. When did your doctor first tell you that 
you had irritable bowel syndrome? 
age at fLrst diagnosis __ 
or 
year of diagnosis ___ _ 
0 don't know 
14. Has a doctor ever told you that you had 
diverticular disease? This may also be 
called diverticulosis or diverticulitis. 
It's a condition in which the bowel may 
become infected, and can lead to pain and 
chronic problems with bowel habits. 
and small intestine. 
0 yes 
0 no-+ Please go to# 15 
0 don't know -+ Please go to # 15 
14a. When did your doctor ftrst tell you that 
you had diverticular disease? 
age at fLrst diagnosis __ 
or 
year of diagnosis ___ _ 
0 don't know 
15. Have you ever had any of your large bowel 
or colon removed? 
0 yes 
0 no-+ Please go to # 16 
0 don't know-+ Please go to# 16 
Was it completed removed, or was only part 
of it removed? 
0 completed removed 
0 partly removed 
0 don' t know 
15a. When did you first have any of your 
bowel or colon removed? 
age at fLrst operation __ 
Or 
year of first operation ___ _ 
0 don't know 
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15b. Have you had more than one surgery to 
remove your bowel or colon? 
0 yes 
0 no-+ Please go to # 16 
0 don't know -+ Please go to # 16 
15c. When did you last have any of your 
bowel or colon removed? 
age at last operation __ 
or 
year of last operation ___ _ 
0 don't know 
16. Have you had your gallbladder removed? 
Oyes 
0 no -+ Please go to # 17 
0 don' t know-+ Please go to # 17 
16a. When did you have your gallbladder 
removed? 
age at operation __ 
or 
year of operation ___ _ 
0 don' t know 
17. Has a doctor ever told you that you had 
diabetes, also known as diabetes mellitus? 
Please do not include diabetes which you 
had only during pregnancy. 
0 yes 
0 no-+ Please go to # 14 
0 don't know-+ Please go to # 14 
17a. When did your doctor first tell you that 
you had diabetes? 
age at ftrst diagnosis __ 
or 
year of diagnosis ___ _ 
0 don' t know 
17b. Did you ever take medication to control 
your diabetes? 
0 yes 
0 no ---+ Please go to # I 8 
0 don't know ---+ Please go to # 18 
17c. What type of medication did you use, pill 
or insulin injections? 
0 pills 
0 insulin injections 
0 both 
0 don't know---+ Please go to# 18 
17d. How often did you usually take it? 
Please choose the most appropriate 
category. 
Pills 
times per day or 
times per week or --
times per month or --
--times per year 
--don' t know 0 
Insulin 
--
--
--
--
0 
17e. About one year before your recent cancer 
diagnosis, were you taking it? 
Oyes 
Ono 
0 don't know 
Pills 
0 
0 
0 
I 7f. How long, in total, have you taken this 
medication? 
Pills 
number of moths or 
--
number of years 
Insulin 
0 
0 
0 
Insulin 
--
-- --don't know 0 0 
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18. Has a doctor ever told you that you had 
high cholesterol? If your doctor told you it 
borderline, please tick no. 
0 yes 
0 no ---+ Please go to # 19 
0 don't know ---+ Please go to # I 9 
18a. When did your doctor tell you that you 
had high cholesterol? 
age at diagnosis __ 
or 
year of diagnosis ___ _ 
0 don't know 
18b. How you ever take medication to control 
your high cholesterol? 
Oyes 
0 no ---+ Please go to # 19 
0 don't know ---+ Please go to # 19 
18c. How often did you usually take it? Please 
choose the most appropriate category. 
__ times per day or 
__ times per week or 
__ times per month or 
__ times per year or 
0 don't know 
I 8d. About one year before your recent cancer 
diagnosis, were you taking it? 
0 yes 
Ono 
0 don't know 
18e. How long, in total, have you taken this 
medication? 
--
number of months or 
- _ number of years 
0 don't know 
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19. Has a doctor ever told you that you bad 
high levels of fat (other than cholesterol) in 
your blood, also called high triglycerides? 
If your doctor told you it was borderline, 
Please tick no. 
0 yes 
0 no ---+ Please go to # 20 
0 don't know---+ Please go to# 20 
19a. What did your doctor frrst tell you that 
you had high triglycerides? 
age at diagnosis 
or 
year of diagnosis 
don't know 
l9b. Did you ever take medication to control 
the high levels of fat in your blood? 
0 yes 
0 no ---+ Please go to # 20 
0 don't know ---+ Please go to # 20 
19c. How often did you usually take it? 
Please choose the most appropriate 
category. 
__ times per day or 
__ times per week or 
__ times per month or 
__ times per year or 
0 don' t know 
19d. About one year before your recent cancer 
diagnosis, were you taking it? 
Oyes 
0 no 
0 don ' t know 
19e. How long, in total, have you taken this 
medication? 
number of months or 
__ number of years 
0 don' t know 
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20. Has a doctor ever told you that you had 
any type of cancer? 
0 yes 
0 no ---+ Please go to # 24 
0 don't know---+ Please go to # 24 
20a. What type of cancer was it? 
___ ______ cancer 
20b. When did your doctor tell you that you 
had this type of cancer? 
age at djagnosis __ 
or 
year of diagnosis ___ _ 
0 don't know 
20c. Were you treated with radiation therapy 
(radiotherapy) for this cancer? 
0 yes 
Ono 
0 don't know 
21. Has a doctor ever told you that you had 
any other cancer? 
Oyes 
0 no ---+ Please go to # 24 
0 don't know ---+ Please go to # 24 
2 1 a. What type of cancer was it? 
___ ______ cancer 
2 1 b. When did your doctor tell you that you 
had thjs type of cancer? 
age at djagnosis __ 
or 
year of diagnosis ___ _ 
0 don' t know 
2 1 c. Were you treated with radiation therapy 
(radjotherapy) for this cancer? 
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0 yes 
Ono 
0 don't know 
22. Has a doctor ever told you that you had 
any cancer? 
0 yes 
0 no -+ Please go to # 24 
0 don't know-+ Please go to# 24 
22a. What type of cancer was it? 
________ cancer 
22b. When did your doctor ftrst tell you that 
you had this type of cancer? 
age at diagnosis 
or 
year of diagnosis 
don't know 
22c. Were you treated with radiation therapy 
(radiotherapy) for this cancer? 
Oyes 
Ono 
0 don't know 
23. Has a doctor ever told you that you had 
any other cancer? 
0 yes 
0 no -+ Please go to # 24 
0 don't know-+ Please go to # 24 
22a. What type of cancer was it? 
________ cancer 
23b. When did your doctor ftrst tell you that 
you had this type of cancer? 
age at diagnosis 
or 
year of diagnosis 
don't know 
23c. Were you treated with radiation therapy 
(radiotherapy) for this cancer? 
Oyes 
Ono 
0 don't know 
Medications 
Have you ever taken any of the following 
medications regular (at least twice a week 
for more than a month)? 
24. Aspirin (such as Anacin, Bufferin, Bayer, 
Excedrin, Ecotrin) 
Oyes 
0 no -+ Please go to # 25 
0 don't know-+ Please go to # 25 
24a. How often did you usually take it when 
you were taking it regularly (that is, at least 
twice a week for more than a month)? _ 
Please choose one of the following. 
__ times per day or 
__ times per week 
0 don't know 
24b. About one year before your recent cancer 
diagnosis, were you taking it regularly? 
Oyes 
Ono 
0 don't know 
24c. How long, in total, have you taken this 
medication regularly? If you started and 
stopped and then started again, please _ 
count only the time you were taking this 
medication. 
number of months or 
--
--number of years 
0 don' t know 
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Have you ever taken any of the following medications regularly 
(at least twice a week for more than a month)? (continued) 
25. Acetaminophen (such as Tylenod, 
Anacin-3, Panadol) 
Oyes 
0 no -+ Please go to # 26 
0 don't know -+ Please go to # 26 
25a. How often did you usually take it when 
you were taking it regularly (that is, at least 
twice a week for more than a month? 
Please choose one of the following. 
_ _ times per day or 
_ _ times per week 
0 don't know 
25b. About one year before your recent cancer 
diagnosis, were you taking it regularly? 
Oyes 
Ono 
0 don't know 
25c. How long, in total, have you taken thjs 
medication regularly? If you started and 
stopped and then started again, please _ 
count only the time you were takffig this 
medication. 
_ _ number of months or 
_ _ number of years 
0 don' t know 
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26. Ibuprofen medications (such as Advil, 
Motrin, Medipren Indocid, Naprosyn, 
NSAIDS (NSAIDS are non-steroidal anti-
inflammatory drugs) 
Oyes 
0 no -+ Please go to # 27 
0 don't know -+ Please go to # 27 
26a. How often did you usually take it when 
you were taking it regularly (that is, at least 
twice a week for more than a month? 
Please choose one of the following. 
__ times per day or 
__ times per week 
0 don't know 
26b. About one year before your recent cancer 
diagnosis, were you taking it regularly? 
Oyes 
Ono 
0 don't know 
26c. How long, in total, have you taken this 
medication regularly? If you started and 
stopped and then started again please _ 
count only the time you were takffig this 
medication. 
number of months or 
--
_ _ numberofyears 
0 don't know 
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Have you ever taken any of the following medications regularly 
(at least twice a week for more than a month)? (continued) 
27. Bulk-forming laxatives (such as 
Metamucil, Citrucel, FiberCon. 
Serutan, psyllium) 
0 yes 
0 no ~ Please go to # 28 
0 don' t know~ Please go to # 28 
27a. How often did you usually take it when 
you were taking it regularly (that is, at least 
twice a week for more than a month? 
Please choose one of the following. 
__ times per day or 
__ times per week 
0 don't know 
27b. About one year before your recent cancer 
diagnosis, were you taking it regularly? 
0 yes 
Ono 
0 don't know 
27c. How long, in total, have you taken this 
medication regularly? If you started and 
stopped and then started again, please _ 
count only the time you were taking this 
medication. 
__ number of months or 
__ number of years 
0 don't know 
28. Other laxatives (such as Ex-Lax, 
Correctol, Dulcolax, Senokot, Colace, 
castor, cod liver oil, mineral oil, 
milk of magnesia, lactulose, Epsom salts) 
0 yes 
0 no ~ Please go to # 29 
0 don' t know~ Please go to # 29 
28a. How often did you usually take it when 
you were taking it regularly (that is, at least 
twice a week for more than a month? 
Please choose one of the following. 
__ times per day or 
__ times per week 
0 don't know 
28b. About one year before your recent cancer 
diagnosis, were you taking it regularly? 
0 yes 
Ono 
0 don' t know 
28c. How long, in total, have you taken this 
medication regularly? If you started and 
stopped and then started again, please _ 
count only the time you were taking this 
medication. 
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number of months or 
__ number of years 
0 don't know 
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Have you ever taken any of the following medications regularly 
(at least twice a week for more than a month)? (continued) 
29. Multivitamin supplements (such as 
One-A-Day, Theragram, Centrum, 
Unicap) (not individual vitamins) 
Oyes 
0 no --+ Please go to # 28 
0 don't know--+ Please go to# 28 
29a. How often did you usually take it when 
you were taking it regularly (that is, at least 
twice a week for more than a month? 
Please choose one of the following. 
__ times per day or 
__ times per week 
0 don't know 
29b. About one year before your recent cancer 
diagnosis, were you taking it regularly? 
0 yes 
Ono 
0 don't know 
29c. How long, in total, have you taken this 
medication regularly? If you started and 
stopped and then started again, please _ 
count only the time you were taking this 
medication. 
number of months or 
--
-_number of years 
0 don't know 
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30. Folic acid or folate pills or tablets 
0 yes 
0 no--+ Please go to # 31 
0 don' t know--+ Please go to # 31 
30a. How often did you usually take it when 
you were taking it regularly (that is, at least 
twice a week for more than a month? 
Please choose one of the following. 
__ times per day or 
__ times per week 
0 don't know 
30b. About one year before your recent cancer 
diagnosis, were you taking it regularly? 
Oyes 
Ono 
0 don' t know 
30c. How long, in total, have you taken this 
medication regularly? If you started and 
stopped and then started again, please _ 
count only the time you were taking this 
medication. 
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__ number of months or 
__ number of years 
0 don' t know 
Have you ever taken any of the following medications regularly 
(at least twice a week for more than a month)? (continued) 
31 . Calcium pills or tablets 
0 yes 
0 no --+ Please go to # 32 
0 don' t know--+ Please go to # 32 
29a. How often did you usually take it when 
you were taking it regularly (that is, at least 
twice a week for more than a month? 
Please choose one ofthe following. 
__ times per day or 
__ times per week 
0 don't know 
29b. About one year before your recent cancer 
diagnosis, were you taking it regularly? 
0 yes 
0 no 
0 don 't know 
29c. How long, in total, have you taken this 
medication regularly? If you started and 
stopped and then started again, please _ 
count only the time you were taking this 
medication. 
number of months or 
--
--number of years 
0 don ' t know 
32. Calcium-based antacids (such as 
Turns, Rolaids, Extra-strength Rolaids, 
Alka-Mints, Chooz Antacid gum) 
O yes 
Ono -+ 
0 don't know --+ 
If female, 
Please go to # 33 
If male. 
Please go to # 44 
If female, 
Please go to # 33 
If male. 
Please go to # 44 
32a. How often did you usually take it when 
you were taking it regularly (that is, at least 
twice a week for more than a month? 
Please choose one of the following. 
__ times per day or 
__ times per week 
0 don ' t know 
32b. About one year before your recent cancer 
diagnosis, were you taking it regularly? 
Oyes 
Ono 
0 don 't know 
32c. How long, in total, have you taken this 
medication regularly? If you started and 
stopped and then started again, please _ 
count only the time you were taking this 
medication. 
number of months or 
__ number of years 
0 don ' t know 
Men: please go to #44 on page 17 
Women: please continue with #33 on page 13 
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Menstruation, Pregnancy, and Menopause 
33. How old were you when you had your ftrst 
menstrual period? 
__ years of age 
0 don't know 
0 never had a menstrual period 
34. Have you ever been pregnant? 
[ 
Oyes 
0 no--> Please go to # 35 
0 don't know--> Please go to # 35 
>How many times have you been 
pregnant? Please include miscarriages, 
stillbirths, tubal pregnancies and 
abortions. 
__ number of pregnancies 
0 don' t know 
34a. How many times were you pregnant with 
more than one baby (twins, triplets or _ 
more)? If you are pregnant now, please do 
not include your current pregnancy. _ 
0 never 
__ number of pregnancies 
with more than one baby 
0 don't know 
34b. How many of your pregnancies lasted 6 
months or longer? (Pregnancy usually lasts 
9 months. Six months is about the earliest a 
baby could survive.) If you are pregnant 
now, please do not include your current _ 
pregnancy. 
0 never 
__ number of pregnancies lasting 
6 months or longer 
0 don't know 
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34c. How many of your pregnancies resulted in 
live births? 
0 never 
__ number of pregnancies with 
live-born children 
0 don' t know 
34d. How old were you at the flrst live birth? 
age at first birth __ or 
year offirst birth ___ _ 
0 don't know 
34e. How old were you at the last live birth? 
age at last birth __ or 
year of last birth 
----
0 don' t know 
35. Have you ever used birth control pills or 
other hormonal contraceptives (implants or 
injections) for at least one year? 
[ 
Oyes 
0 no --> Please go to # 36 
0 don' t know--> Please go to # 36 
>How old were you when you first used 
Any ofthese hormonal contraceptives? 
age at first use __ or 
year offrrst use ___ _ 
0 don't know 
35a. Were you still using hormonal 
contraceptives about one year before your 
recent cancer diagnosis? 
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0 yes 
Ono 
0 don't know 
35b. In total, how long did you take these 
hormonal contraceptives? Ifyou started and 
stopped and then started again, please count 
only the time you were taking these 
contraceptives. 
_ _ number of years 
0 don't know 
36. Have you had a menstrual period in the last 
12 months? Please include only menstrual 
bleeding, not bleeding that results from 
hormonal replacement therapy (HRT) or 
progesterones, progesttins or withdrawal 
bleeding. 
0 yes--+ Please go to #42 
Ono 
0 don' t know--+ Please go to #42 
Have your periods stopped permanently 
or only temporarily due to pregnancy, 
breast-feeding, or other conditions? 
0 permanently 
0 temporarily --+ Please go to #42 
37. How old were you when your periods 
stopped permanently? 
age they stopped _ _ or 
year they stopped ___ _ 
0 don' t know 
38. Why did your menstrual periods stop 
permanently? Please tick all that apply. 
0 natural menopause 
0 surgery 
0 radiation or chemotherapy 
0 other reason 
Please specify: ________ _ 
0 Don' t know 
Please complete the next few questions which 
ask about surgeries you may have had. 
39. Hysterectomy (only the uterus or womb 
Removed) 
[ 
Oyes 
Ono 
0 don' t know 
>age when removed __ or 
years when removed ___ _ 
0 don't know 
39a. Hysterectomy with one ovary or part of an 
Ovary removed) 
[ 
Oyes 
Ono 
0 don' t know 
>age when removed __ or 
years when removed ___ _ 
0 don' t know 
39b. Hysterectomy with both ovaries removed 
[ 
Oyes 
Ono 
0 don' t know 
>age when removed __ or 
years when removed ___ _ 
0 don 't know 
39c. One ovary removed, completely or partly, 
without hysterectomy 
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[ 
Oyes 
Ono 
0 don' t know 
>age when removed __ or 
years when removed 
----
0 don't know 
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39d. Both ovaries removed without 
hysterectomy 
[ 
Oyes 
Ono 
0 don't know 
>age when removed __ or 
years when removed ___ _ 
0 don' t know 
40. If you had radiation or chemotherapy, when 
did you first have it? 
[ 0 had radiation or chemotherapy 
>age when this was given __ or 
year when this was given _ __ _ 
0 don' t know 
0 never had radiation or chemotherapy 
41. if your periods stopped permanently for 
any reason other than surgery, radiation or 
chemotherapy, when did you this occur? 
[ 
0 other reason 
Please specify: _______ _ 
>age when occurred __ or 
year when occurred ___ _ 
0 don't know 
0 not applicable 
42. Doctors prescribe hormonal replacement 
therapy for many reasons, including 
menopausal symptoms, surgical removal of 
the ovaries, osteoporosis, and heart disease 
prevention. (Menopausal symptoms include 
hot flashes, sweating, and depression.) 
Have you ever taken hormonal replacement 
therapy prescribed by a doctor and in the 
form of a pill or a patch? 
Please do not include hormonal therapy that 
was prescribed for birth control, infertility, 
hormone therapy delivered by injections, 
vagina creams or vaginal suppositories, or 
herbal or soy products. 
0 yes 
0 no ----+ Please go to #43 
0 don 't know----+ Please go to #43 
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42a. Were you still having menstrual 
periods when you first took these 
hormones? 
Oyes 
Ono 
0 don' t know 
42b. Were you prescribed either an estrogen-
only pill or patch (such as Premarin) for 
hormone replacement therapy? 
[ 
Oyes 
Ono 
0 don' t know 
>How old were you when you first 
took estrogen-only medication? 
age when first taken __ or 
years when first taken _ ____ _ 
0 don't know 
42c. Were you still using estrogen-only 
medication for hormone replacement 
therapy about one year before your recent 
cancer diagnosis? 
0 yes 
Ono 
0 don' t know 
42d. In total, how long did you take estrogen-
only medication for hormone replacement 
therapy? If you started and stopped and 
then started again, please count only 
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the time you were taking this medication. 
number of months or 
--number of years 
0 don' t know 
42e. Progesterone or progestin is frequently 
prescribed by doctors together with 
estrogen for hormone replacement therapy. 
One common brand name is Provera. 
Another one is Prometrium. Have you ever 
taken progesterone or progestin together 
with estrogens for hormone replacement 
therapy? 
[ 
0 yes 
0 no --+ Please go to #43 
0 don't know--+ Please go to #43 
>How old were you when you first took 
progesterone or progestin 
together with estrogens? 
age when first taken __ or 
year when first taken ___ _ 
0 don't know 
42f. Were you still using progesterone or 
progestin medication about one year before 
your recent cancer diagnosis? 
Oyes 
Ono 
0 don ' t know 
42g. In total, how long did you take 
progesterone or progestin together with 
estrogens? If you started and stopped and 
then started again, please count only the 
time you were taking this medication. 
number of months or 
__ number ofyears 
0 don' t know 
43 . Have you ever taken tamoxifen, raloxifene, 
or other anti-estrogen medication (such as 
Lupron or Depo-Provera)? 
Oyes 
0 no --+ Please go to #44 
0 possibly - 1 have participated in a 
clinical trial for tamoxifen or 
other anti-estrogen medication 
0 don't know 
>What anti-estrogen medication did you 
take? Please tick all that apply. 
0 tamoxifen 
0 raloxifene 
0 other: __________ _ 
Please specify 
43a. How old were you when you first took 
tamoxifen, raloxifene or other anti-
estrogen medication? 
age when first taken __ or 
year when first taken ___ _ 
0 don't know 
43b. Were you still using tamoxifen, 
raloxifene or other anti- estrogen 
medication about one year before your 
recent cancer diagnosis? 
0 yes 
Ono 
0 don't know 
43c. In total, how long did you take tarnoxifen, 
raloxifene or other anti-estrogen 
medication? If you started and stopped and 
then started again, please count only the 
time you were taking this medication. 
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number of months or 
__ number of years 
0 don ' t know 
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Diet 
44. About one year before your recent cancer diagnosis, on average, how often did you eat a piece 
serving of fruit? 
(A serving of fruit is: 1 medium-sized fresh fruit; Y2 cup of chopped, cooked or canned fruit; 
~ cup of dried fruit; 6 ounces of fruit juice (50%-1 00% pure juice).) Please choose one of the 
following. 
__ servings per day or 
__ servings per week or 
__ servings per month 
0 don't know 
45. About one year before your recent cancer diagnosis, on average, how often did you eat a piece 
serving of vegetables? 
(A serving of vegetables is: 1 medium-sized fresh vegetables; Y2 cup of chopped, cooked or 
chopped vegetables; 6 ounces of vegetable juice (50%- I 00% pure juice).) Please choose one 
ofthe following. 
__ servings per day or 
__ servings per week or 
__ servings per month 
0 don ' t know 
46. About one year before your recent cancer diagnosis, on average, how often did you eat a 
serving of red meat (not chicken or fish)? 
(A serving of red meat is: 2-3 ounces of red meat (a piece of meat about the size of a deck 
of cards). Red meats include: beef, steak, hamburger, prime rib, ribs, beef hot dogs, beef-
based processed meat, veal, pork, bacon, pork sausage, ham, lamb, venison.) 
__ servings per day or 
__ servings per week or 
__ servings per month 
0 don' t eat red meat ---+Please go to #47 
0 don ' t know 
46a. About one year before your recent cancer diagnosis, on average, how often did you eat a 
serving of red meat that was cooked by broiling, grilling, barbecueing or pan-frying (not 
stir-fried or deep-fried)? Please choose one of the following. 
__ servings per day or 
__ servings per week or 
__ servings per month 
0 don ' t eat red meat that was cooked by these methods --+ Please go to #47 
0 don ' t know 
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46b. On average, when you ate red meat cooked by these methods, which of the following best 
describes its appearance? 
What was its outside appearance? 
0 lightly browned 
0 medium browned 
0 heavily browned or blackened 
0 don't know 
What was its inside appearance? 
(how well done it was)? 
0 red (rare) 
0 pink (medjum) 
0 brown (well-done) 
0 don't know 
47. About one year before your recent cancer diagnosis, on average, how often did you eat a 
serving of crucken? Please do not include turkey or any other bird. 
(A serving of chicken is: 2-3 ounces of chicken meat; I drumstick; 1 thigh; half a breast; 
2 wings; 3 nuggets.) Please choose one of the following. 
__ servings per day or 
__ servings per week or 
__ servings per month 
0 don' t eat red meat that was cooked by these methods---. Please go to #48 
0 don' t know 
47a. About one year before your recent cancer diagnosis, on average, how often did you eat a 
serving of chicken that was cooked by broiling, grilling, barbecueing or pan-frying (not 
stir-fried or deep-fried)? Please choose one of the following. 
__ servings per day or 
__ servings per week or 
__ servings per month 
0 don't eat chicken that was cooked by these methods ---. Please go to #48 
0 don't know 
47b. On average, when you ate chicken cooked by these methods, which of the following best 
describes its appearance? 
What was its outside appearance? 
0 lightly browned 
0 medium browned 
0 heavily browned or blackened 
0 don' t know 
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Physical Activity 
We would like you to think back to when you were in your 20s and remember the physical 
activities you participated in then. 
48. In your 20s, did you participate regularly in physical activity for a total of at least 30 minutes 
a week? Please describe your activities below. 
For how During those During those months, 
many years? years, for many on average, for how 
months per year? many minutes or 
hours per week? 
Walking 0 yes--+ __ years 
--
months _ minutes per week I 
Ono _ hours per week 
Jogging 0 yes--+ __ years 
--
months _ minutes per week I 
(running slower Ono _ hours per week 
than a mile in 
10 minutes) 
Running 0 yes--+ years 
--
months _ minutes per week I 
(running faster Ono -- _ hours per week 
than a mile in 
10 minutes) 
Bicycling 0 yes--+ __ years 
--
months _ minutes per week I 
(including Ono _ hours per week 
using an 
exercise bicycle 
Swimming laps 0 yes--+ __ years 
--
months _ minutes per week I 
Ono _ hours per week 
Tennis, squash 0 yes--+ __ years 
--
months _ minutes per week I 
racquetball Ono _ hours per week 
Calisthenics, 0 yes--+ years 
--
months _ minutes per week I 
aerobics, Ono -- _ hours per week 
vigorous dance 
(including 
ballet), using a 
rowing machine, 
lifting weights 
Football, soccer 0 yes--+ years 
--
months _ minutes per week I 
rugby, Ono -- _ hours per week 
basketball 
Heavy household 0 yes--+ __ years 
--
months _ minutes per week I 
work (examples: Ono _ hours per week 
using a non-
power mower, 
shoveling, 
moving heavy 
loads, scrubbing 
floors) 
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ln your 20s, did you do any other strenuous activities? Strenuous activity means something that 
really increased your heart rate, make you hot, and caused you to sweat. Some examples are: 
skiing, skating, hockey, hunting, shedding or tobogganmg, water-skiing. 
Activity 
Please specify 
-+ 
For how 
many years? 
__ years 
- -
years 
__ years 
__ years 
__ years 
__ years 
__ years 
During those 
years, for many 
months per year? 
months 
--
months 
--
months 
--
months 
--
months 
--
months 
--
months 
--
During those months, 
on average, for how 
many minutes or 
hours per week? 
_ minutes per week I 
_ hours per week 
_ minutes per week I 
_ hours per week 
_ minutes per week I 
_ hours per week 
_ minutes per week I 
_ hours per week 
_ minutes per week I 
_ hours per week 
_ minutes per week I 
_ hours per week 
_ minutes per week I 
_ hours per week 
49. When you were in your 20s, what was your usual occupation? (When mean what you did for 
the longest time, including any paid or unpaid employment, such as being a student or 
housewife of being unemployed.) 
------------------ ----------occupation 
0 don't know 
If you are younger than 31, please go to the next section (Alcohol Consumption) on page 25. 
Otherwise, please continue with #50. 
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Now, please think back to your 30s and 40s. 
50. ln your 30 and 40s, did you participate regularly in physical activity for a total of at least 30 
minutes a week? Please describe your activities below. 
For how During those During those months, 
many years? years, for many on average, for how 
months per year? many minutes or 
hours per week? 
Walking 0 yes---+ __ years 
--
months _ minutes per week I 
Ono _ hours per week 
Jogging 0 yes---+ __ years 
--
months _ minutes per week I 
(running slower Ono _ hours per week 
than a mile in 
10 minutes) 
Running 0 yes---+ __ years 
--
months _ minutes per week I 
(running faster Ono _ hours per week 
than a mile in 
10 minutes) 
Bicycling 0 yes---+ __ years 
--
months _ minutes per week I 
(including Ono _ hours per week 
using an 
exercise bicycle 
Swimming laps 0 yes---+ __ years 
--
months _ minutes per week I 
Ono _ hours per week 
Tennis, squash 0 yes---+ __ years 
--
months _ minutes per week I 
racquetball Ono _ hours per week 
Calisthenics, 0 yes---+ __ years 
--
months _ minutes per week I 
aerobics, Ono _ hours per week 
vigorous dance 
(including 
ballet), using a 
rowing machine, 
lifting weights 
Football, soccer 0 yes---+ __ years months _ minutes per week I 
rugby, Ono 
--
_ hours per week 
basketball 
Heavy household 0 yes---+ __ years 
--
months _ minutes per week I 
work (examples: Ono _ hours per week 
using a non-
power mower, 
shoveling, 
moving heavy 
loads, scrubbing 
floors) 
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In your 30s and 40s, did you do any other strenuous activities? Strenuous activity means 
something that really increased your heart rate, make you hot, and caused you to sweat. Some 
examples are: skiing, skating, hockey, hunting, shedding or tobogganing, water-skiing. 
Activity 
Please specify 
--+ 
--+ 
For how 
many years? 
__ years 
__ years 
__ years 
__ years 
__ years 
__ years 
__ years 
During those 
years, for many 
months per year? 
months 
--
months 
--
months 
--
months 
--
months 
--
months 
--
months 
--
During those months, 
on average, for how 
many minutes or 
hours per week? 
_ minutes per week I 
_ hours per week 
_ minutes per week I 
_ hours per week 
_ minutes per week I 
_ hours per week 
_ minutes per week I 
_ hours per week 
_ minutes per week I 
_ hours per week 
_ minutes per week I 
_ hours per week 
_ minutes per week I 
_ hours per week 
51 . When you were in your 30s and 40s, what was your usual occupation? (When mean what you 
did for the longest time, including any paid or unpaid employment, such as being a student or 
housewife of being unemployed.) 
-----::----:-- -----------------------occupation 
0 don 't know 
If you are younger than 31 , please go to the next section (Alcohol Consumption) on page 25. 
Otherwise, please continue with #50. 
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Now, please think back to since you turned 50s. 
52. In your 50s, did you participate regularly in physical activity for a total of at least 30 
minutes a week? Please describe your activities below. 
For how During those During those months, 
many years? years, for many on average, for how 
months per year? many minutes or 
hours per week? 
Walking 0 yes--+ __ years 
--
months _ minutes per week I 
Ono-+ _ hours per week 
Jogging 0 yes --+ _ _ years 
- -
months _ minutes per week I 
(running slower 0 no--+ _ hours per week 
than a mile in 
10 minutes) 
Running 0 yes--+ __ years 
--
months _ minutes per week I 
(running faster Ono-+ _ hours per week 
than a mile in 
I 0 minutes) 
Bicycling 0 yes --+ __ years months _ minutes per week I 
(including Ono-+ -- _ hours per week 
using an 
exercise bicycle 
Swimming laps 0 yes --+ __ years 
--
months _ minutes per week I 
Ono -+ _ hours per week 
Tennis, squash 0 yes--+ _ _ years 
--
months _ minutes per week I 
racquetball Ono -+ _ hours per week 
Calisthenics, 0 yes--+ _ _ years 
- -
months _ minutes per week I 
aerobics, 0 no-+ _ hours per week 
vigorous dance 
(including 
ballet), using a 
rowing machine, 
lifting weights 
Football, soccer 0 yes--+ __ years 
- -
months _ minutes per week I 
rugby, 0 no -+ _ hours per week 
basketball 
Heavy household 0 yes --+ __ years 
--
months _ minutes per week I 
work (examples: Ono -+ _ hours per week 
using a non-
power mower, 
shoveling, 
moving heavy 
loads, scrubbing 
floors) 
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ln your 50s, did you do any other strenuous activities? Strenuous activity means 
something that really increased your heart rate, make you hot, and caused you to sweat. Some 
examples are: skiing, skating, hockey, hunting, shedding or tobogganing, water-skiing. 
Activity For how During those During those months, 
Please specify many years? years, for many on average, for how 
months per year? many minutes or 
hours per week? 
__ years months _ minutes per week I 
- -
_ hours per week 
_ _ years months _ minutes per week I 
- -
_ hours per week 
__ years 
--
months _ minutes per week I 
_ hours per week 
__ years 
--
months _ minutes per week I 
_ hours per week 
_ _ years 
- -
months _ minutes per week I 
_ hours per week 
_ _ years 
- -
months _ minutes per week I 
_ hours per week 
__ years 
--
months _ minutes per week I 
_ hours per week 
53. When you were in your 50s, what was your usual occupation? (When mean what you 
did for the longest time, including any paid or unpaid employment, such as being a student or 
housewife of being unemployed.) 
---- ----- --------- ----- ----- occupation 
0 don't know 
259 
Page 24 
Alcohol Consumption 
We would like you to think back to when you were in your 20s. 
54. In your 20s, did you ever consume any alcoholic beverages at least once a week for 6 
months or longer? Please describe your consumption below. 
Beer, hard cider 
(at least 3% 
alcohol) 
Wine 
Sake, sherry, port 
Spirits, liquor 
mixed drinks, 
brandy, liqueurs 
Oyes-
Ono 
0 don't know 
Oyes-
Ono 
0 don't know 
Oyes-
Ono 
0 don't know 
Oyes-
Ono 
0 don't know 
For how many 
years? 
__ years consumed 
__ years consumed 
__ years consumed 
__ years consumed 
During those years, 
how much did you 
typically consume? 
number of 12 ounce 
cans or bottles 
0 per day 
0 per week 
0 don't know 
number of 4 ounce 
glasses of wine 
0 per day 
0 per week 
0 don't know 
number of I ounce 
servings 
0 per day 
0 per week 
0 don't know 
number of I ounce 
- -
shots I iquor or 
spirits 
0 per day 
0 per week 
0 don't know 
55. When you were in your 20s, how many years in total did you consume at least one alcoholic 
beverage (of any type) a week? 
_ _ years consumed 
0 never consumed alcohol 
56. On average, bow many alcoholic beverages a week did you consume during those years? 
That is, how many 4 ounce glasses of wine or 12 ounce cans or bottles of beer or hard cider, or 
1 ounce servings of sake, sherry, port, or spirits, mixed drinks and cocktails. 
__ number of alcoholic beverages a week 
0 never consumed alcohol 
If you are younger than age 31, please go to the next section (Smoking) on page 28. 
Otherwise, please continue with #57. 
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Now, please think back to your 30s and 40s. 
57. In your 30s and 40s, did you ever consume any alcoholic beverages at least once a week for 6 
months or longer? Please describe your consumption below. 
Beer, hard cider 
(at least 3% 
alcohol) 
Wine 
Sake, sherry, port 
Spirits, liquor 
mixed drinks, 
brandy, liqueurs 
0 yes--+ 
Ono 
0 don' t know 
0 yes--+ 
Ono 
0 don't know 
0 yes--+ 
0 no 
0 don't know 
0 yes--+ 
Ono 
0 don't know 
For how many 
years? 
__ years consumed 
__ years consumed 
__ years consumed 
__ years consumed 
During those years, 
how much did you 
typically consume? 
number of 12 ounce 
cans or bottles 
0 per day 
0 per week 
0 don't know 
number of 4 ounce 
glasses of wine 
0 per day 
0 per week 
0 don't know 
number of 1 ounce 
servings 
0 per day 
0 per week 
0 don't know 
number of I ounce 
--
shots liquor or 
spirits 
0 per day 
0 per week 
0 don't know 
58. When you were in your 30s and 40s, how many years in total did you consume at least one 
alcoholic beverage (of any type) a week? 
__ years consumed 
0 never consumed alcohol 
56. On average, how many alcoholic beverages a week did you consume during those years? 
That is, how many 4 ounce glasses of wine or 12 ounce cans or bottles of beer or hard cider, or 
I ounce servings of sake, sherry, port, or spirits, mixed drinks and cocktails. 
__ number of alcoholic beverages a week 
0 never consumed alcohol 
If you are younger than age 51 , please go to the next section (Smoking) on page 28. 
Otherwise, please continue with #60. 
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Now, please think back to since you turned 50s. 
60. ln your 50s, did you ever consume any alcoholic beverages at least once a week for 6 
months or longer? Please describe your consumption below. 
Beer, hard cider 
(at least 3% 
alcohol) 
Wine 
Sake, sherry, port 
Spirits, liquor 
mixed drinks, 
brandy, liqueurs 
0 yes---+ 
Ono 
0 don't know 
0 yes---+ 
Ono 
0 don 't know 
0 yes---+ 
Ono 
0 don't know 
0 yes---+ 
Ono 
0 don't know 
For how many 
years? 
__ years consumed 
__ years consumed 
__ years consumed 
__ years consumed 
During those years, 
how much did you 
typically consume? 
number of 12 ounce 
cans or bottles 
0 per day 
0 per week 
0 don't know 
number of 4 ounce 
glasses of wine 
0 per day 
0 per week 
0 don't know 
number of I ounce 
servings 
0 per day 
0 per week 
0 don't know 
number of I ounce 
--
shots liquor or 
spirits 
0 per day 
0 per week 
0 don' t know 
61. When you were in your 30s and 40s, how many years in total did you consume at least one 
alcoholic beverage (of any type) a week? 
--
years consumed 
0 never consumed alcohol 
62. On average, how many alcoholic beverages a week did you consume during those years? 
That is, how many 4 ounce glasses of wine or 12 ounce cans or bottles of beer or hard cider, or 
I ounce servings of sake, sherry, port, or spirits, mixed drinks and cocktails. 
__ number of alcoholic beverages a week 
0 never consumed alcohol 
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Smoking 
63 . Have you ever smoked at least one 
cigarette a day for 3 months or longer? 
0 yes 
0 no ---+ Please go to #64 
0 don't know ---+ Please go to #64 
63a. When did you first start smoking at 
least one cigarette a day? 
age at first use __ or 
year of first use ___ _ 
0 don't know 
63b. During periods when you smoked 
regularly, how many cigarettes did you 
typically smoke in a day? 
____ cigarettes per day 
0 don't know 
63c. About one year before your recent 
cancer diagnosis, were you still smoking 
at least one cigarette a day? 
0 yes 
Ono 
0 don't know 
63d. Do you still smoke at least one 
cigarette a day? 
Oyes 
0 no ---+ Please go to #63f 
0 don't know---+ Please go to #63f 
63e. When did you stop smoking at least 
one cigarette a day (we mean stop 
smoking permanently)? 
age at first use __ or 
year of first use ___ _ 
0 don' t know 
63f. How many years, in total, did you 
smoke at least one cigarette a day for 3 
months or longer? (Jfyou have stopped 
and restarted at least once, count only 
the time when you were smoking.) 
____ total number ofyears 
0 don't know 
64. Have you ever smoked at least one 
cigar a month for at least 3 months? 
Oyes 
0 no ---+ Please go to #65 
0 don't know---+ Please go to #65 
64a. When did you ftrst start smoking at 
least one cigar a month? 
age at ftrst use __ or 
year of first use ___ _ 
0 don' t know 
64b. During periods when you smoked 
regularly, how many cigar did you 
typically smoke in a month? 
____ cigarettes per month 
0 don't know 
64c. About one year before your recent 
cancer diagnosis, were you still 
smoking at least one cigar a month? 
Oyes 
Ono 
0 don't know 
64d. Do you still smoke at least one 
cigar a month? 
0 yes 
0 no---+ Please go to #64f 
0 don' t know ---+ Please go to #64f 
64e. When did you stop smoking at least 
one cigar a month (we mean stop 
smoking permanently)? 
age at ftrst use __ or 
year of first use ___ _ 
0 don' t know 
64f. How many years, in total, did you 
smoke at least one cigar a month for 3 
months or longer? (If you have stopped 
and restarted at least once, count only 
the time when you were smoking.) 
263 
____ total number ofyears 
0 don't know 
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65. Have you ever smoked at least one 
pipe a month for at least 3 months? 
0 yes 
0 no ----+ Please go to #66 
0 don' t know----+ Please go to #66 
65a. When did you first start smoking at 
least one pipe a month? 
age at first use __ or 
year of first use ___ _ 
0 don't know 
65b. During periods when you smoked 
regularly, how many pipe did you 
typically smoke in a month? 
____ pipe per month 
0 don't know 
65c. About one year before your recent 
cancer diagnosis, were you still smoking 
at least one pipe a month? 
Oyes 
Ono 
0 don't know 
65d. Do you still smoke at least one 
pipe a month? 
Oyes 
0 no----+ Please go to #65f 
0 don't know----+ Please go to #65f 
65e. When did you stop smoking at least 
one pipe a month (we mean stop smoking 
smoking permanently)? 
age at first use __ or 
year of ftrst use ___ _ 
0 don't know 
65f. How many years, in total, did you 
smoke at least one pipe a month for 3 
months or longer? (If you have stopped 
and restarted at least once, count only the 
time when you were smoking.) 
____ total number ofyears 
0 don't know 
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Height and Weight 
66. About how tall are you, without your 
shoes on? 
feet inches 
or 
centimeters 
---
0 don't know 
67. How much did you weigh about one 
year before your recent cancer diagnosis? 
_pounds 
Or 
___ kilograms 
0 don't know 
Additional Information 
69. Previous to this study, have you and 
your relatives ever taken part in any 
family health studies? 
264 
0 yes 
Ono 
0 don't know 
Background Information 
70. What is the highest level of education that you completed? 
0 less than 8 years 0 some college or university 
0 8 to 11 years 0 bachelor's degree 
0 high school graduate 0 graduate degree 
0 vocational or technical school 0 don' t know 
71. Country of birth sometimes affects disease risk. Please fill in country of birth for 
yourself, you parents and your grandparents. 
In addition, scientists have found that some genetic traits are more common or less 
common among Jewish people of different ethnic backgrounds. Please answer the 
questions about Jewish descent for each person. 
Country Is this Ashkenazi Sephardic Other Don' t 
of birth person of (East know 
Jewish European) 
descent? 
You Oyes 0 0 0 0 
Ono 
0 don't know 
Your 0 yes 0 0 0 0 
mother Ono 
0 don't know 
Your 
---
0 yes 0 0 0 0 
father Ono 
0 don' t know 
Your Oyes 0 0 0 0 
mother' s Ono 
mother 0 don't know 
Your Oyes 0 0 0 0 
mother' s Ono 
father 0 don't know 
Your 
---
0 yes 0 0 0 0 
father's Ono 
mother 0 don' t know 
Your Oyes 0 0 0 0 
father's Ono 
father 0 don' t know 
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72. How many years have you lived in Canada? 
0 all my life 
__ number of years 
0 don' t know 
73. Ethnicity and race sometimes affect disease risk. Scientists have found that some 
genetic traits are more common or less common among people of different backgrounds. 
We would like to know if this is true for genes associated with colorectal cancer. 
Please fill in the background for yourself, your parents and your grandparents. 
Please tick all that apply. 
You Your Your Your Your Your Your 
mother father Mother' s Mother's Father's Father's 
mother father mother Father 
Black, 0 0 0 0 0 0 0 
From Africa 
Black, from 0 0 0 0 0 0 0 
Caribbean 
(Trinidad, 
Jamaica, 
Haiti) 
Black from 0 0 0 0 0 0 0 
North America 
Black, other 0 0 0 0 0 0 0 
White 0 0 0 0 0 0 0 
First Nations 0 0 0 0 0 0 0 
(Indian, Inuit) 
North African 0 0 0 0 0 0 0 
(Egyptian) 
Middle East 0 0 0 0 0 0 0 
(iranian) 
Filipino 0 0 0 0 0 0 0 
Japanese 0 0 0 0 0 0 0 
Korean 0 0 0 0 0 0 0 
Chinese 0 0 0 0 0 0 0 
Other South 0 0 0 0 0 0 0 
East Asian 
(Vietnamese) 
South Asian 0 0 0 0 0 0 0 
(East indian, 
Pakistani) 
Other: 
Please specify 
--- ---
---
Don' t know 0 0 0 0 0 0 0 
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74. Which of the following categories best describes your total annual household income 
about one year before your recent diagnosis? 
0 no income 
0 less than $6,000 
0 $6,000 - $11 ,999 
0$12,000-$19,999 
0 $20,000- $29,999 
0 $30,000 - $39,999 
0 $40,000- $49,999 
0 $50,000- $59,999 
0 $60,000-$69,999 
0 $70,000- $79,999 
0$80,000 + 
0 don't know 
75. In case we need to contact you in the future and you have moved, could we have the 
name of someone who is not living with you to whom we might write or call for your 
new address? 
Name of relative or friend: ---------------------
His or her address: -----------------------
His or her telephone number: L_ _ __j ___ - _ _ _ _ 
Thank you very much for taking the time to fill out this questionnaire. 
We appreciate your participation. 
Please mail this completed questionnaire in the return envelope provided. 
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Appendix III: The letter of approval for databases from Wang 
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UNIVERSITY 
Faculty of Medicine 
Division of Community Health and Humanities 
Tioe H.,a:th Sc1ences C -r•!rt· 
S1 ohn':>, NL Can;;da A~B 3V6 
T~!: 709 777 6.?13/66"-.2 f.11 : 709 ;• i I 7 382 www.med.mun.ca 
January 31, 2008 
Jinhui Zhao 
206-1475 Pandora Avenue 
Victoria BC 
V8R 1A6 
RE: Request of epidemiological data of colorectal cancer in Newfoundland 
Dear Jinhui: 
Thank you for your letter regarding the epidemiological data of colorectal cancer in 
Newfoundland population for your research entitled "Alcohol and tobacco use and colorectal 
cancer: a population-based case-control study in Newfoundland" in order for you to write your 
thesis as required by the PhD program in Community Health and Humanities at Memorial 
University ofNewfoundland. 
We have reviewed your request for the data files and will provide you the files requested for 
your research of alcohol and tobacco use and colorectal cancer. Thank you very much for the 
request. 
Sincerely, 
P. Peter Wang, M.D., PhD 
Associate Professor of Epidemiology 
PPW/sch 
Appendix IV: Units of cigarettes sales and cigarette equivalents in Newfoundland and Labrador in 
1980-2008 
Total Cigarettes Sold Cigarettes Smoked among Population Aged 20-74 Years Old t 
Year Units of Cigarette Cigarettes Cigarette Total units Total units (TU) equivalents Cigarettes (UC) Equivalents (CE) (UCx0.9318) (UEx0.9318) (TUx0.9318) 
1980 I 112 600 190 800 I 303 400 I 036 721 177,787 1 214,508 
1981 1 089 800 205 500 I 295 300 1 015 476 191,485 1,206 961 
1982 I 026 400 286 900 1313300 956 400 267 333 1 223 733 
1983 738 600 432 300 1 170 900 688 227 402 817 1,091 045 
1984 734 600 479 200 I 213 800 684 500 446 519 I 131019 
1985 771 500 493 400 I 264,900 718 884 459 750 1178634 
1986 655 700 539 700 1 195,400 610 981 502 892 1 113 874 
1987 * * * * * * 
1988 * * * * * * 
1989 694 956 412 166 1 107 122 647 560 384 056 1 031 616 
1990 752 765 330 604 1,083 369 701 426 308 057 1 009 483 
1991 630 842 304 398 935 240 587819 283 638 871 457 
1992 589 967 370 397 960 364 549,731 345 136 894 867 
1993 476 882 285 384 762 266 444,359 265 921 710,279 
1994 475 082 382 916 857 998 442,681 356 801 799 483 
1995 446,391 397 250 843 641 415,947 370 158 786,105 
1996 432,405 394 360 826 765 402,915 367 465 770 380 
1997 418,343 388 784 807 127 389,812 362 269 752 081 
1998 414,368 392 436 806 804 386,108 365 672 751 780 
1999 430,729 382 214 812 943 401,353 356 147 757 500 
2000 418 374 302 733 721 107 389,841 282 087 671 928 
2001 427,879 259,210 687,089 398,698 241 532 640 230 
2002 384 712 286 159 670 871 358 475 266 643 625 118 
2003 354 939 292,687 647,626 330 733 272 726 603,458 
Average 612 629 354 977 967 606 570 848 330 768 901 615 
Source: Health Canada. Wholesales sales data: cigarette and fine-cut sales charts 1980-2008. Available at the website: http://www.hc-sc.gc.ca/hc-
ps/tobac-tabac/research-recherche/indust/sales-ventes-eng.php (Accessed: September 17, 2009). 
* Provincial sales not available for 1987 and 1988. 
t Assumed 93.18% of absolute alcohol consumed by QOpulation aged 20-74 years old in CCHS 1.1 l357l . 
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Appendix V: Total population and population aged 20-74 years old in Newfoundland and Labrador in 
1971-2008 
Population and Smokers Aged 20-74 Cigarettes Smoked among Population Aged 20-74 Years Old t 
Year Population (P) Smoking Rate (R) t Smokers (S=PxR) Cigarettes in I ,000 Cigarettes I Packs Per Smoker (C) 1 Smoker (PS=C/S) (PP=PS/20) 
1980 321,894 0.6659 214,346 1,214 508 5666.10 283.31 
1981 328 048 0.6372 209 027 1 206 961 5774.20 288.71 
1982 331 847 0.6097 202,331 1,223,733 6048.17 302.41 
1983 340 079 0.5834 198 411 1 091 045 5498.91 274.95 
1984 345 566 0.5583 192 920 1,131 019 5862.62 293.13 
1985 349 836 0.5342 186 884 1 178 634 6306.76 315.34 
1986 351 901 0.5112 179 883 1,113 874 6192.22 309.61 
1987 355 742 0.4891 174 006 * * * 
1988 359,670 0.4680 168 343 * * * 
1989 364 504 0.4479 163 250 1 031 616 6319.22 315.96 
1990 368 385 0.4286 157 876 1 009,483 6394.17 319.71 
1991 374 321 0.4101 153 504 871,457 5677.11 283.86 
1992 378 879 0.3924 148 674 894,867 6018.98 300.95 
1993 382 720 0.3755 143,707 710,279 4942.56 247.13 
1994 382 219 0.3593 137,331 799,483 5821.56 291.08 
1995 380 155 0.3593 136,590 786,105 5755.23 287.76 
1996 378 292 0.3296 124,685 770,380 6178.60 308.93 
1997 375 328 0.3296 123,708 752,081 6079.48 303.97 
1998 370 342 0.3125 115,732 751 ,780 6495.88 324.79 
1999 368 385 0.3125 115,120 757,500 6580.07 329.00 
2000 367,213 0.3183 116,884 671 928 5748.68 287.43 
2001 365 140 0.3183 116 224 640 230 5508.58 275.43 
2002 365716 0.3048 Ill 457 625 II8 5608.59 280.43 
2003 367 759 0.2852 104 877 603 458 5753.98 287.70 
Average 361,414 0.4309 153 990 901 ,615 5919.62 295.98 
Source: The population data were obtained from Statistics Canada. The data are accessible: http://estat.statcan.gc.ca/cgi-win/CNSMCGI.EXE. 
t Annual rate of smoker for 1980-2003 was estimated using the National Population Health Survey (NPHS) cycle 1, 2 and 3 14584601 and CCHS 1.1 and 
3.1 (357,360). 
_1Including cigarettes and fine-cut e_quivalents (see Appendix IV). 
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Appendix VI: Annual sales of alcoholic beverages by volume in Newfoundland and Labrador in 
1992-2003 
Total Beverage in 1000 Litres Total Absolute Alcohol in 1000 Litres t Absolute Alcohol in I 000 Litres Consumed Year by Population Aged 20-74 Years Old t 
Beer Wine Spirit Total Beer Wine Spirit Total Beer Wine Spirit Total 
1992 46,323 1,686 3,508 51 ,517 2,316 194 1,403 3,913 2,074 174 1,257 3,505 
1993 46,048 1,622 3,344 51,014 2,302 187 1,338 3,827 2,062 167 1,198 3,427 
1994 43,61 8 1,631 3,271 48,520 2,181 188 1,308 3,677 1,953 168 1,172 3,293 
1995 42,060 1,629 3,225 46,914 2,103 187 1,290 3,580 1,883 168 I, 155 3,207 
1996 41,103 1,672 3,122 45,897 2,055 192 1,249 3,496 1,841 172 1 ' 118 3,13 1 
1997 39,307 1,746 3,108 44,161 1,965 201 1,243 3,409 1,760 180 I, 113 3,053 
1998 39,811 1,810 3,1 35 44,756 1,991 208 1,254 3,453 1,783 186 1,123 3,092 
1999 41,538 2,069 3,221 46,828 2,077 238 1,288 3,603 1,860 213 1,154 3,227 
2000 41,138 2,291 3,382 46,811 2,057 263 1,353 3,673 1,842 236 1,212 3,290 
2001 42,210 2,492 3,148 47,850 2,111 287 1,259 3,656 1,890 257 1,128 3,275 
2002 40,351 2,808 3,168 46,327 2,018 323 1,267 3,608 1,807 289 1,135 3,231 
2003 43,257 2,160 4,543 49,960 2,163 248 1,817 4,228 1,937 222 1,627 3,787 
Average 42,230 1,968 3,348 47,546 2,112 226 1,339 3,677 1,891 203 1,199 3,293 
Source: Statistics Canada. Table 183-0006 -Sales of alcoholic beverages by volume, value and per capita 15 years and over, fiscal years ended March 
31 , annual (table), CANSIM (database), Using E-ST AT (distributor). Ottawa. http://estat.statcan.gc.ca/cgi-win/CNSMCGI.EXE [3551• 
t Conversion factors for beer=5%; wine= 11 .5% and spirit=40% [346•3551. 
t Assumed 89.56% of absolute alcohol consumed by population aged 20-74 years old in CCHS 1.1 [3571. 
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Appendix VII: Absolute alcohol consumption from beer, wine and spirits and per capita absolute 
alcohol consumption per drinker aged 20-74 years old in Newfoundland and Labrador in 1992-2003 
20-74 Years Old in NL Absolute Alcohol in l 000 Litres Per Capita Alcohol in Litres % of Absolute Alcohol by Year Beverage 
Pop Rate t Drinkers Beer Wine Spirit Total Beer Wine Spirit Total Beer Wine Spirit Total 
1992 378,879 0.7661 290,259 2,074 174 1,257 3,505 7.15 0.60 4.33 12.07 59.19 4.95 35.86 100.00 
1993 382,720 0.7661 293,202 2,062 167 1,198 3,427 7.03 0.57 4.09 11.69 60.17 4.87 34.96 100.00 
1994 382,219 0.7661 292,818 1,953 168 1,172 3,293 6.67 0.57 4.00 11.25 59.31 5.10 35.58 100.00 
1995 380,155 0.7661 291 ,237 1,883 168 1,155 3,207 6.47 0.58 3.97 11.01 58.74 5.23 36.03 100.00 
1996 378,292 0.7677 290,415 1,841 172 1,118 3, 131 6.34 0.59 3.85 10.78 58.78 5.50 35.72 100.00 
1997 375,328 0.7677 288,139 1,760 180 1,113 3,053 6.11 0.62 3.86 10.60 57.65 5.89 36.46 100.00 
1998 370,342 0.7818 289,533 1,783 186 1,123 3,092 6.16 0.64 3.88 10.68 57.65 6.03 36.32 100.00 
1999 368,385 0.7818 288,003 1,860 213 1, 154 3,227 6.46 0.74 4.01 11 .20 57.64 6.60 35.76 100.00 
2000 367,213 0.7835 287,711 1,842 236 1,212 3,290 6.40 0.82 4.21 11.43 56.00 7.1 7 36.83 100.00 
2001 365,140 0.7852 286,708 1,890 257 1,128 3,275 6.59 0.90 3.93 11.42 57.72 7.84 34.44 100.00 
2002 365,716 0.7906 289,127 1,807 289 1,135 3,231 6.25 1.00 3.93 11.18 55.92 8.95 35.13 100.00 
2003 367,759 0.7958 292,657 1,937 222 1,627 3,787 6.62 0.76 5.56 12.94 51.15 5.87 42.98 100.00 
Average 373,512 0.7765 289,984 1,891 203 1,199 3,293 6.52 0.70 4.1 3 11.35 57.42 6.16 36.42 100.00 
Source: Statistics Canada. Table 051-0001- Estimates of population, by age group and sex for July l , Canada, provinces and territories, annual (persons 
unless otherwise noted) (table), CANSIM (database), Using E-STAT (distributor). Ottawa. http://estat.statcan.gc.ca/cgi-win/CNSMCGI.EXE 
(Accessed: September 17, 2009). The data of alcohol sales: see Appendix VI. 
Annual rate of drinker for 1992-2003 was estimated using the National Population Health Survey (NPHS) cycle I, 2 and 3 [4584601 and CCHS 1. 1 and 
3.1 [357,360). 
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